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The two main foci herein are the preparation of sulfatides that activate a subset of type II natural killer T
(NKT) cells and the synthesis and exploitation of the reactivity of unusual strained heterocycles. Chapter
1 describes the synthesis of two unnatural sulfatides. The preparation of one of these, an -sulfatide, was
motivated by the need to probe the effect of a potential-linked sulfatide impurity in a previously
synthesized -sulfatide which had been shown to stimulate higher than expected secretion of both IFN-
and IL-4. The synthesis of the -sulfatide was motivated by the fact that a related plakoside derivative had
shown strong interaction with CD1d, an antigen presenting protein for Natural Killer T (NKT) cells. The
syntheses were achieved by taking into account three different aspects: the preparation of the ceramide
acceptor (sphingoid base and acyl chain), the glycosylation reaction with a suitable galactosyl donor and a
regioselective sulfation reaction. These sulfatides will provide our collaborators with tools to understand
the role of sulfatide-reactive type II NKT cells. The long-range goal is to develop new derivatives for
biomedical applications.
Chapter 2 focuses on new syntheses of 3,4-disubstituted -lactones, such compounds are of importance in
synthetic and medicinal chemistry. Herein, the utilization of -methylene--lactones in transition metalcatalyzed transformations to access 3,4-disubstituted -lactones is described. Two successful
transformations include: a) olefin cross metathesis (CM) of α-methylene-β-lactones scaffolds coupled
with stereoselective reduction and b) rhodium-catalyzed conjugate addition of aryl boronic acids to methylene--lactones. In particular, palmostatin M inspired -lactones were prepared as tools to
investigate the Ras palmitoylation/depalmitoylation cycle, which regulates the subcellular trafficking of
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the N-Ras, H-Ras, and K-Ras4a isoforms, as a therapeutic target for selectively inhibiting the growth of
malignancies with oncogenic N-Ras mutations. The long term goal of this project is to implement
mechanistic strategies to selectively inhibit the growth of cancers with somatic Ras mutations.
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Chapter 1

Synthesis of Unnatural Sulfatides and Examination of their Role in Immunomodulation

1

1.1 Introduction
1.1.1 Glycosphingolipids
Glycosphingolipids are an important class of lipids found in membranes of vertebrate cells. They play a
major role in many biological processes, such as the formation of membrane microdomains and the
interaction of pathogenic microbes or their secreted toxins with host cells.1 The basic structure for a
glycosphingolipid consist of glucose or galactose, attached directly to a ceramide molecule and resulting
in, respectively, glucosylceramide (glucocerebroside; GlcCer) or galactosylceramide (galactocerebroside;
GalCer) (Figure 1a). The ceramide is made up of a sphingoid base (phytosphingosine, sphingosine, or
sphinganine) (Figure 1b) and fatty acyl chain connected through N-acylation. The sugar is connected to
the ceramide via a glycosidic bond that can be either alpha or beta linked (Figure 1c). This combination
structure results in an amphiphilic molecule with a hydrophilic carbohydrate region and a hydrophobic
lipid region.

Figure 1. Basic structure for a glycosphingolipid: a) structural skeleton of glycolipids; b) types of
sphingoid bases; c) glycosidic bonds

2

Most mammalian glycolipids are -configured with the exception of C24:1--galactosylceramide (1),
which was recently reported by Kain and co-workers (Figure 2).2 Agelasphin-9b (2) is another example of
a glycolipid isolated from a natural source with the galactose unit -linked to the ceramide portion.

Figure 2. Examples of natural -glycolipids
1.1.2 Sulfatides
Sulfatides consist of sulfated galactosylceramides, in which the galactose is sulfated at position 3 and is
linked via a -glycosidic bond to the primary hydroxyl group of a N-acylated D-erythro-sphingosine base,
typically with a C-18 backbone (Figure 3).3

Figure 3. Structures of the glycolipid sulfatide and of the most abundant mammalian fatty acids
Sulfatides display structural variation in the composition of the fatty acid residue that 3rimethyl the amino
group of sphingosine. The alkyl or alkenyl residues are different in lengths, and they can be also
hydroxylated. The variation in structure represents a cell type-specific pattern, which at least in part can
be explained by the different expression of the enzymes involved in sulfatide biosynthesis. The nervonic
acid (C24:1)-containing sulfatide is the most abundant in myelin, while significantly elevated levels of
stearic acid (C18:0)-containing sulfatide are found in the cortical grey matter.4 Mammalian kidney
sulfatides are instead particularly rich in C22:0 acid, which is found in quantities more than 10 times
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higher than those in the brain. On the other hand, mass spectroscopic analyses of pancreatic sulfatides
revealed a high proportion of short chain C-16 fatty acid and no hydroxylated form.5
Several glycolipids and phospholipids derived from mammalian, bacterial, protozoan and plant species
have recently been identified as natural ligands (antigens) for NKT cells.6 Natural killer T (NKT) cells
have been shown by a number of studies to play a protective role against cancers, autoimmune diseases
and infectious diseases.6 The hydrophobic alkyl portions of these glycolipids binds directly to CD1
proteins and position the polar or hydrophilic head groups of bound lipids and glycolipids for highly
specific interactions with T cell antigen receptors. The following introductory sections will include a
background on the roles of CD1 molecules and NKT cells. NKT cells’ activation mechanism and
sulfatides as activators of type II NKT cells will also be highlighted. Lastly, synthetic strategies to access
sulfatides are described.
1.1.3 CD1 Proteins
CD1 proteins are specialized antigen-presenting molecules that directly bind a wide variety of lipids and
present them for T cell recognition at the surface of antigen-presenting cells (APCs) such as dendritic
cells, macrophages, and subsets of B cells. CD1 proteins are homologous to major histocompatibility
complex (MHC) class I proteins. Unlike MHC which binds to an invariant partner, CD1 proteins bind and
present a variety of lipids and glycolipids, both innate (e.g. phospholipids, 7 glycosphingolipids and
sulfoglycolipids8a) and foreign (e.g. mycobacterial)9 to NKT receptors. The human CD1 family is
composed of five nonpolymorphic MHC class I–like glycoproteins (CD1a to CD1e). These proteins can
be classified into two groups based mainly on the homology of nucleotide and amino acid sequences.10
Group 1 consists of CD1a, CD1b, CD1c and CD1e, whereas human CD1d together with the only murine
isoform, mouse CD1d, are members of group 2. Based on mouse(m) CD1d’s crystal structure, its antigen
binding groove is narrow, but deep, when compared with MHC class I and class II peptide-binding
grooves.11 In general, the secondary, tertiary, and quaternary structural units in mCD1d displays similarity
to those of MHC class I and II molecules and related proteins (Figs. 4). The  chain, which is closely
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related to 2-microblobulin (2M), folds into the standard three domains (1, 2, 3). An eight-stranded
antiparallel -pleated sheet with two long antiparallel -helical structures that sit on the top of, and
traverse the -sheet platform forms a binding groove superdomain that constitutes the 1 and 2 domains
(Figure 4). A c-type Ig folds is displayed by 3 and 2M domains.

Figure 4. The mouse CD1d structure a) the ribbon diagram of mouse CD1d with each domain labeled,
with strands in purple and helices in red; b) top view of the ligand binding 1 and  2 domains11a

1.1.4 Natural Killer T (NKT) Cells
Natural killer T (NKT) cells are innate-like T cells that express TCR-αβ chains in addition to the typical
NK cell markers and possess a crucial immunoregulatory role in inflammatory conditions, including
autoimmune diseases, infectious diseases and cancer.12 NKT cells perform a function of traversing
between innate and adaptive immunities.13 Both exogenous and endogenous lipid antigens can be
recognized by NKT cells.14 NKT cells are CD1d-restricted, which means they only recognize lipid
antigens presented by CD1d proteins for their activation. The two main subsets of CD1d-restricted NKT
cells include type I or invariant, NKT cells and type II or diverse NKT cells. Type I NKT cells are the
most common in mice and comprise ~50% of murine intrahepatic lymphocytes.15 Type I NKT cells
express a conserved semi-invariant αβTCR that is encoded predominantly by germ line Vα gene (Vα24 in
humans and Vα14 in mice) and Jα18 gene segments. Type I NKT cells comprise ~0.1–1% of the
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circulating T cells in humans. CD4- and CD4+ type I NKT cells predominantly secrete Th1- and Th2type cytokines, respectively. Extensive research has been conducted on type I NKT cells utilizing a potent
-galactosylceramide, KRN7000 (3) (Figure 5) and its analogs.16

Figure 5. Structure of KRN7000 (3) and sulfatide (4)
Type II NKT cells are more abundant than type I NKT cells in humans, and as in mice, they express
relatively diverse TCR-α- and TCR-β chains. While many ligands that activate type I NKT cells have
been described, few SAR studies have been conducted around ligands that activate type II NKT cells.
Currently, the most widely studied antigen for type II NKT cells is sulfatide (4) (Figure 5).8 Some biases
in TCR chain usage have been described in type II NKT cells. A good example is in mice type II NKT
cells, where they appear to be enriched for particular TCR -chain V segments (namely V3 and V8 for
V8).17 Additionally, the TCRs of sulfatide-reactive type II NKT cells can have a more conserved CDR3
region than type I NKT TCRs.8b Interestingly, a recent study of human sulfatide-reactive type II NKT
cells suggested that this population includes some V1+  T cells. The diverse nature of type II NKT
cells highlights the fact that a great deal needs to be learned about CD1d-restricted antigen specificity and
recognition by type II NKT TCRs. The aim of this work is to design and synthesize unnatural sulfatides to
provide our collaborators with tools to understand the role of the sulfatide-reactive type II NKT cells and
ultimately to harness their activation for therapeutic purposes. In the following section, the mechanism of
NKT cells activation is described.
1.1.5 NKT Cells Activation.
Two important consecutive cellular recognitions are necessary for a glycolipid to promote activation.
First, the glycolipid is recognized by the CD1d protein to form a binary complex. Then, the binary
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complex interacts with the NKT cell receptor (TCR) to form the active ternary complex. The
crystallographic data of the mouse-CD1d/alpha-galactosylceramide analog OCH complex reported by
Sullivan et al18 and of sulfatide-mCD1d reported by Zajonc et al19 have provided useful information that
allowed the study of the stabilizing interactions between the ligand and its host (Figure 6).

Figure 6. Structural features of the mCD1d-glycolipids complex: a) side view of bound glycolipid OCH
(yellow);18 b) bound cis-tetracosenoyl sulfatide (C24:1).19
Hydrogen-bonding between the glycolipid ligand and CD1d plays a crucial role in anchoring the ligand in
a distinct orientation which allows each of the two alkyl chains to be inserted into its respective pocket
(Figure 7). The 2’ and 3’ hydroxyl groups of the galactose head group are stabilized by Asp153 (2helix) of CD1d and the 3-, 4-hydroxyl groups of the phytosphingosine hydrogen bond to Asp80.
Additionally, interaction of the 1-helix (Asp80) with the C3, C4-hydroxyl groups of the sphingosine
backbone leads to a ligand orientation in which the sphingosine chain can only be accommodated in the
F’ pocket and not in the A’ pocket. The A and C (or F) pockets are further stabilized with -helix sheets
via van der Waals interactions. The same hydrogen bonds seen in the CD1d-KRN7000 binary complex
are also observed in CD1d-sulfatide (galactose moiety C2-OH-D153, C1-O’-T156, sphingoid base moiety
C3-OH-D80 and the amide NH-T156) (Figure 7b). Furthermore, sulfatides form three extra H-bonds with
CD1d (C6-OH-R79, sulfate group with Q154, and the carbonyl group of the amide with Met69). The
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hydrogen bond between the sulfate group and the backbone nitrogen of Gln154 is H2O mediated (Figure
7b).

Figure 7. Stereo view of the hydrogen-bond network between CD1d and glycolipid; a) H-bond network
between mCD1d and an -Galcer ligand;18 b) H-bond network between sulfatide and mCD1d19
As shown in figure 6, galactose rings in the binary complex crystal structures are well ordered and extend
above the surfaces of the lipid-binding grooves (pinned down between the -1 and -2 helices of CD1d).
These exposed positions seem suitable for recognition by the NKT TCR leading to the formation of the
ternary complex. Successful formation of the ternary complex activates NKT cells to release different
cytokines, communication devices for immune responses (Figure 8). Depending on their biological
activities, these cytokines can be classified as having T helper 1 (Th1) and T helper 2 (Th2) types of
responses. Th1 cytokines include IFN-IL-2, IL-3 and TNF-; they induce proinflammatory activities, a
defense mechanism for the immune system to fight diseases, such as viral, bacterial, and parasitic
infections. Th1 cytokines have also been shown to have antitumor activity.16 Th2 cytokines include IL-4,
IL-5, IL-10 and IL-13. They are responsible for autoimmuno-regulatory activities, which are relevant for
the treatment of diabetes and other autoimmune conditions. The most studied glycolipids for NKT cell
activation are KRN7000 for type I NKT cells and recently sulfatides for type II NKT cells. In the next
section, sulfatides as activators of type II NKT cells is emphasized.
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Figure 8. Cytokine secretion from NKT cell activation
1.1.6 Sulfatides as Activators of a Subset of Type II NKT Cells
Sulfatides make up to 4-6% of the myelin lipids and are also found in various other tissues, including
membranes in the kidneys, the pancreas, and the gastrointestinal and respiratory tracts.20,21 Sulfatides
participate in intracellular signaling mechanisms and can be presented to the immune system by the CD1
family of antigen-presenting surface proteins to T cells to activate them for cytokine secretion.22 The glycosidic linkage in sulfatides causes their sugar moieties to protrude from the -helices of CD1d. Under
these condition, structural studies showed a diagonal docking mode arising from the interactions of
sulfatides with the TCR’s on the surface of some type II NKT cells found above the A pocket of CD1d.23
In contrast, the -glycosidic bond in KRN7000 causes the sugar moiety to be buried more in the -helices
of CD1d, favoring its presentation to type I NKT cells positioned above the F or C pocket of CD1d in a
parallel docking mode (Figure 9).

9

Figure 9. Overview of the docking orientations: a) type II NKT cell complex with the mCD1d-sulfatide;
b) type I NKT cell complex with mCD1d-KRN7000; c) view looking down showing the orthogonal
docking mode in the type II-sulfatide-CD1d complex; d) view looking down showing the parallel docking
mode in the type I-KRN7000-CD1d complex.23

In spite of the antigen specificity of type II NKT cells being poorly understood, they are clearly distinct
from that of type I NKT cells. Indeed, type II NKT cells are partly defined by their lack of reactivity to
CD1d–KRN7000; instead, some of these cells recognize a range of sulfatides presented by CD1d.24 The
key factors in the understanding of type II NKT cell biology lies in elucidating how their TCRs recognize
CD1d-restricted antigens. This has inspired crystal structure studies of CD1d-sulfatide-type II complexes
to unravel how sulfatides interact with the NKT cells. The crystal structure of sulfatide reactive-TCRs of
type II NKT cells was recently solved using cis-tetracosenoyl sulfatide-CD1d-XV19 TCR complex, in a
study conducted by the group of Rossjohn.23 They showed lack of H-bonding between the sulfate moiety
and any amino acid residues of the TCRs (Figure 10). The only H-bonding interaction observed was
between the C2-OH of the sugar and tryptophan residue W97unlike the KRN7000-type I NKT TCR

10

interaction, which showed a compacted H-bonding interaction of the sugar moiety and TCRs). The
complexes were stabilized, in addition to the C2-OH-W97H-bond, by van der Waal interactions of the
TCRs amino acid residues and the ligands (Figure 10b). Similar results were obtained when the group of
Zajonc solved the structure of sulfatide reactive-TCRs type II NkT cells using lyso-sulfatide (free amine,
has no acyl chain)-CD1d-Hy19.3 TCR complex. From both studies, the lack of an intricate H-bonding
network between the sulfate moieties of sulfatides suggested that other -glycolipids can activate type II
NKT cells. It also validated -GalCer stimulation of XV19 (a sulfatide reactive type II NKT cell) TCR,
although this happens to a lesser extent than with sulfatides. 25

Figure 10. Type II NKT cells TCR interactions with sulfatides; a) XV19 TCR interaction with cistetracosenoyl sulfatide shown in magenta, van der Wall interaction shown in red dashes and H-bonds
shown in black dash;23 b) Hy19.3 TCR interaction with lyso-sulfatide (free amine, has no acyl chain
attached) shown in yellow, H-bond and van der Waal interactions are shown in blue dashes.25

1.1.7 Type II NKT Cell Function in Mice and Humans
Natural killer T cells have potent immunoregulatory functions that determine the outcome of activation of
the immune system, including autoimmunity and response to infections and tumors. Because of this,
research has focused on activation of NKT cells as an approach to the treatment of a variety of
diseases/conditions. Promising developments in the field suggests that NKT cell-directed therapy can be
developed to enhance tumor immunity, prevent autoimmunity and improve vaccines. However in order to
fully explore NKT cells for biological purposes it is imperative for the less characterized type II NKT cell
activation and cytokine secretion mechanism to be understood. For example, type II NKT cells have been
demonstrated to be the innate arm of immunoregulatory T cells; the majority of their function being
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attributed so far to their role in inhibiting the proinflammatory functions of type I NKT cells,
conventional T cells, and dendritic cells.26 The discovery of sulfatide as one of the major antigens for
CD1d-restricted type II NKT cells in mice has been instrumental in the characterization of these cells,
including the TCR repertoire, the crystal structure of the CD1d/lipid/TCR complex, and their function,
even though initial experiments conducted to identify active sulfatides were difficult. This is mainly due
to sulfatide structural similarities which make the isolation of individual species challenging. Early
analyses were performed with a mixture of sulfatides. Modifications in the ceramide moiety can influence
the interactions the ligands have with CD1d and T cell receptors and, consequently, also the type of
responses induced.
In a study carried out by Jahng et al.8a in their effort to find out ligands that can activate type II NKT cells,
a first sulfatide-CD1d complex recognition by type II NKT cells was reported using Hy 19.3 (which is a
subclone of XV19, a sulfatide reactive type II NKT cell). They treated Hy 19.3 with different CD1dglycolipid complexes, including sulfatide mixtures, KRN7000 (-GalCer), -GalCer (-anomer of
KRN7000) and mono-GM1 (with a negatively charged sialic acid instead of sulfate). From this study,
they found out that only the sulfatide mixtures were able to stimulate the secretion of cytokines (IFN-
and IL-4). Later on, Kumar and co-workers demonstrated that the sulfatide active against Hy 19.3 was
lyso-sulfatide 5 (Figure 11).27 Sulfatides, 4, 6 and 7, which were part of the previously analyzed mixture,
were found to be inactive. While working on development of the first CD1d-sulfatide binary complex
(CD1d-sulfatide 7), Wilson and co-workers tested 7 with other sulfatides (its saturated acyl chain version
4, lyso-sulfatide 5 and short chain 6) for cytokine proliferation, and 7 displayed the highest stimulation of
3

H-thymidine (a cell proliferation assay to test the potency of ligands in stimulating lymphocytes)

secretion.19
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Figure 11. Examples of natural sulfatides
Despite the fact that many factors influence glycolipid stimulation of NKT cells, information thus far on
sulfatide activation of type II NKT cells infer the stability of the antigen-NKT cell ternary complex to be
the determining factor for individual sulfatide stimulatory results. 28 Highlighted below is an overview of
different human and murine immune responses in which type II NKT cells have been shown to play a
crucial role.
1.1.7.1 Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS)
Multiple sclerosis is a demyelinating autoimmune disease in which myelin-derived protein antigens are
targets for autoimmune attack by conventional T cells. The CD1-restricted T cells from peripheral blood
lymphocytes (PBL) were found to be activated by several glycolipid components of the myelin sheath,
including sulfatide. An increase in the frequencies of reactive cells in PBL from patients with MS,
suggested that the cells may be involved in the autoimmune reaction of this disease.29 However, in these
studies, it was not addressed whether the sulfatide reactivity of these T cells was restricted by CD1d or by
other human CD1 isoforms that are all known to present sulfatide to T cells.
Subsequently, a study done by Kumar et al. demonstrated that sulfatide was a ligand for a murine type II
NKT hybridoma.12a The infiltration of the CNS during the course of EAE (a murine model for MS) by
sulfatide-specific type II NKT cells, but not type I NKT cells, suggested that sulfatide may act as a selfligand, activating type II NKT cells during this disease. Moreover, sulfatide administration at the time of
induction of EAE leads to decreased IFN- and IL-4 production by pathogenic autoantigen-reactive T
cells and almost completely prevented the disease in WT mice, but not in CD1d-deficient mice.
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1.1.7.2 Type 1 Diabetes
Type 1 diabetes (T1D) results from the T cell-mediated destruction of pancreatic β-cells of the
Langerhans’ islets. Initial work on the non-obese diabetic (NOD) mouse model has established a
protective role of type I NKT cells in T1D.30 Utilizing 24αβ transgenic mice overexpressing a type II
NKT cell TCR on the NOD genetic background, it has been shown that type II NKT cells also have a
disease regulatory function in this model.31 Mice overexpressing type II NKT cells were protected from
disease, and T1D induced by diabetogenic NOD T cells in transfer models was inhibited by 24αβ type II
NKT cells demonstrating a dominant protection. Sulfatide is associated with insulin in the β-cells of
pancreatic islets of Langerhans, suggesting that sulfatide-specific type II NKT cells might be activated by
pancreas-associated sulfatide during the destruction of this tissue. The fact that antibodies to sulfatide are
found in patients with T1D but not in healthy individuals nor in patients with type 2 diabetes, suggests
that sulfatide induces an immune response in this disease.32 A recent work provides data supporting that
sulfatide-reactive type II NKT cells can ameliorate T1D; sulfatide treatment of NOD mice reduced T1D
incidence and islet-specific T cell responses, and further, cells positive for the CD1d-tetramer loaded with
sulfatide were found in pancreas-draining lymph nodes in diabetic mice.33
1.1.7.3 Ulcerative Colitis
Ulcerative colitis is an inflammatory bowel disease characterized by superficial mucosal inflammation
and tissue destruction in the colon associated with a TH2-skewed cytokine profile. A search for NKT
cells in the inflamed tissue of patients with colitis revealed a high frequency of type II NKT cells, and not
type I NKT cells.34 The colitis-associated type II NKT cells produced high amounts of IL-13 upon
activation and were cytotoxic for intestinal epithelial cells. Thus, both murine and human studies suggest
a proinflammatory role for IL-13 producing NKT cells in colitis.
1.1.7.4 Bone Marrow Transfer and Graft-Versus-Host Disease
Bone marrow transplantation is an efficient therapy for some haematological malignancies; however,
graft-versus-host disease (GVHD) is a serious complication that can follow this treatment. Bone marrow,
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together with the liver, is the site where NKT cells are found in the highest proportion among T
lymphocytes. Study of GVHD in mice aiming to elucidate immunoregulatory mechanisms demonstrated
that type II NKT cells in the bone marrow graft could protect the recipient mice from GVHD. Protection
was mediated by type II NKT cell-derived IFN- that induced apoptosis in donor-derived T cells and IL-4
that skewed the immune response to a protective TH2 profile.35 In human bone marrow, the type II NKT
cells (which are more frequent than type I NKT cells) displayed a TH2-biased cytokine profile and
suppressed mixed lymphocyte reactions in vitro.
1.1.7.5 Obesity
Type II NKT cells have been recently implied in diet-induced obesity, in a study conducted using mice
lacking type I NKT cells only, or both type I and type II NKT cells (CD1d-deficient mice). Less body
weight gain and development of hepatosteatosis was observed in high fat diet fed CD1d-deficient mice
compared both to mice lacking type I NKT cells only and to wild-type mice. Further investigation
suggested that type II NKT cells initiated liver and adipose tissue inflammation and aggravated the course
of obesity leading to insulin resistance.36
1.1.7.6 Hepatitis
NKT cells are a target for hepatitis treatment, a disease condition characterized by the presence of
inflammatory cells and tissues in the liver. Type I NKT cells have been shown to mediate concanavalin A
(a letin carbohydrate binding protein) induced experimental hepatitis. Kumar and co-workers have
reported cytokines secreted by type II NKT cells upon sulfatide injection to prevent this type I induced
liver damage.37 The mode of this prevention is through the inactivation of pathogenic type I NKT cells.
1.1.7.7 Other Infectious Diseases
Recent studies have demonstrated that type II NKT cells have a unique role in infections with the parasite
Trypanosoma cruzi38 by promoting an excessive inflammation and mortality, accompanied by decreased
pathogen-specific antibody production. Conversely, type I NKT cells prevented the detrimental effects of
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type II NKT cells, reducing inflammation and improving mortality and antibody titres. In addition, during
murine Schistosoma mansoni infection, type I and type II NKT cells had opposing roles whereby type II
NKT cells skewed the immune response to the parasite towards decreased IFN- production and increased
TH2 cytokine secretion, while type I NKT cells restored the IFN- response.
1.1.7.8 Tumor Immunity
Type I NKT cells have been screened for tumor immunity due to the fact that they can produce cytokines
capable of preventing tumor metastasis in mice. In contrast, sulfatide-reactive type II NKT cells released
cytokines enhance tumor metastasis by suppressing immunosurveillance (the method employed by the
immune system to recognize transformed cells in order to inhibit their growth into neoplastic tissues). 26
Ambrosino et al. evaluated sulfatides’ stimulatory activity in tumor metastasis using three mice
genotypes, J18KO mice (only express type II NKT cells not type I NKT cells), WT mice (contain both
type I and type II NKT cells) and CD1dKO mice (do not express either NKT cells). The J18KO mice
showed augmented tumor metastasis while type I NKT cells prevented metastasis. The CD1dKO mice
showed no response.
1.1.8 Purpose of Study
Sulfatides participate in intracellular signaling mechanisms and are presented to the immune system by
the CD1 family of antigen-presenting surface proteins. Herein we focus on sulfatides that are presented by
CD1d to a subset of Natural Killer T (NKT) cells. While many ligands that activate invariant NKT
(iNKT) cells (or Type I NKT cells) have been described, few SAR studies have been conducted around
sulfatides that activate a subset of Type II NKT cells. With the potential of exploring type II NKT cells
for therapeutic purposes based on their vital role in immune responses, the Howell group has focused on
the preparation of analogues of the natural glycolipid antigens, combining the structural features of
sulfated -GalCer (sulfatide 4) and KRN7000 as shown in figure 12.
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Working with our collaborators at the NIH, biological analysis on sulfatide 7, which possesses a double
bond in its acyl chain, showed it stimulated a higher secretion of both IFN- and IL-4 than sulfatide 4,
which has no double bond in its acyl chain. This outcome suggested that the degree of unsaturation in the
acyl chain could be important in determining the ability of lipids to stimulate type II NKT cells. This
discovery sparked an interest in accessing targets containing double bonds in their acyl chain (Figure 12).
In order to evaluate the effect of a higher degree of unsaturation in the acyl chain, sulfatide 10 with an
extra double bond in its acyl chain was also synthesized. Furthermore, our group prepared analogs 8, 9
and 11, which are phytosphingosine analogs of compounds 4, 7 and 10 respectively. These analogs (8, 9
and 11) were of interest owing to the ability of phytosphingosine-containing -galactosylceramide to
activate type I NKT cells (the natural sulfatides that have been reported to activate type II NKT cells have
sphingosine bases). These analogs possessing a phytosphingosine are important in determining the role of
the sphingosine-phytosphingosine difference in the specificity of these glycolipids for various subsets of
NKT cells.One of my goals was to prepare -sulfatide 12 to probe the effect of a potential -linked
sulfatide impurity that may be present in previously synthesized -sulfatide 7.

Figure 12. Previously synthesized sulfatides
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To further understand the nature of the immune response of sulfatide reactive type II NKT cells, analogs
containing a fluorinated phenyl ring on their acyl chains were synthesized (compound 14 and 15) (Figure
13). These analogs were designed based on KRN7000 analog 13, which was reported to induce Th1 type
response in type I NKT cells. The Th1 bias is attributed to - stacking with aromatic residues in the A’
pocket of CD1d.39 Our goal is to see if the stimulatory activity of analog 13 can be replicated in
corresponding -sulfatides analogs 14 and 15.

Figure 13. KRN7000 analog and unnatural sulfatides targets
Analog 17 shown in Figure 14 was designed based on plakoside A analog 16 of KRN7000 which has
previously been reported to possess strong interaction with CD1d.40 The ternary crystal structure of 16
displayed an increased buried surface area of the sphingoid base.40 It is not clear how such interactions
with CD1d are going to impact the response of type II NKT cells in comparison to type I NKT cells, as
structural information about CD1d/ceramide interactions have not been exploited with sulfatides. Herein
we will focus on the preparation of sulfatides targets 12 and 17 as described in the next section.

Figure 14. Plakoside A analog 16 of KRN7000 and its sulfatide analog target 17
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1.1.9 Synthetic Strategies
A careful analysis of sulfatide structures reveals that their synthesis requires three different aspects: the
preparation of the ceramide acceptor (sphingoid base and acyl chain), the glycosylation reaction with a
suitable galactosyl donor and a regioselective sulfation reaction. The construction of the lipid part and of
the galactosylceramide (GalCer) scaffold are indeed the most challenging tasks during the preparation, as
the sulfation reaction is now well established. Lately, much effort has been focused on the synthesis and
glycosylation of sphingosine and ceramides as a consequence of the extensive studies on the activation of
the immune system mediated by CD1 proteins.41 The following sections will describe approaches utilized
to accomplish the two key steps (glycosylation and sulfation reaction) in the preparation of sulfatides.
1.1.9.1 The Glycosylation Reaction
The formation of the glycosidic bond between a carbohydrate and ceramide or sphingoid base is the key
step in the synthesis of glycosphingolipids. A variety of glycosyl donors have been utilized, including
glycosyl trichloroacetamidates, fluorides, phosphates and sulfides.42 Nevertheless, the glycosylation
reaction is still one of the main challenges in the synthesis, because glycosylations of ceramides are
generally plagued by low yields.43 This problem has been attributed to the low nucleophilicity of
ceramides. Among others, the use of azido-sphingosine instead of ceramides has been applied to
circumvent this challenge (Scheme 1).44

Scheme 1. Glycosylation approaches
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One of the most pertinent factors to consider in glycoconjugate synthesis is the control of stereochemical
outcome in the glycosylation. The strategic choice relies mainly in the type of acceptor used in the
glycosylation, either sphingoid base or ceramide, and in the selection of the proper galactosyl donor. The
formation of the 1,2-cis glycosidic bond (-glycosidic bond) linkages can be achieved by working under
thermodynamic conditions (anomeric effect), in appropriate solvents (ethereal solvent effect),45 and by
using non-participating protecting groups at the C-2 hydroxyl, typically benzyl groups. Solvent
manipulations have been successful in favoring -anomers and have been extensively utilized in the
synthesis of -glycosphingolipids (KRN7000 and analogs).
1,2-trans Glycosidic bonds (-glycosidic bond) can be readily accessed by taking advantage of
neighboring group assistance by ester protecting groups such as O-acetyl or O-benzoyl at C-2 of
galactose. This principle is known as anchimeric assistance, also referred to as neighboring group
participation, and is a common strategy utilized in carbohydrate chemistry to give-selectivity. During
the glycosylation processes, the neighboring acyl group of the donor assists in the departure of an
activated leaving group and subsequently leads to the formation of a more stable dioxolenium ion.
Consequently, the glycosyl acceptor can only attack from the backside to form -glycoside (Figure 15).

Figure 15. Anchimeric assistance to enhance-selectivity
1.1.9.2 The Sulfation Reaction
The presence of the sulfate group at the C3-OH position of the galactose unit is the characterizing element
which differentiates sulfatides from other glycolipids. Therefore, regioselective installation of the sulfate
group at the C3-OH position of the galactose unit is a critical step in sulfatide synthesis. Due to the fact
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that the sulfate moiety is acid sensitive, its installation always takes place in the late stages of the
synthesis.
Traditional methods for regioselective installation of a sulfate moiety relied on protecting group
manipulation strategies. Tanahashi and co-workers demonstrated the synthesis of various sulfatides as
selectin ligands/inhibitors via glycosylation utilizing a ceramide as a glycosyl acceptor, followed by
protecting group manipulation to insert the sulfate group at the C3-OH position (Scheme 2).46 Their
synthetic work involved coupling of trichloroacetimidate donor 18 (prepared using at least three
orthogonal protecting groups) with ceramide acceptor 19 to give 20. Selective removal of the levulinoyl
(Lev) protecting group gave 21. Sulfation of the C3-OH with sulfur trioxide pyridine (Py•SO3) complex,
followed by cleavage of the benzoyl groups, gave the desired sulfatide 22.

Scheme 2. Tanahashi’s synthesis of sulfatide 22
A similar strategy was employed by Marinier et al. in the synthesis of sulfatide 23 utilizing
azidosphingosine (24) as the glycosyl acceptor (Scheme 3).47 Helferich glycosylation conditions were
used to couple the bromo galactose donor 25 with acceptor 24 to give the -glycoside. Global cleavage of
the acetyl and benzoyl protecting groups gave azido-glycolipid 26. Protection of the C3- and C4-cis
hydroxyl groups using 2,2-dimethoxypropane, followed by benzoyl protection of the remaining hydroxyl
groups, gave glycolipid 27. Azide reduction, followed by N-acylation, provided 28. Cleavage of the 2,2dimethoxypropane group, followed by acetate protection of the C4-OH via an orthoester, gave the free
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C3-OH product 29. This compound underwent sulfation with either 22rimethylamine sulfur trioxide
(Me3N•SO3) complex or sulfur trioxide pyridine (Py•SO3) complex to give 30. Removal of all protecting
groups provided the desired product 23.

Scheme 3. Marinier’s synthesis of sulfatide 23
Arguably, the most straightforward and well-established selective sulfation protocol utilizes the treatment
of deprotected galactoside with dibutyltin oxide and the reactive sulfation reagent, sulfur trioxidetrimethylamine complex (Me3N∙SO3). This strategy was first pioneered by Flitsch and co-workers,48 and
it allows for the presence of other common functional groups in the system. The methodology relies on
the almost exclusive formation of the five membered cyclic dibutylstannylene acetal with the C-3 and C-4
cis hydroxyl groups after the addition of dibutyltin oxide to the deprotected galactoside (Figure 16).
Under these conditions, the nucleophilicity of the equatorial 3-OH group is enhanced towards acylation,
alkylation and even silylation. Therefore, the introduction of dibutylstannylene acetal to the reactive
sulfation reagent (Me3N∙SO3) gives almost exclusively the 3-O-sulfated derivative with no sulfation at the
ceramide allylic hydroxyl group. This sulfation protocol is now the most widely used in the synthesis of
sulfatides and is applied here in both syntheses.
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Figure 16. A model of Flitsch’s regioselective sulfation of deprotected galactoside
1.1.10 Summary
Sulfatides are among the most ubiquitous endogenous acidic glycolipids found in mammalian
membranes. They exist in various isoforms with different physicochemical properties. The
immunostimulatory activity of sulfatides has sparked interest in their isolation from human cells and in
the evaluation of their role in type II NKT cell activation as testified by an increasing number of literature
reports. This work focuses on the syntheses of two unnatural sulfatides differing in the sphingoid base to
provide our collaborators at NIH with tools to better understand the role of these sulfatide-reactive type II
NKT cells and, ultimately, to harness their activation for therapeutic applications.
1.2 Results and Discussion
1.2.1 Research Objective
The specific aim of this work was to synthesize two unnatural sulfatides: 1)-sulfatide 12, motivated by
the need to probe the effect of potential-linked sulfatide impurity present in the previously
synthesized-sulfatide 7 and 2) -sulfatide 17 motivated by a highly stimulatory related -linked
plakoside A derivative (16) that showed strong interaction with CD1d.
1.2.2 Synthesis of -Sulfatide 12
The plan to access -linked sulfatide 12 was to utilize azido-sphingosine 31 and 2,3,4,6-tetra-Otetramethylsilyl-,D-galactopyranosyl iodide (32) as the key building blocks in the synthesis. Both 31 and
32 could be obtained from commercially available D-ribo-phytosphingosine 33 and D-galactose
respectively. Condensation of 31 with 32 followed by cleavage of the protecting groups should give
glycoside 34. Reduction of the azide followed by N-acylation with activated cis-15-tetracosenoic fatty
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acid 35 will provide galactosylceramide 36. The key step will be achieved by selective sulfation of the
desired hydroxyl group on the sugar residue of galactosylceramide 36 using the stannylene methodology
described in section 1.1.8.2 to give 3′-sulfated -galactosyl ceramide 12 (Figure 17).

Figure 17. Synthetic strategy to -sulfatide 12
1.2.2.1 Synthesis of Azidosphingosine 31
Azidosphingosine 31 was synthesized from D-ribo-phytosphingosine (33) following a procedure reported
by Kim et al.49 The synthesis commenced with the protection of the amine functional group and the
primary hydroxyl group of D-ribo-phytosphingosine (33). The amine was protected by converting it to the
corresponding azide 37 following a methodology developed by Wong et al.50 The amine-azide
interconversion proceeded via a diazo transfer reaction of the amine with Tf3N, generated in situ from
NaN3 and Tf2O. The primary alcohol was protected selectively as its silyl ether using tertbutyldiphenylsilyl chloride (TBDPSCl) to give diol 38. The free diols in 38 were activated with thionyl
chloride to give the cyclic sulfite, which was oxidized with a catalytic amount of ruthenium (III) chloride
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hydrate (RuCl2•3H2O) to give cyclic sulfate 39. Opening of 39 with tetrabutylammonium iodide (Bu4NI),
followed by 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) promoted elimination, gave a sulfated olefin.
Subsequent hydrolysis with aqueous H2SO4 gave desired allylic alcohol 40 with complete E-selectivity.
The cleavage of the silyl group with tetra-n-butylammonium fluoride (TBAF) furnished the desired
azido-sphingosine acceptor 31 in 65% isolated yield.49

Scheme 4. Synthesis of azido-sphingosine acceptor 31
1.2.2.2 Synthesis of -Glycoside 41
Due to the fact that the formation of the glycosidic bond between a carbohydrate and ceramide or
sphingoid base is the key step in the synthesis of glycosphingolipids, the choice of both glycosyl donor
and acceptor plays a crucial role in determining the stereochemical outcomes. With the aim to achieve selectivity, the glycosylation protocol developed by Gervay-Hague, which potentially provides
straightforward access to -glycosides in high yields and with complete -selectivity was explored.51
According to this procedure, transient TMS-protected glycosyl iodide 32 is reacted with fully
functionalized and unprotected azido-sphingosine 31. TBAI was utilized to enhance in situ anomerization
of -glycosyl iodide 32 to the corresponding -iodide, which is more reactive and which subsequently
undergoes SN2-like displacement, affording -glycosides almost quantitatively. This technology allows
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for the presence of other functional groups such as esters, amides and alkenes. Furthermore, the
trimethylsilyl protecting group is readily removed upon exposure to p-toluenesulfonic acid (PTSA). We
applied this protocol to azido-sphingosine acceptor 31, conducting glycosylation as shown (Scheme 5).
Cleavage of the silyl protecting groups of 42 gave free glycolipid 34 which was then subjected to
trimethylphosphine (Pme3) azide reduction to give free amino-glycolipid 41. This was utilized in the
subsequent N-acylation step without purification.

Scheme 5. Synthesis of -glycoside 41
1.2.2.3 N-Acylation and Selective Sulfation
N-Acylation of 41 with activated cis-15-tetracosenoic acid (35) gave intermediate 36, which was then
subjected to Flitsch’s protocol for regioselective sulfation of the C3-OH of the galactose unit.48 Glycolipid
36 was refluxed with Bu2SnO in MeOH to give cyclic dibutylstannylene acetal 44. Treatment of 44 with
Me3N•SO3 complex provided desired -sulfatide 12 (Scheme 6).
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Scheme 6. Synthesis of -sulfatide 12
1.2.3 Synthesis of -sulfatide 17
Our synthetic plan for the preparation of -sulfatide 17 was to carry out an N-acylation between
sphinganine 45 and activated fatty acid 35, followed by protecting group manipulation to form ceramide
acceptor 46. Sphingoid base 45 could be obtained in eleven total steps from commercially available 1,7heptanediol 49. The glycosylation reaction between galactose unit 47 (obtained in 4 steps from
commercially available D-galactose) with ceramide acceptor 46, followed by global cleavage of all
protecting groups should provide -glycoside 48. A final selective sulfation of the 3-OH of galactose unit
would give the desired -sulfatide 17 (Figure 18).
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Figure 18. Synthetic strategy to -sulfatide 17
1.2.3.1 Synthesis of Sphinganine 45
The synthesis of sphinganine 45 commenced with monobromination of commercially available 1,7heptanediol (49) to give bromo-alcohol 50. Protection of the primary alcohol as its silyl ether gave
compound 51. The subjection of the bromide to Finklestein reaction conditions gave iodide 52 (Scheme
7)
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Scheme 7. Synthesis of iodide 52
Starting with commercially available 1-dodecyne (53), the synthesized iodide 52 was subjected to an
iodide-alkyne coupling reaction mediated by n-butyllithium to give alkyne 54. Hydrogenation under
palladium on carbon catalysis poisoned with traces of lead and quinolone (Lindlar’s catalyst)52 gave the
Z-isomer of alkene 55. Alkene 55 was then subjected to Simmons-Smith cyclopropanation reaction53
conditions using highly inflammable diethyl zinc and diiodomethane in dichloromethane, yielding
cyclopropane 56. Cleavage of the silyl group using TBAF gave alcohol 57 which was then converted to
bromide 58 utilizing Appel’s bromination reaction conditions.54 The bromide was then used in a Grignard
reaction whereby it was reacted with magnesium metal in THF under reflux to form an alkyl magnesium
bromide.55 The resultant Grignard product was immediately reacted with serine derived Weinreb amide
59 to give carbamate protected aminoketone 60. As demonstrated by Hoffman et al., diastereoselective
reduction of aminoketone 60 using lithium tri-tertbutoxyaluminum hydride gave the anti-carbamate
protected amino alcohol 61.55 Cleavage of the t-butyl carbamate using in-situ generated HCl from acetyl
chloride in a mixture of ethanol and ethyl ether gave sphinganine 45 in 54% isolated yield (Scheme 8).
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Scheme 8. Synthesis of sphinganine 45
1.2.3.2 Synthesis of Ceramide Acceptor 46
Having synthesized sphinganine 45, we directed our effort towards the preparation of the appropriate
ceramide acceptor 46 in readiness for the glycosylation reaction. In this synthesis, the choice of hydroxyl
protecting groups is of great significance in order to avoid their cleavage and/or migration. The
sphinganine (45) was first subjected to N-acylation with activated cis-15-tetracosenoic fatty acid 35 to
obtain ceramide 62. The primary alcohol in 62 was then protected using a silyl group while the secondary
alcohol was protected using a benzoyl protecting group to yield compound 64. An attempt to cleave the
silyl group selectively, using tert-butyl ammonium fluoride (TBAF) or using in-situ generated HCl from
acetyl chloride in MeOH/H2O, resulted in the migration of the benzoyl protecting group from the
secondary alcohol to the primary alcohol. To circumvent the benzoyl migration, we decided to employ
pyridinium p-toluenesulfonate (PPTS), a weakly acidic catalyst. To our delight, the reaction gave the
desired ceramide 46 with no migration of the benzoyl group (Scheme 9).
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Scheme 9. Synthesis of benzoyl-protected ceramide acceptor 46
1.2.3.3 Synthesis of Pivaloyl-protected Trichloroacetimidate Sugar 47
Pivaloyl-protected trichloroacetimidate sugar 47 was chosen as the sugar donor because of the successes
reported in the literature in obtaining -selectivity and the ease of activating the trichloroacetimidate
group under mildly acidic conditions.56 Its synthesis, which was carried out by Dr. Stewart K. Richardson
(a senior member of the Howell group), involved an initial global protection of D-galactose 65 to give 66
(Scheme 10).57 Cleavage of the anomeric pivaloyl group can be achieved via a two-step hydrolysis, as
employed by Menger and Mbadugha in the cleavage of an anomeric benzoyl–protected sugar, to give
lactol 67.58 Pentapivaloyl galactose 66 was first treated with HBr (33% in AcOH) to give a bromo sugar,
which was then reacted with Ag2CO3 in aqueous acetone to give lactol 67. Activation of lactol 67 using
trichloroacetonitrile and DBU gave trichloroacetimidate sugar donor 47 (Scheme 10).
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Scheme 10. Synthesis of sugar donor 47
1.2.3.4 Glycosylation and Selective Sulfation
Sugar donor 47 and acceptor 46 were coupled in the presence of BF3•Oet2 as an activator to give
glycolipid 68 along with traces of its -isomer. The -isomer was readily separated via column
chromatography providing -product 68. Global cleavage of all protecting groups of 68 gave the free
glycoside 48, which was then subjected to Flitsch’s protocol for regioselective sulfation of the C3-OH of
the galactose unit to give the desired -sulfatide 17 (scheme 11).

Scheme 11. Synthesis of -sulfatide 17
In summary we have completed the synthesis of two sulfatides (12 and 17). -Sulfatide 12 was prepared
in 14 steps from commercially available phytosphingosine and -sulfatide 17 was prepared in 18 steps
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from commercially available 1,7-heptanediol (49). These compounds have been sent to our collaborators
at the National Cancer Institute for investigation of the role of sulfatide-reactive type II NKT cells for
therapeutic applications.
1.3 Experimental
1.3.1 General Information
All moisture sensitive reactions were run in a flame-dried flask under N2. Tetrahydrofuran (THF) was
dried using a J. C. Meyer Solvent Dispensing System (SDS) and dispensed under N2. All other solvents
were dried over CaH2 or 4 Å molecular sieves. Deuterated chloroform (CDCl3), was dried over 4 Å
molecular sieves. All starting materials and reagents were purchased from commercial sources and used
as received. All 1H NMR experiments were recorded on a 400 MHz spectrometer. All
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C NMR

experiments were recorded at 100 MHz. Chemical shifts () are given in ppm, and coupling constants (J)
are given in Hz. The 7.26 resonance of residual CHCl3 for proton spectra and the 77.23 ppm resonance of
CDCl3 for carbon spectra were used as internal references. High resolution mass spectroscopy (HRMS)
was performed on a TOF instrument with ESI in positive ionization mode.
Unless otherwise stated, reaction progress was monitored by thin layer chromatography (TLC) performed
on glass plates coated with silica gel UV254. Visualization was achieved by ultraviolet light (254 nm),
0.5% KmnO4 in 0.1 M aqueous NaOH solution and/or 5% phosphomolybdic acid in ethanol. Column
chromatography was performed using silica gel, 40 microns flash silica.
1.3.2 Synthesis of -sulfatide 12

(2S,3S,4R)-2-Azidooctadecan-1,3,4-triol (37). TfN3 was freshly prepared prior to the reaction as

follows: DCM (82 mL) was added to a stirred solution of NaN3 (19.7 g, 301 mmol) in H2O (50 mL) at 0
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C, then Tf2O (10.0 mL, 60.2 mmol) was added dropwise over 15 min with vigorous stirring of the

mixture. The flask was left open and the mixture stirred at 0 oC for 2 h. The reaction was stopped by
careful addition of saturated NaHCO3 (150 mL), while stirring until gas evolution ceased. The organic
layer was separated, and the aqueous layer was extracted with DCM (2 x 100 mL). The combined organic
layers were used in the subsequent step. K2CO3 (6.2 g, 45.0 mmol) and CuSO4 (75 mg, 0.30 mmol) in
H2O (100 mL) and a solution of triflyl azide in DCM (∼60 mmol, 300 mL) were added to a stirred
suspension of D-ribo-phytosphingosine (33) (9.6 g, 30.1 mmol) in MeOH (300 mL). Stirring was
continued for 18 h. The reaction was stopped by addition of H2O (400 mL). The organic phase was
separated, and the aqueous layer was extracted with EtOAc (3 x 200 mL). The combined organic extracts
were dried (MgSO4) and then concentrated, after which a white solid was collected. Purification by flash
column chromatography on silica gel (EtOAc/hexane 9:1) provided 37 as white crystals (10.1 g, 97%):49
H NMR (400 MHz, CDCl3/CD3OD 3:1) 3.78 (dd, J = 11.8, 4.3 Hz, 1H), 3.64 (dd, J = 11.7, 5.9 Hz, 1H)
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3.51–3.44 (m, 2H), 3.39 (ddd, J = 5.4, 5.4, 5.4 Hz, 1H), 1.50–1.34 (m, 2H), 1.32–1.05 (m, 24H), 0.72 (t, J
= 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3/CD3OD 3:1) 74.4, 72.0, 63.8, 61.4, 32.1, 31.8, 29.6, 29.3,
25.7, 22.6, 13.9.

(2S,3S,4R)-2-Azido-1-(tert-butyldiphenylsilyloxy)octadecan-3,4-diol

(38).

Dimethylaminopyridine

(DMAP) (0.084 g, 0.69 mmol) was added to a mixture of (2S,3S,4R)-2-azidooctadecan-1,3,4-triol (37)
(4.72 g, 13.7 mmol) and chlorodiphenyl-t-butylsilane (4.53 g, 16.5 mmol) in pyridine (15 mL) and DCM
(70 mL) at 0 oC. The reaction was stirred for 24 h, diluted with EtOAc (50 mL) and washed with brine
(100 mL). The aqueous layer was extracted with EtOAc (2 x 70 mL). The combined organic extracts were
dried (Na2SO4) and concentrated. Purification by flash column chromatography on silica gel
(hexanes/EtOAc 17:3) provided 38 as a pale yellow oil (7.90 g, 98%):49 1H NMR (400 MHz, CDCl3) 
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7.74–7.68 (m, 4H), 7.49–7.38 (m, 6H) 4.05 (dd, J = 11.0, 4.1 Hz, 1H), 3.93 (dd, J = 11.0, 5.8 Hz, 1H),
3.72–3.66 (m, 2H), 3.61–3.55 (m, 1H), 1.61–1.38 (m, 3H), 1.37–1.24 (m, 23H), 1.10 (s, 9H), 0.90 (t, J =
6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3)  135.8, 135.8, 132.8, 132.7, 130.2, 128.1, 74.3, 72.6, 64.4,
63.7, 32.1, 32.0, 29.9, 29.9, 29.8, 29.8, 29.6, 27.0, 25.9, 22.9, 19.3, 14.3.

(2S,4S,5R)-[2-Azido-2-(2,2-dioxo-5-tetradecyl-2λ6-[1,3,2]dioxathiolan-4-yl)ethoxy]-tert-butyldiphenylsilane (39). Et3N (6.29 mL, 45.3 mmol) and thionyl chloride (2.20 mL, 30.2 mmol) were added to a
solution of (2S,3S,4R)-2-azido-1-(tert-butyldiphenylsilyloxy)octadecan-3,4-diol (38) (8.81 g, 15.1 mmol)
in DCM (80 mL) at 0 °C. After 30 min, the reaction mixture was poured into brine (70 mL) and extracted
with EtOAc (3 x 70 mL). The organic extracts were dried (Na2SO4) and concentrated. The crude cyclic
sulfite was dried in vacuo for 3 h and then dissolved in a mixture of CCl4/CH3CN/H2O (102 mL, 1:1:1)
while stirring. RuCl3•3H2O (0.47 g, 2.27 mmol) and NaIO4 (9.69 g, 45.3 mmol) were added to the
resulting solution. After this reaction mixture was stirred at rt for 2 h, it was diluted with EtOAc (100 mL)
and washed with saturated aqueous NaHSO3 (150 mL). The organic layer was dried (Na2SO4) and
concentrated to give 39 as a colorless oil (12.4 g) which was utilized in the subsequent step without
further purification.

(2S,3R,4E)-2-Azido-1-(tert-butyldiphenylsilyoxy)octadec-4-en-3-ol (40). Bu4NI (9.3 g, 28.8 mmol) and
DBU (4.3 mL, 28.8 mmol) were added to a solution of (2S,4S,5R)-[2-azido-2-(2,2-dioxo-5-tetradecyl-2λ6[1,3,2]dioxathiolan-4-yl)ethoxy]-tert-butyldiphenylsilane (39) (12.4 g, 19.2 mmol) in toluene (100 mL).
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The reaction mixture was heated at reflux for 2 h. The reaction was allowed to cool to rt, and a mixture of
conc. H2SO4/H2O/THF (56 mL, 3.4:4.6:48.0) was added while stirring. The mixture was stirred for 1 h at
rt and then diluted with EtOAc (100 mL). It was washed with saturated aqueous NaHCO3 (150 mL) and
brine (150 mL). The organic layer was dried (Na2SO4) and concentrated. Purification by flash column
chromatography on silica gel (hexane/EtOAc 97:3) provided 40 as a colorless oil (5.37 g, 63%):49 1H
NMR (400 MHz, CDCl3) 7.73–7.66 (m, 4H), 7.48–7.38 (m, 6H) 5.75 (ddd, J = 15.4, 6.6, 6.6 Hz, 1H),
5.45 (dd, J = 15.4, 7.2 Hz, 1H), 4.23 (ddd, J = 5.2, 5.2, 5.2 Hz, 1H), 3.83 (dd, J = 10.8, 6.3 Hz, 1H), 3.79
(dd, J = 10.6, 4.6 Hz, 1H), 3.52 (ddd, J = 5.0, 5.0, 5.0 Hz, 1H), 2.12 (d, J = 5.0 Hz, 1H), 2.06–1.98 (m,
2H), 1.37–1.24 (m, 22H), 1.09 (s, 9H), 0.90 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3)  135.8,
135.6, 133.0, 130.1, 128.1, 128.0, 73.0, 67.1, 64.3, 32.5, 32.1, 29.9, 29.8, 29.7, 29.6, 29.4, 29.2, 26.9,
22.9, 19.3, 14.3.

(2S,3R,4E)-2-Azidooctadec-4-ene-1,3-diol (31). TBAF (19.1 mL, 19.1 mmol, 1M in THF) was added to
a solution of (2S,3R,4E)-2-azido-1-(tert-butyldiphenylsilyoxy)octadec-4-en-3-ol (40) (5.37 g, 9.53 mmol)
in THF (47 mL) at rt. The reaction mixture was stirred for 2 h, diluted with H2O (50 mL) and extracted
with EtOAc (3 x 70 mL). The combined organic layers were washed with brine (150 mL), dried (Na 2SO4)
and concentrated. Purification by flash column chromatography on silica gel (hexane/EtOAc 7:3)
provided 31 as a colorless oil (1.88 g, 60%):49 1H NMR (400 MHz, CDCl3) 5.81 (ddd, J = 15.4, 6.7, 6.7
Hz, 1H), 5.52 (dd, J = 15.4, 7.3 Hz, 1H), 4.23 (t, J = 6.4 Hz, 1H), 3.78 (dd, J = 11.8, 4.8 Hz, 1H), 3.75
(dd, J = 11.8, 5.6 Hz, 1H), 3.47 (ddd, J = 5.4, 5.4, 5.4 Hz, 1H), 2.54 (br s, 2H), 2.11–2.00 (m, 2H), 1.42–
1.23 (m, 22H), 0.90 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3):  136.2, 128.2, 73.9, 66.9, 62.7,
32.5, 32.1, 29.9, 29.8, 29.7, 29.5, 29.4, 29.1, 22.9, 14.3.
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(2S,3R,4E)-2-Azido-1-(2,3,4,6-tetra-O-trimethylsilyl-α-D-galactopyranosyloxy)octadec-4-ene-3-ol
(42). TMSI (500 μL, 3.69 mmol) was added to a solution of per-O-silylated sugar (43) (2.00 g, 3.69
mmol) in DCM (20 mL) at 0 °C. The reaction mixture was stirred under N2 for 15 min. Approximately
three quarter of the solvent was removed under reduced pressure, and the glycosyl iodide intermediate
(32) obtained was dissolved in toluene (10 mL) and kept under N2 . In a separate flask, a mixture of
activated 4 Å molecular sieves (1.0 g), n-Bu4NI (3.00 g, 8.1 mmol), i-Pr2Net (1.00 mL, 5.9 mmol), and
(2S,3R,4E)-2-azidooctadec-4-ene-1,3-diol (31) (0.90 g, 2.8 mmol) in toluene (25 mL) was prepared and
stirred under N2 at 50 °C for 30 min. The solution of glycosyl iodide in toluene was then added dropwise
over 20 min to this mixture, and the resulting mixture was stirred overnight. After removal of the solvent
under reduced pressure, DCM (50 mL) and H2O (50 mL) were added, and the phases were separated. The
aqueous layer was extracted with DCM (3 x 40 mL). The combined organic extracts were dried (Na2SO4)
and concentrated. Purification by flash column chromatography on silica gel (hexane/EtOAc 19:1)
provided 42 (single α-anomer) as a colorless oil (1.38 g, 64%): IR (neat) 3427 (br), 2924, 2854, 2098,
1249, 1144, 1103, 1033 cm-1; 1H NMR (400 MHz, CDCl3) 5.80 (ddd, J = 15.4, 6.8, 6.8 Hz, 1H), 5.47
(dd, J = 15.4, 6.4 Hz, 1H), 4.70 (d, J = 3.4 Hz, 1H), 4.46–4.41 (m, 1H), 4.11 (dd, J = 10.4, 2.4 Hz, 1H),
3.93 (dd, J = 9.5, 3.4 Hz, 1H), 3.93–3.89 (m, 1H), 3.85 (dd, J = 9.5, 2.6 Hz, 1H), 3.83–3.76 (m, 2H),
3.69–3.55 (m, 2H), 3.43 (d, J = 8.8 Hz, 1H), 3.09–3.04 (m, 1H), 2.10–2.01 (m, 2H), 1.43–1.34 (m, 2H),
1.33–1.23 (m, 20H), 0.88 (t, J = 6.6 Hz, 3H), 0.16 (s, 9H), 0.14 (s, 9H), 0.14 (s, 9H), 0.13 (s, 9H); 13C
NMR (100 MHz, CDCl3)  134.0, 129.3, 101.1, 74.9, 72.4, 70.6, 69.6, 69.3, 63.1, 61.5, 32.5, 32.1, 29.9,
29.8, 29.7, 29.5, 29.4, 29.2, 22.9, 14.3, 0.8, 0.5, 0.4, 0.3; HRMS (ESI) calcd for C36H78N3O7Si4 (M + H)+
m/z 776.4917, found 776.4923.
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(2S,3R,4E)-2-Azido-1-(α-D-galactopyranosyloxy)octadec-4-ene-3-ol (34). PTSA (20.0 mg, 0.12 mmol)
was added to the solution of (2S,3R,4E)-2-azido-1-(2,3,4,6-tetra-O-trimethylsilyl-α-D-galactopyranosyloxy)octadec-4-ene-3-ol (42) (0.89 g, 1.14 mmol) in MeOH (15 mL), and the mixture was stirred for 5h at
rt. Aqueous NaHCO3 (100 mg, 1.19 mmol) was added and the mixture was filtered. The filtrate was then
concentrated in vacuo. Purification by flash column chromatography on silica gel (DCM/MeOH 9.4:0.6)
provided 34 as a white foam (638 mg, 70%): IR (neat) 3348 (br), 2923, 2853, 1667, 1520, 1464, 1111 cm; H NMR (400 MHz, CDCl3/CH3OD 3:1) 5.79 (ddd, J = 15.4, 6.7, 6.7 Hz, 1H), 5.50 (dd, J = 15.4, 7.3
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Hz, 1H), 4.88 (d, J = 3.4 Hz, 1H), 4.17 (dd, J = 6.9, 6.9 Hz, 1H), 4.02–3.92 (m, 2H), 3.90–3.84 (m, 1H),
3.84–3.72 (m, 4H), 3.66 (dd, J = 10.6, 5.9 Hz, 1H), 3.44–3.37 (m, 1H), 2.10–2.02 (m, 2H), 1.44–1.34 (m,
2H), 1.33–1.22 (m, 20H), 0.87 (t, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3/CH3OD 3:1)  134.9,
128.3, 99.6, 71.6, 70.6, 70.0, 69.8, 68.8, 67.9, 65.2, 61.8, 32.2, 31.8, 29.5, 29.3, 29.2, 29.1, 28.9, 22.5,
13.8; HRMS (ESI) calcd for C24H46N3O7 (M + H)+ m/z 488.3336, found 488.3582.

(2S,3R,4E)-2-Amino-1-(α-D-galactopyranosyloxy)octadec-4-ene-3-ol (41). Pme3 (38.0 μL, 0.36 mmol)
was added to a solution of (2S,3R,4E)-2-azido-1-(α-D-galactopyranosyloxy)octadec-4-ene-3-ol (34) (50
mg, 0.10 mmol) in wet MeOH (2.9 mL) at rt, and the resulting solution was stirred for 2 h. Solvent was
removed under reduced pressure to give a white residue which was then subjected to high vacuum to
remove the Me3PO byproduct. Amine 41 was used in the next step without further purification.
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Succinimidyl (Z)-tetracos-15-enoate (33). N,N-Dicyclohexylcarbodiimide (0.31 g, 1.50 mmol) was
added to a mixture of 15-tetracosenoic acid (43) (0.50 g, 1.36 mmol) and N-hydroxysuccinimide (0.17 g,
1.50 mmol) in EtOAc (50 mL) at 0 °C and stirred at this temperature for 2 h, followed by stirring at 35 °C
for 15 h. The mixture was allowed to cool to rt, filtered through celite and the celite was then washed with
EtOAc (30 mL). The filtrate was concentrated to give 35 as a white solid which was utilized in the next
step without further purification.

(2S,3R,4E)-1-(-D-Galactopyranosyloxy)-2-(N-15Z-tetracosenoylamino)octadec-4-ene-3-ol

(36).

(2S,3R,4E)-2-Amino-1-(α-D-galactopyranosyloxy)octadec-4-ene-3-ol (41) (32 mg, 0.10 mmol) and Et3N
(81μL, 0.58 mmol) were added to a solution of succinimidyl (Z)-tetracos-15-enoate (35) (100 mg, 0.215
mmol) in THF (3 mL) and the solution was stirred at rt for 15 h. The mixture was then concentrated.
Purification by flash column chromatography on silica gel (DCM/MeOH 9.5:0.5) provided 36 as a white
foam (50 mg, 60%): IR (neat) 3397 (br), 2917, 2850, 1708, 1642, 1071, 1029 cm-1; 1H NMR (400 MHz,
CDCl3/CH3OD 3:1) 5.72 (ddd, J = 15.4, 6.7, 6.7 Hz, 1H), 5.44 (dd, J = 15.4, 6.9 Hz, 1H), 5.38–5.28 (m,
2H), 4.87 (d, J = 2.3 Hz, 1H), 4.07 (dd, J = 6.7, 6.7 Hz, 1H), 4.01–3.90 (m, 2H), 3.83–3.67 (m, 7H), 2.18
(t, J = 7.5 Hz, 2H), 2.07–1.97 (m, 6H), 1.64–1.53 (m, 2H), 1.39–1.22 (m, 54H), 0.87 (t, J = 6.4 Hz, 6H);
C NMR (100 MHz, CDCl3/CH3OD 3:1)  174.6, 133.8, 129.5, 129.1, 99.7 (C-1, anomeric carbon),
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71.8, 70.5, 70.0, 69.5, 68.8, 67.2, 61.4, 53.6, 53.5, 36.2, 32.1, 31.6, 29.4, 29.3, 29.2, 29.1, 29.0, 29.0, 26.8,
25.7, 22.3, 13.5; HRMS (ESI) calcd for C48H91NnaO8 (M + Na)+ m/z 832.6642, found 832.6596.
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(2S,3R,4E)-1-(3-O-Sodiumsulfonyl--D-galactopyranosyloxy)-2-(N-15Z-tetracosenoylamino)octadec-4-ene-3-ol (12). (2S,3R,4E)-1-(-D-Galactopyranosyloxy)-2-(N-15Z-tetracosenoylamino)octadec-4ene-3-ol (36) (0.023 g, 0.029 mmol) and Bu2SnO (0.011 g, 0.044 mmol) were stirred in MeOH (1.5 mL)
at reflux under argon for 2h. The solvent was evaporated under reduced pressure, and the
dibutylstannylene complex (44) was treated with Me3N•SO3 (0.010 g, 0.070 mmol) in THF (2 mL) and
stirred for 2 h. The solvent was removed under reduced pressure. The residue was dissolved in
CHCl3/MeOH (2 mL, 1:1), loaded onto a cation-exchange resin column (Dowex 50 x 8 Na+ form, 0.5 x 6
cm), eluted with CHCl3/MeOH (1:1) and concentrated. Purification by flash column chromatography on
silica gel (CHCl3/MeOH 9:1) provided 12 as a white foam (70%, 0.030 g): IR (neat) 3407 (br), 2923,
2852, 1638, 1465, 1214, 1012 cm-1; 1H NMR (500 MHz, CDCl3/CH3OD 3:1) 5.73 (ddd, J = 14.4, 6.6,
6.6 Hz, 1H), 5.43 (dd, J = 15.3, 7.0 Hz, 1H), 5.37–5.29 (m, 2H), 4.91 (d, J = 3.9 Hz, 1H), 4.45 (dd, J =
10.2, 3.1 Hz, 1H), 4.33–4.32 (m, 1H), 4.10 (dd, J = 7.1, 7.1 Hz, 1H), 4.01–3.94 (m, 2H), 3.85–3.69 (m,
5H), 2.18 (dd, J = 7.7 Hz, 2H), 2.05–1.96 (m, 6H), 1.63–1.53 (m, 2H), 1.38–1.22 (m, 54H), 0.86 (t, J =
5.3 Hz, 6H); 13C NMR (125 MHz, CDCl3):  174.9, 134.3, 129.8, 128.9, 99.5, 77.9, 72.0, 70.4, 68.3, 67.6,
66.7, 61.7, 53.5, 36.3, 32.3, 31.8, 31.8, 29.7, 29.6, 29.6, 29.5, 29.5, 29.4, 29.3, 29.3, 29.2, 29.2, 27.1, 25.9,
22.6, 13.9; HRMS (ESI) calcd for C48H90NnaO11S (M  Na) m/z 888.6240, found 888.6238.
1.3.3 Synthesis of -sulfatide 17

7-Bromoheptan-1-ol (50). A mixture of 1,7-heptanediol (49) (20.0 g, 151 mmol) and 48% HBr (aq.)
(18.8 ml, 166 mmol) in toluene (360 ml) was refluxed for 15 h. The mixture was allowed to cool to rt and
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then H2O (150 mL) and EtOAc (150 mL) were added. The organic layer was separated, and the aqueous
layer was extracted with EtOAc (2 x 100 mL). The combined organic extracts were washed with brine,
dried (MgSO4) and concentrated. Purification by flash column chromatography on silica gel
(hexanes/EtOAc 7:3) provided 50 as a colorless oil (25.7 g, 87%): IR (neat) 3324 (br), 2929, 2855, 1460,
1430, 1250, 1053 cm-1; 1H NMR (400 MHz, CDCl3) 3.60 (t, J = 6.6 Hz, 2H), 3.38 (t, J = 6.8 Hz, 2H),
1.83 (br s, 1H), 1.83 (quin, J = 14.1, 6.9 Hz, 2H), 1.54 (quin, J = 13.6, 6.6 Hz, 2H), 1.46–1.37 (m, 2H),
1.37–1.26 (m, 4H); 13C NMR (100 MHz, CDCl3)  62.9, 34.1, 32.8, 32.7, 28.7, 28.2, 25.7; HRMS (ESI)
calcd for C7H16BrO (M + H)+ m/z 195.0385, found 195.0374.

7-Bromo-1-(tert-butyldimethylsilyloxy)heptane (51). Imidazole (10.8 g, 158 mmol) was added over 20
min to a mixture of 7-bromoheptan-1-ol (50) (25.7 g, 132 mmol) and chlorodimethyl-t-butylsilane (23.8
g, 158 mmol) in DCM (660 mL) at 0 °C. After 10 min, the reaction mixture was allowed to warm to rt
and then stirred for 4 h. H2O (200 mL) was added, the organic layer separated, and the aqueous layer was
extracted with DCM (3 x 150 mL). The combined organic extracts were washed with brine (300 mL),
dried (MgSO4) and concentrated. Purification by flash column chromatography on silica gel
(hexanes/EtOAc 49:1) provided 51 as a pale yellow oil (40.0 g, 96%): IR (neat) 2929, 2856, 1471, 1462,
1253, 1096 cm-1; 1H NMR (400 MHz, CDCl3) 3.59 (t, J = 6.5 Hz, 2H), 3.40 (t, J = 6.9 Hz, 2H), 1.85
(quin, J = 14.1, 7.0 Hz, 2H), 1.55–1.47 (m, 2H), 1.46–1.38 (m, 2H), 1.37–1.28 (m, 4H), 0.89 (s, 9H),
0.04 (s, 6H);
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C NMR (100 MHz, CDCl3)  63.4, 34.1, 33.0, 32.9, 28.8, 28.4, 26.2, 25.9, 18.6, 5.1;

HRMS (ESI) calcd for C13H30BrOSi (M + H)+ m/z 309.1249, found 309.1259.

1-(tert-Butyldimethylsilyloxy)-7-iodoheptane (52). 7-Bromo-1-(tert-butyldimethylsilyloxy)heptane (51)
(39.0 g, 126 mmol) was dissolved in dry acetone (428 mL) containing NaI (56.6 g, 378 mmol). The
41

mixture was stirred in the dark for 24 h. The crystallized salts were filtered and washed with petroleum
ether twice. Solvents were evaporated, and Et2O (150 mL) was added to the crude residue. This organic
phase was then washed with H2O (100 mL), and brine (100 mL), dried (MgSO4), and concentrated.
Purification by flash column chromatography on silica gel (hexanes) provided 52 as a pale yellow liquid
(40.0 g, 89%): IR (neat) 2928, 2855, 1470, 1462, 1251, 1097 cm-1; 1H NMR (400 MHz, CDCl3) 3.59 (t,
J = 6.5 Hz, 2H), 3.18 (t, J = 7.0 Hz, 2H), 1.82 (quin, J = 14.2, 7.0 Hz, 2H), 1.55–1.45 (m, 2H), 1.44–1.28
(m, 6H), 0.89 (s, 9H), 0.04 (s, 6H); 13C NMR (100 MHz, CDCl3)  63.3, 33.7, 32.9, 30.7, 28.5, 26.2, 25.8,
18.7, 7.3, 5.1; HRMS (ESI) calcd for C13H30IOSi (M + H)+ m/z 357.1111, found 357.1127.

1-(tert-Butyldimethylsilyloxy)-nonadec-8-yne (54). n-Butyllithium (2.20 g, 35.1 mmol) was added to a
solution of 1-dodecyne (53) (3.90 g, 23.3 mmol) in THF (15 mL) at 0 °C under N2 over a period of 30
min. The reaction was stirred at 0 °C for 20 min. 1-(tert-Butyldimethylsilyloxy)-7-iodoheptane (52) (10.0
g, 28.1 mmol) in HMPA (14.8 mL) was added, and the reaction mixture was allowed to warm to rt and
was stirred for 20 h. The reaction was stopped by the addition of concentrated aqueous NH4Cl (70 mL)
and then Et2O (50 mL). The organic layer was separated and the aqueous layer was extracted with Et2O (3
x 80 mL). The combined organic extracts were washed with brine (150 mL), dried (MgSO4) and
concentrated. Purification by flash column chromatography on silica gel (hexanes/EtOAc 99.75:0.25)
provided 54 as a colorless oil (5.40 g, 59%): IR (neat) 2925, 2854, 1462, 1252, 1098 cm-1; 1H NMR (400
MHz, CDCl3) 3.60 (t, J = 6.6 Hz, 2H), 2.18–2.10 (m, 4H), 1.56–1.42 (m, 6H), 1.42–1.24 (m, 20H),
0.89 (s, 9H), 0.88 (t, J = 7.0 Hz, 3H), 0.05 (s, 6H); 13C NMR (100 MHz, CDCl3)  80.5, 80.4, 63.5, 33.1,
32.1, 29.9, 29.8, 29.8, 29.7, 29.6, 29.4, 29.4, 29.2, 29.1, 26.3, 26.2, 26.0, 22.9, 19.0, 18.6, 14.3, 5.1;
HRMS (ESI) calcd for C25H51Osi (M + H)+ m/z 395.3709, found 395.3710.
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(Z)-1-(tert-Butyldimethylsilyloxy)-nonadec-8-ene (55). A solution of 1-(tert-butyldimethylsilyloxy)nona-dec-8-yne (54) (6.00 g, 15.1 mmol) in hexanes (170 mL) was hydrogenated by stirring in an
atmosphere of hydrogen in the presence of 10 percent palladium on barium sulfate (0.98 g, 0.92 mmol)
and quinolone (2.4 mL). After 12 h of stirring, the mixture was filtered through a pad of celite, the celite
washed with hexanes (50 mL) and the filtrate concentrated. Purification by flash column chromatography
on silica gel (hexanes/EtOAc 99.5:0.5) provided 55 as a colorless oil (3.9 g, 65%): IR (neat) 2923, 2853,
1462, 1253, 1098 cm-1; 1H NMR (400 MHz, CDCl3) 5.41–5.30 (m, 2H), 3.61 (t, J = 6.6 Hz, 2H), 2.07–
1.96 (m, 4H), 1.56–1.47 (m, 2H), 1.38–1.25 (m, 24H), 0.91 (s, 9H), 0.89 (t, J = 7.0 Hz, 3H), 0.05 (s, 6H);
C NMR (100 MHz, CDCl3)  130.2, 130.1, 63.5, 33.2, 32.2, 30.0, 30.0, 29.9, 29.8, 29.6, 29.6, 29.6,
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27.5, 26.2, 26.1, 23.0, 18.6, 14.4, 5.0; HRMS (ESI) calcd for C25H53Osi (M + H)+ m/z 397.3866, found
397.3868.

(8S*,9R*)-1-(tert-Butyldimethylsilyloxy)-8,9-methylenenonadecane (56). Diethylzinc (3.1 mL, 30.6
mmol) was added dropwise to a stirred solution of 2,4,6-tricholorophenol (6.0 g, 30.6 mmol) in DCM
(140 mL) at –40 ºC. The reaction mixture was stirred at this temperature for 15 min. Diodomethane (8.2
g, 30.6 mmol) was then added and the reaction mixture stirred for another 15 min. 1-(tertButyldimethylsilyloxy)-nonadec-8-ene (55) was added and the reaction mixture was allowed to warm to
rt. After 15 h of stirring, the reaction was stopped by dropwise addition of petroleum ether (100 mL) and
10% HCl solution (100 mL). The mixture was extracted with DCM (3 x 150 mL), then the combined
organic extracts were washed with saturated aqueous NaHCO3 (250 mL), saturated aqueous Na2SO3 (200
mL), brine (250 mL), dried (MgSO4) and concentrated. Purification by flash column chromatography on
silica gel (hexanes) provided 56 as a colorless oil (3.4 g, 54%): IR (neat) 2923, 2853, 1462, 1253, 1097
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cm-1; 1H NMR (400 MHz, CDCl3) 3.61 (t, J = 6.6 Hz, 2H), 1.56–1.48 (m, 2H), 1.44–1.25 (m, 26H),
1.19–1.10 (m, 2H), 0.90 (s, 9H), 0.89 (t, J = 7.0 Hz, 3H), 0.67–0.61 (m, 2H), 0.60–0.51 (m, 1H), 0.05 (s,
6H), 0.33 (ddd, J = 5.1, 5.1, 5.1 Hz, 1H); 13C NMR (100 MHz, CDCl3)  63.6, 33.2, 32.2, 30.5, 30.4,
30.0, 30.0, 29.9, 29.8, 29.6, 29.0, 29.0, 26.2, 26.1, 23.0, 18.6, 16.0, 14.4, 11.2, 5.0; HRMS (ESI) calcd
for C26H55Osi (M + H)+ m/z 411.4022, found 411.5027.

(8S*,9R*)-8,9-methylenenonadecan-1-ol (57). A solution of (8S*,9R*)-1-(tert-Butyldimethylsilyloxy)8,9-methylenenonadecane (56) (7.3 g, 17.7 mmol) in DCM (102 mL) was treated with TBAF (36 mL, 1M
soln in THF) at 0 oC. After 15 min, the reaction mixture was allowed to warm to rt. After 5 h, the solution
was concentrated and then DCM (70 mL) was added. The resulting mixture was washed with H 2O (80
mL) and brine (70 mL), dried (MgSO4), filtered and concentrated. Purification by flash column
chromatography on silica gel (hexanes/EtOAc 9:1) provided 57 as a colorless oil (3.5 g, 65%): IR (neat)
3310 (br), 2921, 2852, 1464, 1054, 1020 cm-1; 1H NMR (400 MHz, CDCl3) 3.63 (t, J = 6.6 Hz, 2H),
1.61–1.52 (m, 2H), 1.41–1.22 (m, 26H), 1.17–1.08 (m, 2H), 0.87 (t, J = 6.6 Hz, 3H), 0.68–0.60 (m, 2H),
0.59–0.52 (m, 1H), 0.34 (ddd, J = 5.1, 5.1, 5.1 Hz, 1H); 13C NMR (100 MHz, CDCl3)  63.3, 33.0, 32.1,
30.4, 30.4, 30.0, 29.9, 29.8, 29.7, 29.6, 28.9, 28.9, 26.0, 22.9, 16.0, 14.3, 11.1; HRMS (ESI) calcd for
C20H41O (M + H)+ m/z 297.3157, found 297.3139.

(8S*,9R*)-1-Bromo-8,9-methylenenonadecane (58). Tetrabromomethane (5.84 g, 17.6 mmol) and triphenylphosphine (9.23 g, 35.1 mmol) were added to a solution of (8S*,9R*)-8,9-methylenenonadecan-1ol (57) (3.5 g, 11.7 mmol) in DCM (216 mL) at 0 oC. After 1 h, the reaction mixture was diluted with
petroleum ether (150 mL) and then concentrated. Purification by flash column chromatography on silica
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gel (hexanes) provided 58 as a colorless oil (2.9 g, 69%): IR (neat) 2921, 2852, 1462, 1020 cm-1; 1H NMR
(400 MHz, CDCl3) 3.41 (t, J = 6.9 Hz, 2H), 1.90–1.81 (m, 2H), 1.48–1.23 (m, 26H), 1.18–1.09 (m, 2H),
0.88 (t, J = 6.6 Hz, 3H), 0.69–0.61 (m, 2H), 0.60–0.53 (m, 1H), 0.33 (ddd, J = 5.1, 5.1, 5.1 Hz, 1H); 13C
NMR (100 MHz, CDCl3)  34.2, 33.1, 32.2, 30.4, 30.3, 30.0, 29.9, 29.7, 29.6, 29.1, 29.0, 28.9, 28.4, 22.9,
16.0, 16.0, 14.3, 11.2; HRMS (ESI) calcd for C20H40Br (M + H)+ m/z 359.2313, found 359.2342.

(2S,11S*,12R*)-2-(N-tert-Butyloxycarbonylamino)-1-hydroxy-11,12-methylenedocosan-3-one

(60).

(8S*,9R*)-1-Bromo-8,9-methylenenonadecane (58) (0.94 g, 2.62 mmol), polished magnesium turnings
(82 mg, 3.4 mmols) and THF (7.0 mL) were charged into a flame-dried and N2-flushed round-bottom
flask equipped with a stir-bar and a septum. The mixture was then placed in a pre-heated oil bath at 80 oC
and stirred under reflux. As refluxing started, 2 crystals of iodine were quickly added and the reaction
refluxed for 1 h. This was then left to cool to rt. Weinreb amide (59) (0.47 g, 1.90 mmol) and THF (10
mL) were charged into a separate flame-dried and N2-flushed 50 ml round-bottom flask equipped with a
stir-bar and a septum. The solution was then cooled to –15 oC. Isopropylmagnesium chloride was added
dropwise using a syringe, and the solution was stirred for 15 min. The prepared Grignard reagent was
then transferred via cannula into this solution. The mixture was allowed to warm to rt and was stirred for
20 h. The reaction was stopped by first cooling it to –15 oC, followed by the dropwise addition of conc.
aqueous NH4Cl (20 mL). The biphasic mixture was allowed to warm to rt and was diluted with EtOAc
(50 mL). The organic phase was separated and the aqueous layer extracted with EtOAc (3 x 50 mL). The
combined organic extracts were washed with H2O (100 mL) and brine (100 mL), dried (MgSO4) and then
concentrated. Purification by flash column chromatography on silica gel (hexanes/EtOAc 17:3) provided
60 as a colorless oil (0.40 g, 45%): IR (neat) 3409 (br), 2921, 2852, 1708, 1496, 1456, 1366, 1165 cm-1;
H NMR (400 MHz, CDCl3) 5.63 (br s, 1H), 4.33 (br s, 1H) 3.98–3.86 (m, 2H), 2.65–2.47 (m, 2H),
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1.75–1.05 (m, 39H), 0.87 (t, J = 6.6 Hz, 3H), 0.68–0.59 (m, 2H), 0.59–0.52 (m, 1H), 0.34 (ddd, J = 5.0,
5.0, 5.0 Hz, 1H); 13C NMR (100 MHz, CDCl3)  208.1, 156.2, 80.5, 63.5, 61.8, 40.2, 32.1, 30.4, 30.3,
29.9, 29.9, 29.9, 29.6, 29.6, 29.4, 28.9, 28.9, 28.5, 23.7, 22.9, 16.0, 15.9, 14.3, 11.1; HRMS (ESI) calcd
for C28H54NO4 (M + H)+ m/z 468.4053, found 468.4067.

(2S,3R,11S*,12R*)-2-(N-tert-Butyloxycarbonylamino)-11,12-methylenedocosan-1,3-diol

(61).

A

solution of lithium tri-tert-butoxyaluminohydride (2.08 g, 8.2 mm0l) in EtOH (17 mL) was stirred at –78
o

C

in

a

dry

and

N2-flushed

flask

equipped

with

a

septum.

(2S,11S*,12R*)-2-(N-tert-

Butyloxycarbonylamino)-1-hydroxy-11,12-methylenedocosan-3-one (60) (0.64 g, 1.4 mmol) in EtOH (17
mL) was then added dropwise and the solution stirred at –78 oC for 7 h. The reaction was stopped by the
addition of 10% aqueous citric acid (25 mL); then DCM (25 mL) was added. The mixture was then
allowed to warm to rt and was stirred for 3 h. The organic phase was separated, and the aqueous layer was
extracted with DCM (3 x 80 mL). The combined organic extracts were washed with brine (100 mL), dried
(Na2SO4) and concentrated. Purification by flash column chromatography on silica gel (hexanes/EtOAc
4:1) provided 61 as a colorless oil (0.60 g, 94%): IR (neat) 3409 (br), 2921, 2852, 1169 cm-1; 1H NMR
(400 MHz, CDCl3) 5.41 (d, J = 7.3 Hz, 1H), 4.03–3.93 (m, 1H) 3.83–3.69 (m, 2H), 3.58–3.47 (m, 1H),
2.90–2.60 (m, 2H), 1.70–1.05 (m, 41H), 0.87 (t, J = 6.5 Hz, 3H), 0.68–0.60 (m, 2H), 0.59–0.52 (m, 1H),
0.34 (ddd, J = 5.0, 5.0, 5.0 Hz, 1H); 13C NMR (100 MHz, CDCl3)  156.3, 79.9, 74.6, 62.9, 55.0, 34.7,
32.1, 30.4, 30.4, 29.9, 29.9, 29.9, 29.8, 29.6, 28.9, 28.9, 28.6, 26.2, 22.9, 16.0, 16.0, 14.3, 11.1; HRMS
(ESI) calcd for C28H56NO4 (M + H)+ m/z 470.4209, found 470.4215.
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(2S,3R,11S*,12R*)-2-Amino-11,12-methylenedocosan-1,3-diol (45). Acetyl chloride (4.0 mL, 57
mmol) was added dropwise to a flask containing stirring MeOH (34 mL) at 0 oC. This solution was then
treated with (2S,3R,11S*,12R*)-2-(N-tert-butyloxycarbonylamino)-11,12-methylenedocosan-1,3-diol (61)
(0.60 g, 1.3 mmol) solution in Et2O (34 mL). The resulting mixture was allowed to warm to rt and was
stirred for 15 h. The reaction mixture was cooled to 0 oC and conc. aqueous NH4Cl (50 mL) was added
while stirring. After 15 min, DCM (60 mL) was added and the organic phase separated. The aqueous
layer was extracted with DCM (3 x 40 mL). The combined organic extracts were washed with brine (100
mL), dried (Na2SO4) and concentrated. Purification by flash column chromatography on silica gel
(CH3Cl/MeOH/NH4OH 135:25:4) provided 45 as white foam (0.33 g, 70%): IR (neat) 3349 (br), 2920,
2851, 1464, 1019 cm-1; 1H NMR (400 MHz, CDCl3) 3.78–3.65 (m, 2H), 3.64–3.54 (m, 1H) 2.95–2.70
(m, 1H), 2.27 (br s, 4H), 1.53–1.442 (m, 2H), 1.42–1.22 (m, 28H), 1.19–1.08 (m, 2H) 0.88 (t, J = 6.5 Hz,
3H), 0.69–0.60 (m, 2H), 0.59–0.52 (m, 1H), 0.34 (ddd, J = 5.0, 5.0, 5.0 Hz, 1H); 13C NMR (100 MHz,
CDCl3)  74.8, 63.7, 55.9, 34.6, 34.0, 32.1, 30.4, 29.9, 29.8, 29.6, 28.9, 26.3, 22.9, 19.0, 16.0, 16.0, 14.3,
11,1; HRMS (ESI) calcd for C23H48NO2 (M + H)+ m/z 370.3685, found 370.3709.

(2S,3R,11S*,12R*)-2-(N-15Z-Tetracosenoylamino)-11,12-methylenedocosan-1,3-diol (62). A solution
of succinimidyl (Z)-tetracos-15-enoate (35) (0.25 g, 0.54 mmol) in THF (8 mL) was treated with (2S,3R,)2-amino-11,12-methylenedocosan-1,3-diol (45) (0.12 g, 0.26 mmol) and Et3N (0.2 mL). The reaction was
stirred at rt for 20 h. EtOAc (10 mL) was added to the mixture and then concentrated. Purification by
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flash column chromatography on silica gel (DCM/MeOH 49:1) provided 62 as a white foam (0.24 g,
75%): IR (neat) 3294 (br), 2919, 2851, 1642, 1547, 1461, 1072 cm-1; 1H NMR (400 MHz, CDCl3) 6.39
(d, J = 7.8 Hz, 1H), 5.39–5.29 (m, 2H), 3.99 (dd, J = 11.3, 3.3 Hz, 1H), 3.82 (ddd, J = 7.0, 7.0, 3.4 Hz,
1H), 3.79–3.70 (m, 2H), 2.96 (br s, 1H), 2.83 (br s, 1H), 2.22 (t, J = 7.5 Hz, 2H), 2.07–1.95 (m, 4H),
1.68–1.58 (m, 2H), 1.57–1.48 (m, 2H), 1.40–0.08 (m, 62H), 0.88 (t, J = 6.6 Hz, 6H), 0.68–0.60 (m, 2H),
0.59–0.52 (m, 1H), 0.34 (ddd, J = 5.0, 5.0, 5.0 Hz, 1H); 13C NMR (100 MHz, CDCl3)  173.9, 130.1,
74.4, 62.7, 54.0, 37.1, 34.7, 32.1, 30.4, 30.0, 30.0, 29.9, 29.8, 29.7, 29.6, 29.5, 28.9, 27.4, 26.2, 26.0, 22.9,
16.0, 16.0, 14.3, 11.2; HRMS (ESI) calcd for C47H92NO3 (M + H)+ m/z 718.7077, found 718.7093.

(2S,3R,11S*,12R*)-1-(tert-Butyldiphenylsilyloxy)-2-(N-15Z-tetracosenoylamino)-11,12-methylenedocosan-3-ol (69). Imidazole (0.068 g, 1.0 mmol) was added over 5 min to a solution of
(2S,3R,11S*,12R*)-2-(N-15Z-tetracosenoylamino)-11,12-methylenedocosan-1,3-diol (62) (0.24 g, 0.33
mmol) and chlorodiphenyl-t-butylsilane (0.10 g, 0.365 mmol) in DMF (1 mL) at rt. A catalytic amount of
DMAP was added, and the mixture was stirred for 15 h. H2O (15 mL) was added, and the solution was
extracted with DCM (3 x 20 mL). The combined organic extracts were washed with brine (50 mL), dried
(Na2SO4) and concentrated. Purification by flash column chromatography on silica gel (hexanes/EtOAc
17:3) provided 69 as colorless oil (0.11 g, 36%): IR (neat) 3307 (br), 2922, 2852, 1639, 1427, 1361, 1110
cm-1; 1H NMR (400 MHz, CDCl3) 7.68–7.59 (m, 4H), 7.48–7.35 (m, 6H), 6.23 (d, J = 7.8 Hz, 1H),
5.40–5.30 (m, 2H), 3.99 (dd, J = 10.6, 3.4 Hz, 1H), 3.94–3.86 (m, 1H), 3.84 (dd, J = 10.6, 2.8 Hz, 1H),
3.70–3.58 (m, 1H), 3.19 (d, J = 8.6 Hz, 1H), 2.15 (t, J = 7.4 Hz, 2H), 2.06–1.98 (m, 4H), 1.66–1.57 (m,
2H), 1.55–1.45 (m, 2H), 1.42–1.23 (m, 62H), 1.08 (s, 9H), 0.89 (t, J = 6.5 Hz, 6H), 0.70–0.61 (m, 2H),
0.60–0.53 (m, 1H), 0.32 (ddd, J = 5.0, 5.0, 5.0 Hz, 1H); 13C NMR (100 MHz, CDCl3)  173.2, 135.7,
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135.7, 132.6, 130.3, 130.3, 130.1, 128.1, 74.0, 64.3, 53.6, 37.0, 34.7, 32.1, 30.4, 30.0, 29.9, 29.9, 29.8,
29.8, 29.7, 29.6, 29.6, 29.5, 28.9, 27.4, 27.1, 26.2, 26.0, 22.9, 19.3, 16.0, 14.3, 11.1; HRMS (ESI) calcd
for C63H110NO3Si (M + H)+ m/z 956.8255, found 956.8220.

(2S,3R,11S*,12R*)-1-(tert-Butyldimethylsilyloxy)-2-(N-15Z-tetracosenoylamino)-11,12-methylenedocosan-3-ol (63). Imidazole (49 mg, 0.72 mmol) was added over 5 min to a solution of
(2S,3R,11S*,12R*)-2-(N-15Z-tetracosenoylamino)-11,12-methylenedocosan-1,3-diol (62) (0.17 g, 0.24
mmol) and chlorodimethyl-t-butylsilane (0.043 g, 0.29 mmol) in DCM (6 mL) at 0 °C. After 10 min, the
reaction mixture was allowed to warm to rt and then stirred for 12 h. H2O (10 mL) was added, the organic
layer was separated, and the aqueous layer was extracted with DCM (3 x 20 mL). The combined organic
extracts were washed with brine (40 mL), dried (MgSO4) and concentrated. Purification by flash column
chromatography on silica gel (hexanes/EtOAc 9:1) provided 63 as a colorless oil (156 mg, 78%): IR
(neat) 2921, 2852, 1642, 1463, 1252, 1086 cm-1; 1H NMR (400 MHz, CDCl3) 6.30 (d, J = 7.7 Hz, 1H),
5.39–5.28 (m, 2H), 3.97 (dd, J = 10.2, 2.3 Hz, 1H), 3.88–3.78 (m, 2H), 3.65–3.55 (m, 1H), 3.22 (d, J =
9.5 Hz, 1H), 2.20 (t, J = 7.4 Hz, 2H), 2.05–1.95 (m, 4H) 1.68–1.46 (m, 4H), 1.41–1.21 (m, 62H), 0.89 (s,
9H), 0.87 (t, J = 7.0 Hz, 6H), 0.68–0.59 (m, 2H), 0.58–0.51 (m, 1H), 0.07 (s, 3H), 0.06 (s, 3H), 0.34
(ddd, J = 5.0, 5.0, 5.0 Hz, 1H); 13C NMR (100 MHz, CDCl3)  173.2, 130.1, 74.5, 63.7, 52.8, 37.1, 35.1,
32.1, 30.4, 30.0, 30.0, 29.9, 29.8, 29.7, 29.7, 29.6, 29.5, 28.9, 27.4, 26.2, 26.0, 22.9, 18.3, 16.0, 16.0, 14.3,
11.1, 5.4; HRMS (ESI) calcd for C53H106NO3Si (M + H)+ m/z 832.7897, found 832.7957.
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(2S,3R,11S*,12R*)-3-Benzoyloxy-1-(tert-butyldimethylsilyloxy)-2-(N-15Z-tetracosenoylamino)11,12-methylen-edocosane (64). Benzoyl chloride (0.091 mL, 0.75 mmol) was added dropwise over 5
min to a mixture of (2S,3R,11S*,12R*)-1-(tert-butyldimethylsilyloxy)-2-(N-15Z-tetracosenoylamino)11,12-methylenedocosan-3-ol (63) (156 mg, 0.187 mmol) and a catalytic amount of DMAP in pyridine
(3.7 mL) at 0 oC. The reaction mixture was allowed to warm to rt and stirred for 20 h. H2O (10 mL) was
added, the organic layer separated, and the aqueous layer was extracted with DCM (3 x 15 mL). The
combined organic extracts were washed with brine (40 mL), dried (Na2SO4) and concentrated.
Purification by flash column chromatography on silica gel (hexanes/EtOAc 97.5:2.5) provided 64 as a
brown oil (83 mg, 46%): IR (neat) 2922, 2852, 1720, 1644, 1267, 1174 cm-1; 1H NMR (400 MHz, CDCl3)
8.06–8.01 (m, 2H), 7.56–7.53 (m, 1H), 7.48–7.41 (m, 2H), 5.97 (d, J = 9.2 Hz, 1H), 5.40–5.30 (m, 2H),
5.24–5.17 (m, 1H), 4.36–4.28 (m, 1H), 3.78 (dd, J = 10.3, 2.9 Hz, 1H), 3.63 (dd, J = 10.2, 4.2 Hz, 1H),
2.20 (t, J = 7.4 Hz, 2H), 2.06–1.95 (m, 4H), 1.82–1.70 (m, 2H), 1.69–1.58 (m, 2H), 1.45–1.04 (m, 62H),
0.87 (t, J = 6.4 Hz, 6H), 0.86 (s, 9H), 0.67–0.57 (m, 2H), 0.57–0.50 (m, 1H), 0.02 (s, 3H), 0.03 (s, 3H),
0.36 (ddd, J = 5.0, 5.0, 5.0 Hz, 1H); 13C NMR (100 MHz, CDCl3)  172.8, 166.3, 133.2, 130.5, 130.1,
129.9, 128.6, 74.4, 61.9, 52.3, 37.3, 32.1, 31.9, 30.4, 30.4, 30.0, 30.0, 29.9, 29.8, 29.7, 29.6, 29.6, 29.5,
29.5, 28.9, 28.9, 27.4, 26.0, 25.6, 22.9, 18.4, 16.0, 16.0, 14.3, 11.1, 5.4, 5.5; HRMS (ESI) calcd for
C60H110NO4Si (M + H)+ m/z 936.8193 found 936.8100.
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(2S,3R,11S*,12R*)-3-Benzoyloxy-2-(N-15Z-tetracosenoylamino)-11,12-methylenedocosan-1-ol (46).
Pyridinium p-toluenesulfonate (PPTS) (7 mg, 0.03 mmol) was added to a mixture of (2S,3R,11S*,12R*)3-benzoyloxy-1-(tert-butyldimethylsilyloxy)-2-(N-15Z-tetracosenoylamino)-11,12-methylen-edocosane
(64) (0.083 g, 0.089 mmol) and EtOH/DCM (3 mL, 1:1). The resulting mixture was then placed in a preheated oil bath (55 oC) for 3 h under reflux. The reaction was allowed to cool to rt, Et3N (0.5 mL) was
added, and then the solution was concentrated. Purification by flash column chromatography on silica gel
(hexanes/EtOAc 4:1) provided 46 as a colorless oil (70 mg, 96%): IR (neat) 3287 br, 2922, 2852, 1721,
1649, 1463, 1271 cm-1; 1H NMR (400 MHz, CDCl3) 8.08–8.02 (m, 2H), 7.63–7.57 (m, 1H), 7.50–7.43
(m, 2H), 6.32 (d, J = 8.7 Hz, 1H), 5.40–5.29 (m, 2H), 5.09 (ddd, J = 8.8, 8.8, 3.4 Hz, 1H), 4.23–4.15 (m,
1H), 3.71–3.57 (m, 2H), 3.18 (br s, 1H), 2.22 (t, J = 7.5 Hz, 2H), 2.06–1.95 (m, 4H), 1.89–1.70 (m, 2H),
1.69–1.59 (m, 2H), 1.40–1.05 (m, 62H), 0.88 (t, J = 6.3 Hz, 6H), 0.67–0.57 (m, 2H), 0.53 (ddd, J = 7.6,
7.6, 3.7 Hz, 1H), 0.36 (ddd, J = 5.0, 5.0, 5.0 Hz, 1H);

C NMR (100 MHz, CDCl3)  173.7, 168.0,
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133.8, 130.1, 130.1, 129.5, 128.8, 74.6, 62.1, 53.6, 37.1, 32.1, 31.8, 30.4, 30.3, 30.0, 29.9, 29.9, 29.8,
29.7, 29.6, 29.5, 28.9, 28.9, 27.4, 25.9, 25.9, 22.9, 16.0, 15.9, 14.3, 11.1; HRMS (ESI) calcd for
C54H96NO4 (M + H)+ m/z 822.7328, found 822.7322.

(2S,3R,11S*,12R*)-2-(N-15Z-Tetracosenoylamino)-1-(2,3,4,6-tetra-O-pivaloyl--D-galactopyranosyloxy)-11,12-methylenedocosane (68). (2,3,4,6-Tetra-O-pivaloyl--D-galactopyranosyl)-1-trichloroacetimidate (47) (85 mg, 0.13 mmol) and (2S,3R,11S*,12R*)-3-benzoyloxy-2-(N-15Z-tetracosenoylamino)51

11,12-methylenedocosan-1-ol (46) (0.070 g, 0.086 mmol) were added to dry DCM (1 mL), and the
mixture stirred in the presence of 4Å MS (100 mg) at 0 oC for 10 min. BF3•Oet2 (3.2 µL, 0.021 mmol) in
dry DCM (2 mL) was added dropwise over 10 min. The reaction mixture was then allowed to warm to rt
and stirred for 12 h. The reaction mixture was diluted with petroleum ether (6 mL) and then filtered. The
filtrate was treated with saturated aqueous NaHCO3 (15 mL). The organic layer was separated and the
aqueous phase was extracted with DCM (3 x 15 mL). The combined organic extracts were dried (NaSO4),
filtered and concentrated. Purification by flash column chromatography on silica gel (hexanes/EtOAc 9:1)
provided 68 as a colorless oil (67 mg, 43%): IR (neat) 2923, 2853, 1740, 1276, 1144 cm-1; 1H NMR (400
MHz, CDCl3) 8.05–7.99 (m, 2H), 7.58–7.53 (m, 1H), 7.48–7.41 (m, 2H), 5.92 (d, J = 8.9 Hz, 1H),
5.40–5.29 (m, 3H), 5.26–5.18 (m, 1H), 5.18–5.12 (m, 1H), 5.07 (dd, J = 10.4, 3.2 Hz, 1H), 4.52–4.40 (m,
2H), 4.00 (dd, J = 10.0, 4.0 Hz, 1H), 3.91–3.80 (m, 3H), 3.64 (dd, J = 9.9, 3.9 Hz, 1H), 2.15 (t, J = 7.6
Hz, 2H), 2.05–1.95 (m, 4H), 1.80–1.52 (m, 4H), 1.44–1.00 (m, 98H), 0.87 (t, J = 6.4 Hz, 6H), 0.66–0.56
(m, 2H), 0.53 (ddd, J = 7.7, 7.7, 3.8 Hz, 1H), 0.36 (ddd, J = 5.0, 5.0, 5.0 Hz, 1H); 13C NMR (100 MHz,
CDCl3)  177.9, 177.5, 177.0, 177.0, 173.0, 166.0, 133.2, 130.4, 130.1, 129.9, 128.7, 101.1, 74.2, 71.2,
71.0, 69.1, 67.6, 66.7, 61.0, 50.8, 39.3, 39.0, 39.0, 38.9, 37.1, 32.1, 31.7, 30.4, 30.4, 30.0, 30.0, 29.9, 29.8,
29.7, 29.6, 29.6, 29.5, 28.9, 27.4, 27.4, 27.3, 27.3, 25.9, 25.5, 22.9, 16.0, 15.9, 14.3, 11.1; HRMS (ESI)
calcd for C80H137NnaO13 (M + Na)+ m/z 1342.9977, found 1342.9890.

(2S,3R,11S*,12R*)-1-(-D-Galactopyranosyloxy)-2-(N-15Z-tetracosenoylamino)-11,12-methylenedocosan-3-ol (48). NaOMe (0.012 g, 0.224 mmol) was added to a solution of (2S,3R,11S*,12R*)-2-(N-15Ztetracosenoylamino)-1-(2,3,4,6-tetra-O-pivaloyl--D-galactopyranosyl-oxy)-11,12-methylenedocosa-ne
(68) (0.049 g, 0.037 mmol) in a solution of DCM/MeOH (0.6 mL, 1:1). The solution was stirred at rt for 1
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h and then neutralized to pH 2 with dowex (H+ resin). The mixture was filtered through a pad of celite,
and the celite was washed with a 1:1 mixture of CHCl3 and MeOH (15 mL) and then concentrated.
Purification by flash column chromatography on silica gel (DCM/MeOH 23:2) provided 48 as a white
foam (27 mg, 82%): IR (neat) 3332 (br), 2922, 2852, 1649, 1458, 1021 cm-1; 1H NMR (400 MHz,
CDCl3/CD3OD 3:1) 7.54 (d, J = 9.1 Hz, 1H), 5.35–5.25 (m, 2H), 4.20–4.14 (m, 2H), 3.95–3.87 (m, 1H),
3.86–3.81 (m, 1H), 3.77 (dd, J = 11.6, 6.7 Hz, 1H), 3.70 (dd, J = 11.6, 5.0 Hz, 1H), 3.61–3.43 (m, 5H),
2.17 (t, J = 7.3 Hz, 2H), 2.04–1.92 (m, 4H), 1.65–1.45 (m, 4H), 1.42–1.05 (m, 62H), 0.85 (t, J = 6.3 Hz,
6H), 0.66–0.57 (m, 2H), 0.56–0.49 (m, 1H), 0.37 (ddd, J = 4.8, 4.8, 4.8 Hz, 1H); 13C NMR (100 MHz,
CDCl3/CD3OD 3:1)  174.5, 129.6, 103.5, 74.9, 73.2, 71.2, 70.6, 68.8, 68.7, 61.2, 53.2, 36.2, 33.5, 31.7,
30.0, 30.0, 29.5, 29.3, 29.3, 29.2, 29.1, 29.1, 29.0, 28.9, 28.5, 26.9, 25.8, 25.7, 22.4,15.5, 13.6, 10.6;
HRMS (ESI) calcd for C53H101NnaO8 (M + Na)+ m/z 902.7414, found 902.7250.

(2S,3R,11S*,12R*)-1-(3-O-Sodiumsulfonyl--D-galactopyranosyloxy)-2-(N-15Z-tetracosenoylamino)-11,12-methylenedocosan-3-ol

(17).

(2S,3R,11S*,12R*)-1-(-D-Galactopyranosyloxy)-2-(N-15Z-

tetracosenoylamino)-11,12-methylenedocosan-3-ol (48) (0.024 g, 0.029 mmol) and Bu2SnO (0.011 g,
0.045 mmol) were stirred in MeOH (1.5 mL) at reflux under N2 for 2h. The solvent was evaporated under
reduced pressure, and the dibutylstannylene complex was treated with Me3N·SO3 (0.009 g, 0.062 mmol)
in THF (2 mL) with stirring for 2 h. The solvent was removed under reduced pressure, and the residue
was then dissolved in CHCl3/MeOH (2 mL, 1:1), loaded onto a cation-exchange resin column (Dowex 50
x 8 Na+ form, 0.5 x 6 cm), eluted with CHCl3/MeOH (1:1) and concentrated. Purification by flash column
chromatography on silica gel (CH2Cl2/MeOH 9:1) provided -sulfatide 17 as a white foam (19 mg, 71%):
IR (neat) 3379 (br), 2923, 2853, 2495 (br), 2246, 2137, 2072, 1627, 1463, 1221, 1120 cm-1; 1H NMR (400
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MHz, CDCl3/CD3OD 3:1) 7.55 (d, J = 9.1 Hz, 1H), 5.35–5.24 (m, 2H), 4.29 (d, J = 7.7 Hz, 1H), 4.26–
4.20 (m, 2H), 3.95–3.85 (m, 1H), 3.81–3.66 (m, 4H), 3.60–3.50 (m, 3H), 2.17 (t, J = 7.4 Hz, 2H), 2.04–
1.90 (m, 4H), 1.64–1.44 (m, 4H), 1.39–1.05 (m, 62H), 0.84 (t, J = 6.5 Hz, 6H), 0.65–0.56 (m, 2H), 0.52
(ddd, J = 7.6, 7.6, 3.8 Hz, 1H), 0.38 (ddd, J = 5.0, 5.0, 5.0 Hz, 1H); 13C NMR (100 MHz, CDCl3/CD3OD
3:1)  174.8, 129.8, 103.2, 79.9, 74.4, 70.8, 69.3, 69.1, 67.5, 61.4, 54.7, 53.3, 36.4, 33.7, 31.8, 30.1, 30.1,
29.6, 29.6, 29.5, 29.4, 29.3, 29.2, 28.6, 27.1, 25.9, 25.8, 22.5, 15.6, 13.8, 10.7; HRMS (ESI) calcd for
C53H100NnaO11S (M + Na)+ m/z 958.7019, found 958.6970.

54

1.4 References
1. Degroote, S.; Wolthoorn, J.; van Meer, G. Semin. Cell Dev. Biol. 2004, 15, 375.
2. Kain, L.; Webb, B.; Anderson, B. L.; Deng, S.; Holt, M.; Costanzo, A.; Zhao, M.; Self, K.;
Teyton, A.; Everett, C.; Kronenberg, M.; Zajonc, D. M.; Bendelac, A.; Savage, P. B.; Teyton, L.
Immunity 2014, 41, 543.
3. Ishizuka, I. Prog. Lipid Res. 1997, 36, 245.
4. Isaac, G.; Pernber, Z.; Gieselmann, V.; Hansson, E.; Bergquist, J.; Månsson, J. E. FEBS J. 2006,
273, 1782.
5. Fredman, P.; Mânsson, J. E.; Rynmark, B. M.; Josefsen, K.; Ekblond, A.; Halldner, L.; Osterbye,
T.; Horn, T.; Bushard, K. Glycobiology 2000, 10, 39.
6. Tsuji, M. Cell Mol. Life Sci. 2006, 63, 1889.
7. Giabbai, B.; Sidobre, S.; Cripsin, M. D. M.; Sanchez-Ruiz, Y.; Bachi, A.; Kronenberg, M.;
Wilson, I. A.; Degano, M. J. Immunol. 2005, 175, 977.
8. a) Jahng, A.; Maricic, I.; Aguilera, C.; Cardell, S.; Halder, R. C.; Kumar, V. J. Exp. Med. 2004,
199, 947; b) Arrenberg, P.; Halder, R. C.; Dai, Y.; Maricic, I.; Kumar, V. Proc. Natl. Acad. Sci.
USA 2010, 107, 10984.
9. Wu, D.; Xin, G.-W.; Poles, M. A.; Horowitz, A.; Kinjo, Y.; Sullivan, B.; Bodmer-Narkevitch, V.;
Plettenburg, O.; Kronenberg, M.; Tsuji, M.; Ho, D. D.; Wong, C,-H. Proc. Natl. Acad. Sci. USA
2005, 102, 1351.
10. Calabi, F.; Jarvis, J. M.; Martin, L.; Milstein, C. Eur. J. Immunol. 1989, 19, 285.
11. Zeng, Z.-H.; Castaño, A. R.; Segelke, B. W.; Stura, E. A.; Peterson, P. A.; Wilson, I. A. Science
1997, 277, 339.
12. (a) Arrenberg, P.; Halder, R. C.; Kumar, V. J. Cell Physiol. 2009, 218, 246; (b) Kumar, V.;
Delovitch, T. L. Immunology 2014, 142, 321; (c) Rhost, S.; Sedimbi, S.; Kadri, N.; Cardell, S. L.
J. Immunol. 2012, 76, 246.
13. Taniguchi, M.; Seino, K.; Nakayama, T. Nat. Immunol. 2003, 4, 1164.
55

14. (a) Bendelac, A.; Savage, P. B.; Teyton, L. Annu. Rev. Immunol. 2007, 25, 297; (b) Godfrey, D.
I.; Stankovic, S.; Baxter, A. G. Nat. Immunol. 2010, 11, 197; (c) Brigl, M.; Brenner, M. B. Annu.
Rev. Immunol. 2004, 22, 817.
15. Benlagha, K.; Weiss, A.; Beavis, A.; Teyton, L.; Bendelac, A. J. Exp. Med. 2000, 191, 1895.
16. Terabe, M.; Berzofsky, J. A. Trends Immunol. 2005, 175, 977.
17. Park, S,-H.; Weiss, A.; Benlagha, K.; Kyin, T.; Teyton, L.; Bendelac, A. J. Exp. Med. 2001, 193,
893.
18. Sullivan, B. A.; Nagaraja, N. A.; Wingender, G.; Wang, J.; Scott, I.; Tsuji, M.; Franck, R. W.
Porcelli, S. A.; Zajonc, D. M.; Kronenberg, M. J. Immunol. 2010, 184, 141.
19. Zajonc, D. M.; Maricic, I.; Wu, D.; Halder, R. C.; Roy, K.; Wong, C.-H.; Kumar, V.; Wilson, I.
A. J. Exp. Med. 2005, 202, 1517.
20. Blix, G. Hoppe-Seyler’s Zeitschriff Fur Physiologische 1933, 219, 82.
21. Lingwood, C. A.; Hay, G.; Schachter, H. Can. J. Biochem. 1981, 59, 556.
22. Shamshiev, A.; Gober, H.-J.; Donda, A.; Mazorra, Z.; Mori, L.; De Libero, G. J. Exp. Med. 2002,
195, 1013.
23. Patel, O.; Pellicci, D. G.; Gras, S.; Sandoval-Romero, M. L.; Uldrich, A. P.; Mallevaey, T.;
Clarke, A. J.; Le Nours, J.; Theodossis, A.; Cardell, S. L.; Gapin, L.; Godfrey, D. I.; Rossjohn, J.
Nat. Immunol. 2012, 13, 857.
24. Godfrey, D. I.; MacDonald, H. R.; Kronenberg, M.; Smyth, M. J.; Van Kaer, L. Nat. Rev.
Immunol. 2004, 4, 231.
25. Girardi, E.; Maricic, I.; Wang, J.; Mac, T.-T.; Iyer, P.; Kumar, V.; Zajonc, D. M. Nat. Immunol.
2012, 13, 851.
26. Ambrosino, E.; Terabe, M.; Halder, R. C.; Peng, J.; Takaku, S.; Miyake, S.; Yamamura, T.;
Kumar, V.; Berzofsky, J. A. J. Immunol. 2007, 179, 5126.
27. Roy, K. C.; Maricic, I.; Khurana, A.; Smith, T. R. F.; Halder, R. C.; Kumar, V. J. Immunol. 2008,
180, 2942.
56

28. Duarte, N.; Stenström, M.; Campino, S.; Bergman, M.-L.; Lundholm, M.; Holmberg, D.; Cardell,
S. L. J. Immunol. 2004, 173, 3112.
29. Shamshiev, A.; Donda, A.; Carena, I.; Mori, L.; Kappos, L.; De Libero, G. Eur. J. Immunol.
1999, 29, 1667.
30. Lehuen, A.; Diana, J.; Zaccone, P.; Cooke, A. Nat. Rev. Immunol. 2010, 10, 501.
31. Skold, M.; Faizunnessa, N. N.; Wang, C. R.; Cardell, S. J. Immunol. 2000, 165, 168.
32. Andersson, K.; Buschard, K.; Fredman, P.; Kaas, A.; Lidström, A.-M.; Madsbad, S.; Mortensen,
H.; Mansson, J.-E. Autoimmunity 2002, 35, 463.
33. Subramanian, L.; Blumenfeld, H.; Tohn, R.; Ly, D.; Aguilera, C.; Maricic, I.; Mansson, J.-E.;
Buschard, K.; Kumar, V.; Delovitch, T. L. PloS One 2012, 7, e37771.
34. Fuss, I. J.; Heller, F.; Boirivant, M.; Leon, F.; Yoshida, M.; Fichtner-Feigl, S.; Yang, Z.; Exley,
M.; Kitani, A.; Blumberg, R. S.; Mannon, P.; Strober, W. J. Clin. Invest. 2004, 113, 1490.
35. Pillai, A. B.; George, T. I.; Dutt, S.; Teo, P.; Strober, S. J. Immunol. 2007, 178, 6242.
36. Satoh, M.; Andoh, Y.; Clingan, C. S.; Ogura, H.; Fujii, S.; Eshima, K.; Nakayama, T.; Taniguchi,
M.; Hirata, N.; Ishimori, N.; Tsutsui, H.; Onoé, K.; Iwabuchi, K. PloS One 2012, 7, e30568.
37. Halder, R. C.; Aguielera, C.; Maricic, I.; Kumar, V. J. Clin. Invest. 2007, 117, 2302.
38. Baron, J. L.; Gardiner, L.; Nishimura, S.; Shinkai, K.; Locksley, R.; Ganem, D. Immunity 2002,
16, 583.
39. Li, X.; Fujio, M.; Imamura, M.; Wu, D.; Vasan, S.; Wong, C-H.; Ho, D. D.; Tsuji, M. Proc. Natl.
Acad. Sci. USA 2010, 107, 13010.
40. Tyznik, A. J.; Farber, E.; Girardi, E.; Birkholz, A.; Li, Y.; Chitale, S.; So, R.; Arora, P.; Khurana,
A.; Porcelli, S. A.; Zajonc, D. M.; Kronenberg, M.; Howell, A. R. Chem. Biol. 2011, 18, 1620.
41. Banchet-Cadeddu, A.; Hénon, E.; Dauchez, M.; Renault, J.-H.; Monneaux, F.; Haudrechy, A.
Org. Biomol. Chem. 2011, 9, 3080.
42. Juang, K.-H.; Schmidt, R. R. CRC Press: Sheffield 1999, 208.

57

43. (a) Martin, T. J.; Schimidt, R. R. Tetrahedron Lett. 1992, 33, 6123; (b) Schmidt, R. R.;
Zimmermann, P. Angew. Chem. Int. Ed. 1986, 27, 481.
44. Du, W.; Gervay-Hague, J. Org. Lett. 2005, 7, 2063.
45. For a general review about O-glycosylation see: (a) Pellissier, H. Tetrahedron 2005, 61, 2947; (b)
Demchenko, A. V. Synlett 2003, 1225.
46. Tanahashi, E.; Murase, K.; Shibuya, M.; Igarashi, Y.; Ishida, H.; Hasegawa, A.; Kiso, M. J.
Carbohydr. Chem. 1997, 16, 831.
47. Marinier, A.; Martel, A.; Banville, J.; Bachand, C.; Remillard, R.; Lapointe, P.; Turmel, B.;
Menard, M.; Harte, J. W. E.; Wright, J. J.; Todderud, G.; Tramposch, K. M.; Bajorath, J.;
Hollenbaugh, D.; Aruffo, A. J. Med. Chem. 1997, 40, 3234.
48. Guilbert, B.; Davis, N. J.; Pearce, M.; Aplin, R. T.; Flitsch, S. L. Tetrahedron: Asymmetry 1994,
5, 2163.
49. Kim, S.; Lee, S.; Lee, T.; Ko, H.; Kim, D. J. Org. Chem. 2006, 71, 8661.
50. Alper, P. B.; Hung, S.-C.; Wong, C.-H. Tetrahedron Lett. 1996, 37, 6029.
51. Schombs, M.; Park, F. E.; Du, W.; Kulkarni, S. S.; Gervay-Hague, J. J. Org. Chem. 2010, 75,
4891.
52. Lindlar, H.; Dubuis, R. Org. Synth. 1966, 46, 89.
53. (a) Simmons, H. E.; Smith, R. D. J. Am. Chem. Soc. 1958, 80, 5323; (b) Simmons, H. E.; Smith,
R. D. J. Am. Chem. Soc. 1959, 81, 4256.
54. Appel, R. Angew. Chem. Int. Ed. 1975, 14, 801.
55. (a) Hoffman, R. V.; Maslouh, N.; Cervantes-Lee, F. J. Org. Chem. 2002, 67, 1045; (b) So, R. C.;
Ndonye, R.; Izmirian, D. P.; Richardson, S. K. Howell, A. R. J. Org. Chem. 2004, 69, 3233.
56. Schmidt, R. R.; Stumpp, M. Liebigs Ann. Chem. 1983, 1249.
57. Kunz, H.; Harreus, A. Liebigs Ann. Chem. 1982, 41.
58. Mbadugha, B. N. A.; Menger, F. M. Org. Lett. 2003, 5, 4041.

58

Chapter 2

Synthesis of Palmostatin M-derived Probes
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2.1 Introduction
One of the major foci of research in the Howell group is exploiting the reactivity of architecturally
strained heterocycles such as -lactones (oxetan-2-one). The interest in -lactones arises from the fact
that they are present in a number of biologically active natural products and pharmaceutical agents.1
Additionally, their versatile reactive nature, coupled with the unusual structural features of this species,
makes them useful synthetic intermediates for transformations to more advanced structures.2,3
Herein, we describe the utilization of -methylene--lactones in transition metal-catalyzed
transformations to access -lactones that are of importance in synthetic and medicinal chemistry. Two
successful transformations include: (a) olefin cross metathesis (CM) of -methylene--lactones coupled
with stereoselective reductions and (b) Rh-catalyzed conjugate addition of aryl boronic acids to methylene--lactones. This work targets the discovery of novel -lactone inhibitors of NRas
palmitoylation. The following introductory sections will include a general background on -lactones as
biologically active compounds and as intermediates in organic synthesis. We will particularly focus on
reactivities of -lactones and their biological relevance. Recent transformations involving-methylene-lactones are emphasized in the later sections.
2.1.1 -Lactones in Natural Products
Over the last four decades a notable amount of natural product possessing oxetan-2-one ring with
interesting biological activity have been recognized. For example, lipstatin (70) (isolated from
Streptomyces toxytricini)4,5 and its crystalline, non-natural derivative, tetrahydrolipstatin (THL) (71), are
known to be potent and irreversible pancreatic lipase inhibitors.6,7,8 Esterastin (72) (first isolated from
Streptomyces lavendulae MD4-C1)9,10 is an oxetan-2-one closely related to lipstatin. Esterastin acts as a
pancreatic lipase inhibitor but is less efficient than lipstatin and hence has received less attention.
Ebelactones A (73) and B (74) (both isolated from Streptomyces aburaviensis MG7-G1) were reported to
display inhibition of N-formylmethionine aminopeptidases located on the cellular membrane of various
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kinds of animals cells.11 Antibiotic 1233A (75), which was first isolated from Cephalosporium sp, has
been shown to inhibit 3-hydroxy-3-methylglutaryl coenzyme A synthase (HMG-CoA synthase), a key
regulatory enzyme in the cholesterol biosynthetic pathway.12,13,14 Obafluorin (76), isolated from
Pseudomonas sp. SC 11,637, is known to display weak antibacterial activity (Figure 19).15

Figure 19. -Lactone-containing natural products
The presence of the oxetan-2-one ring in these compounds is significant since often the ring is essential to
the biological activity of the molecule. A good example is displayed by THL, an irreversible pancreatic
lipase inhibitor. The purpose of pancreatic lipase is to cleave free fatty acids from their triglyceride
precursors and facilitate their subsequent absorption by the organism. For these reasons, the inhibition of
this enzyme should allow dietary fat to pass into the gut without being absorbed; hence making THL
promising candidate for obesity control. THL’s mechanism of action involves an irreversible
transesterification of the of oxetan-2-one ring by the hydroxyl group of serine 152 in pancreatic lipase,
thereby inhibiting the enzyme (Figure 20).16,17 Thus, the strain associated with -lactone scaffold plays an
important role in enhancing susceptibility to nucleophilic attack. This property results in easy irreversible
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acylation of enzymes which prove therapeutically useful. The following section describes the general
reactivity of -lactones.

Figure 20. Acylation of enzymes
2.1.2 General Reactivity of -Lactones
The strained nature of -lactones has presented opportunities for the invention of novel transformations.
These include: (a) rearrangement leading to ring expansion (b) electrophilic reactions of -lactone
enolates and (c) nucleophilic ring opening to obtain 1,3-functionalized acyclic products (Figure 21).

Figure 21. Primary reactivity modes of -lactones
2.1.2.1 Lewis Acid Promoted Rearrangement
Treatment of -lactones with various Lewis acids can lead to dyotropic rearrangement (a transformation
in which two-bonds simultaneously migrate intramolecularly).18 This concerted process leads to ring
expansion from four-membered lactones to five-membered lactones through the antiperiplanar
transposition of the CO bond and the neighboring CY bond (Scheme 12a). Lewis acids that promote
this process include MgBr2, MgCl2, TiCl4, Ti(OiPr)4, BF3, FeBr3, AlBr3, SnCl4, ZnCl2, and Cu(acac)2.19 βLactones

bearing

neighboring

benzyl

ethers
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transacylation/debenzylation sequence in the presence of BF3, BCl3, or FeCl3 (Scheme 12b).20 Recent
studies have demonstrated the extension of rearrangement process to β-lactones with pendant silyl ethers
(Scheme 12c).21 ,-Unsaturated acids can also be accessed via dyotropic rearrangements.22

Scheme 12. Lewis acid promoted rearrangements; a) dyotropic rearrangements; b) ring expansion via a
transacylation/debenzylation sequence; c) rearrangement of β-lactones with pendant silyl ethers

2.1.2.2 Reaction with Electrophiles
-Lactones can be deprotonated at low temperature (–78 °C) by lithium diisopropylamide (LDA) in
THF.23 The formed enolates were found to be stable at such a temperature and reacted with various
electrophiles including alkyl, allyl and propargyl halides, aldehydes, dimethyl maleate and
phenylisothiocyanate. The attack usually takes place opposite to the-substituent for steric reasons, thus
allowing control of asymmetric centers (diastereoselectivity) in a single operation (Scheme 13). Lithium
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enolates of -substituted -lactones were found to be stable and reacted with electrophiles smoothly. On
the contrary, alkylation of -lactone enolates without -substitution was difficult and often thwarted by
side reactions such as self-acylation.24 Recently, Parsons and Cowell had success in a total synthesis of
(+/-)-tetrahydrolipstatin using low temperature, inverse addition, and an allyl iodide as electrophile.25

Scheme 13. Diastereoselective electrophilic reactions of -lactones enolates
2.1.2.3 Reaction with Nucleophiles
Just as -lactones can be prepared via oxygen-alkyl or oxygen-acyl bond formation, they also undergo, in
the presence of nucleophiles, oxygen-alkyl or oxygen-acyl bond cleavage (Scheme 14).26 Thus, -lactones
are ambident electrophiles, a property that renders them versatile intermediates for a variety of
transformations. As a rule of thumb, hard nucleophiles such as alkoxides, alkyllithium reagents, and
Grignard reagents react with-lactones to cleave the acyl CO bond (C2O1), while alkyl CO (C4O1)
cleavage occurs with soft nucleophiles, including organocuprates, azides, halides and thiolates.

Scheme 14. Nucleophilic ring-opening of-lactones
From the perspective of biological activities, the strain associated with the -lactone ring is responsible
for its reactions in the biological systems i.e the enhanced susceptibility to nucleophilic attack. Like the
better known azetidinone (-lactam), this trait leads to easy, irreversible acylation of enzymes, which has
proved to be therapeutically worthwhile. The following section will highlight the function of acyl protein
thioesterase (APT) inhibitors as probes of dynamic S-palmitoylation and the role of -lactones as
inhibitors.
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2.1.3 Acyl Protein Thioesterase (APT) inhibitors as Probes of Dynamic S-Palmitoylation
Protein palmitoylation refers to the formation of a thioester bond between a cysteine thiol side chain and a
saturated 16-carbon fatty acid.27 This hydrophobic modification is crucial in the functioning, trafficking,
and localization of various proteins. From recent proteomics studies, hundreds of palmitoylated proteins28
have been disclosed and shown to play an extensive role. Compared to the other lipid modifications that
occur in the cell (prenylation and myristoylation), palmitoylation is readily reversible, which is accredited
to the unstable thioester linkage. Therefore the rapid cycles of palmitoylation and depalmitoylation
facilitate facile movement of proteins between the plasma membrane and the Golgi apparatus to regulate
many cellular functions.
Protein palmitoyl thioesterases (PPTs) catalyze the de-palmitoylation and release of certain proteins from
the plasma membrane, with the capacity of attenuating membrane coupled signaling pathways (Figure
22). The released proteins can then go through repalmitoylation by endomembrane-bound DHHC
palmitoyl-transferases, sequentially imposing palmitoylation and resetting the cycle. Diverse proteins
have been indicated as acyl protein thioesterase substrates in in vitro assays.29 Ras proteins, which
participate in an acylation/deacylation cycle, are an excellent example in this regard.30

65

Figure 22. A dynamic S-palmitoylation
APTs belong to the metabolic serine hydrolase (SH) superfamily, characterized by the presence of an
active site serine used for substrate hydrolysis that is implicated in amide, ester or thioester bond cleavage
in peptides, proteins and lipids.31 The identification of the cytosolic APT1 as the enzyme responsible for
palmitate removal was first reported by Duncan and Gilman in 1998.29 APT1 is a highly conserved /
hydrolase that contains both the S-H-D catalytic triad and a G-X-S-X-G motif and it is found mostly in
cytosolic fractions in both Sacharomyces cerevisiae and mammalian cells. A second enzyme that plays a
role in palmitate removal from proteins is APT2, also known as lysophospholipase II. Phylogenic analysis
shows that invertebrates evolved only one APT enzyme, while vertebrates evolved two (APT1 and
APT2). In spite of the fact that the palmitoylation site is not conserved in canine APT1 or invertebrate
APTs, they (APT1 and APT2) have all been recognized as palmitoylated proteins.28d,32
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The serine nucleophilic nature of APTs is crucial in enhancing the formation of a covalent acylintermediate with substrates, thereby creating the opportunity to develop covalent, mechanism-based
inhibitors. The development of small molecule inhibitors of APTs has received much attention in recent
years.27 These include both competitive and non-competitive inhibitors, which have been useful tools in
several studies supporting a functional role for APTs in enzymatic depalmitoylation. In the next section,
we focus our attention on -lactones as APT inhibitors.
2.1.4 -Lactones as APT Inhibitors
Previous work, focused on the synthesis and screening of a small library of -lactones on the basis of
active-site similarity between APT1 and gastric lipase (and the fact that -lactones are known lipase
acylating reagents), led to the discovery of palmostatin B (Figure 23b).33a,34 Palmostatin B was found to
be membrane-permeable and to display direct reactivities with APT1 and APT2 as both a substrate and an
inhibitor in live cells.33a

Figure 23. a) APT competitive enzyme inhibition by -lactones; b) structure of palmostatin B; c)
structure of palmostatin M

Experimental studies on the effect of APT inhibition have shown that palmostatin B (77) (with the half
maximal inhibitory concentration, IC50: APT1 = 5.4 nM, APT2 = 37.7 nM) impedes the growth of H-Ras
or N-Ras transduced hematopoietic cells, but does not affect cells transduced with a non-palmitoylated
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isoform of K-Ras.33b Such effects provide important pharmacological evidence of protein palmitoylation
dynamics in live cells and clearly define a role for de-palmitoylation in Ras regulation.
The cytosolic enzyme (APT1) has a very broad substrate scope. APT1 not only performs the
depalmitoylation of the C terminus of small GTPases, but also other G proteins, ghlerin, viral
glycoproteins and lysophospholipds.34 The unusual and exceptionally wide substrate tolerance of APT1
inspired Waldmann group34 to employ the structural characteristics of different substrates as guiding
arguments in designing a more potent family of inhibitors. From the fact that the activity of palmostatin B
was found to rely on the stereochemistry of its electrophilic -lactone core and the aliphatic substitution at
its position, they surmised that selective recognition may be enhanced by the introduction of
functionalities that enable hydrogen bonding and electrostatic interaction to the  position. Comparison
of two known native APT1 substrates, lysophospholipid 79 and the H-Ras C terminus 80 led to the
identification of a common recognition motif that consists of a negatively charged group at a distance five
to six bonds (red) from the (thio-)ester functional group and a positively charged tail group ten to twelve
bonds away (blue) (Figure 24a).
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Figure 24. Inhibitor development based on substrate similarity34
They found that the phosphatidyl choline moiety 81 would provide the required electrostatic interactions
but were worried that its zwitterionic nature might limit application in the cells. This moiety was then
replaced by a sulfonyl-1,3-propylene-N,N-dimethylamino functionality 82 (Figure 24b). Fragment 82 was
fused via a variable spacer to a trans--lactone core 83, which addressed the stereochemical preferences
of APT133a and served as a covalent modifier of the nucleophilic residue in the active site of the enzyme.
In order to create affinity to the lipid-binding pocket of the enzyme, a lipophilic tail mimicking the
palmitate moiety was introduced on the opposite side of the -lactone core (Figure 24c). These criteria led
to the design of a small focused library of three series of inhibitors, denoted A-C, which would define the
structure-activity relationship (Figure 24d). This provided palmostin M which was found to be several
times more active (with IC50 of 2.5 nM for APT1 and 19.6 nM for APT2) than palmstatin B (IC50 of 5.4
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nM for APT1and 37.7 nM for APT2). This represents an improved analog in comparison to palmostatin B
(Figure 6b).34
Additionally, inspired by the fact that -lactones form a semi-stable covalent complex with their targets,
the Waldmann group developed an alkynyl palmostatin M analog to annotate potential cellular targets
(Figure 25).35 Lysates were labeled with an alkynyl probe (84), which was conjugated to a tri-functional
rhodamine/biotin-azide by copper catalyzed click chemistry, enriched with streptavidin, and analyzed by
in-gel fluorescence or mass spectrometry to identify candidate target proteins. These studies confirmed
APT1 and APT2 as major palmostatin M targets, but also identified other serine hydrolases, including the
lysosomal thioesterase PPT1 and retinoid-inducible serine carboxypeptidase (RISC). While these
compounds are exceptionally potent, non-specific inhibition and poor drug-like properties limit the
application of these probes for in vivo studies. The following section highlights the potential of -lactones
as targets for oncogenic N-Ras in cancer, which forms the basis of this study.

Figure 25. An alkynyl palmostatin M analogue (84)
2.1.5 Targeting Oncogenic N-Ras in Cancer
The kinetic trapping of the proteins at the Golgi by site-specific S-palmitoylation and S-depalmitoylation
is the driving force that creates a precise steady-state localization of H-Ras and N-Ras, predominantly at
the plasma membrane and the Golgi in the cytoplasm. This cyclic process, coupled with the directionality
of the secretory pathway, is important for the maintenance of the dynamic spatial distribution of
palmitoylated Ras-proteins.36 In a study carried out by Waldmann group, they found that interference with
the dynamic acylation cycle with small molecules at the level of depalmitoylation provided a means for
randomizing Ras localization to all membranes, thereby affecting its signaling in the cell.33a A loss of the
precise steady-state localization of still palmitoylated Ras proteins and a partial phenotype reversion of
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MDCK-F3 cells were identified during long term palmostatin B inhibition of the cellular thioesterase
activity. These studies revealed that the major contribution to the phenotype reversion is from the
redistribution of palmitoylated oncogenic Ras, even though it is likely that other palmitoylated peripheral
membrane proteins might also be affected in their spatial distribution. Furthermore, cell viability was not
affected by thioesterase inhibition at the concentrations of palmostatin B used, showing that basal
signaling necessary for cell survival remained active.
In another study, the Shannon group showed that the palmitoylation/depalmitoylation cycle of
posttranslational processing is a potential therapeutic target for selectively inhibiting the growth of
hematologic cancers with somatic N-Ras mutations.33b The investigation was carried out by constructing
murine stem cell virus vectors and assaying the growth of myeloid progenitors. The outcome of this work
proved that mutations within the N-Ras hypervariable region influenced N-Ras-mislocalization and
attenuated aberrant progenitor growth. Similar findings were obtained when the transduced hematopoietic
cells and bone marrow from N-Ras and K-Ras mutant mice were subjected to the acyl protein thioesterase
inhibitor palmostatin B. Remarkably, the inhibition mediated by palmostatin B was selective for N-Ras
mutant cells. Because interference with Ras signaling is regarded as a feasible strategy towards realization
of new anticancer drugs,37,38 palmostatins may be a valuable starting point for the development of
modulators of pathological signaling by palmitoylated Ras proteins and hence validating this study. The
following section will highlight the purpose of the study.
2.1.6 Purpose of Study
Ras proto-oncogenes are mutated in ~30% of human cancers resulting in an abnormal protein that drives
malignant growth. To date, there are no mechanism-based treatments for reversing the biochemical output
of oncogenic Ras proteins, and this has presented an exceedingly difficult target for rational drug
discovery. Previous studies proved that APT1 and APT2 catalyze N-Ras depalmitoylation and that first
generation chemical inhibitors designed to inhibit these enzymes (palmostatin B and palmostatin M)
selectively reduced the growth of primary hematopoietic progenitors and leukemia cells expressing
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oncogenic N-RasG12D.33b In a collaborative work with the Cravatt (Scripps Research Institute) and
Shannon groups (UCSF), we are looking at generating preliminary data and novel reagents, which we will
use to pursue the goals of: (1) identifying additional biochemical targets of the palmostatins; (2)
developing new chemical inhibitors with improved potency and selectivity for palmostatin targets; (3)
using these inhibitors combined with genetic methods to discern the relevant enzyme(s) that regulate NRas depalmitoylation in cancer cells, and, (4) utilizing human cancer cell lines and a new strains of mice
to interrogate the palmitoylation/depalmitoylation cycle as a therapeutic target in early stage and
advanced N-Ras-mutant cancers. With our expertise in synthetic chemistry, the objective of the Howell
group is to synthesize the palmostatin M inspired -lactones to provide our collaborators with tools to
investigate the Ras palmitoylation/depalmitoylation cycle, which regulates the subcellular trafficking of
the N-Ras, H-Ras, and K-Ras4a isoforms, as a therapeutic target for selectively inhibiting the growth of
malignancies with oncogenic N-Ras mutations. In particular, we envisioned that palmostatin M derivative
targets (Figure 26) with either sulfone or amine functional group in the C4 chain would answer whether
both the sulfone and the amine functionalities in palmostatin M are vital for inhibitory activities. More,
based on Howell group chemistry, there is the possibility of modifications in the C3 chain because methylene--lactones can undergo an olefin cross-metathesis (CM) with terminal alkenes. Herein, our
initial targets are palmostatin M analogs containing a C4 chain with no sulfone moiety (targets 85 and
86). The chain at C3 was fixed with 10 carbon atoms for initial analogs. The long term goal of this project
is to implement mechanistic strategies to selectively inhibit the growth of cancers with somatic Ras
mutations. The next section highlights various methodologies utilized to access 3,4-disubstituted lactones.
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Figure 26. Targeted palmostatin M derivatives
2.2 Approaches to -Lactone Inhibitors of Fatty Acid Synthase (FAS)
Due to the fact that -lactone moiety is present in many biologically active natural products, much
attention has been focused on the development of practical routes to various disubstituted -lactones. The
Howell group and others have reported methods to easily access various disubstituted β-lactones as small
molecule inhibitors of FAS or other serine/threonine proteases.
2.2.1 Ketene Dimerization/Hydrogenation Sequence
The Romo research group39 has made a significant effort in the development of asymmetric reaction
sequences that provide disubstituted -lactone libraries. Their described methodology is based on a twostep process involving Calter’s2b,40 organocatalytic, asymmetric ketene dimerization, starting from acid
chlorides, followed by a facial-selective hydrogenation leading to cis-substituted--lactones (Scheme 15).
This route is attractive in that the ketene dimer intermediates were found to be stable to flash
chromatography, enabling opportunities for subsequent transformations of these optically active, reactive
73

intermediates. A number of acyl chlorides were subjected to quinidine catalyzed ketene dimerization and
gave isolable -alkylidene--lactones in good enantioselectivities. Hydrogenation of the ketene dimers
under Pd catalysis provided cis--lactones with excellent diastereoselectivities. Subsequent base mediated
α-epimerization allowed access to trans--lactones (Scheme 16). The two major downsides of this
protocol are: 1) the epimerization step is low yielding and 2) the approach is only applicable for
synthesizing substrates with identical substituents (R groups). Nevertheless, this two-step process
provided a practical and scalable process to prepare simple, pseudosymmetric dialkyl -lactones from
readily available acid chlorides in good overall yields and high enantioselectivities. Several ketene
dimers and -lactones obtained from this protocol showed antagonistic activity in competition with a
fluorogenic substrate toward a recombinant form of the thioesterase domain FAS. -Lactone 87 (both cis
and trans, Schemes 15 and 16) displayed significant FAS inhibitory activities, only 10-fold lower than
that of orlistat. The promising FAS inhibitory activity displayed by simple, disubstituted -lactones opens
opportunities specifically in developing other methods than can provide access to a more diverse range of
-lactones.
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Scheme 15. Disubstituted -lactone synthesis via ketene dimerization/hydrogenation sequence

Scheme 16. Epimerization of cis--lactones to the trans-isomers
2.2.2 Tandem Mukaiyama Aldol Lactonization (TMAL) Approach
In order to avoid depletion of the material in the epimerization step in the ketene
dimerization/hydrogenation sequence, Smith et al.41 developed a tandem Mukaiyama Aldol lactonization
(TMAL) to give access to trans--lactones with high enantiomeric purities (Scheme 17). The reaction
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employs readily available thiopyridyl ketene and aldehydes providing direct access to 3,4-disubstituted-lactones. This approach was best suited for diversification studies. It was utilized in the synthesis of
orlistat together with some of its derivatives. It was also applied in the synthesis of valollactone (88),
which has a higher inhibitory activity toward the thioesterase domain of FAS than orlistat, possibly due to
its better solubility.

Scheme 17. Tandem Mukaiyama Aldol lactonization (TMAL) approach
2.2.3 Olefin Cross-Metathesis (CM) of -Methylene--Lactones
In exploring the reactivities of strained heterocycles with exocyclic unsaturation, the Howell group found
that -methylene--lactones such as 89 participated in cross-metathesis (CM) reactions with Type I
alkenes.42 The reactions proceeded in high yields and with excellent Z-selectivities in the presence of
either Grubb’s 2nd or Grubb’s-Hoveyda 2nd generation catalysts (Cat. 90 and 92 respectively) (Table 1).
The predominant Z-stereochemistries of the products were unexpected, because CM reactions of ,unsaturated carbonyl compounds, including 1,1-disubstituted enones, with simple alkenes usually proceed
with high E-selectivity.43 The high Z-selectivity observed was attributed to steric effects from the group at
C-4 position. A bulky substituent at C-4 position was anticipated to both direct reaction with the
ruthenium alkylidene to the opposite lactone face and to direct the terminal alkenyl substituent toward the
carbonyl moiety. The steric argument was confirmed by a drop in the selectivity when a less bulky group
at C-4 was utilized.
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Table 1. Synthesis of alkylidene -lactones 92 via cross-metathesis
The CM reaction between-methylene--lactones and terminal alkenes presents an attractive approach to
a focused libraries of 3,4-disubstituted -lactones 93. This is due to fact that -alkylidene--lactones 93
themselves can be used as probes. In addition to being used as probes, -alkylidene--lactones can be
converted selectively to trans- or cis--lactones 94 via diastereoselective reductions. cis--Lactones can
be accessed by hydrogenation reactions under palladium on carbon catalysis, while their trans
counterparts can be obtained via 1,4-reduction using NaBH4 under cobalt catalysis (Scheme 18).42b In a
combination of competitive gel- and MS-based ABPP experiments, individual -alkylidene--lactones
and their reduced -lactone counterparts were found to display a broad reactivity profiles against a
diverse array of serine hydrolases, including disease-relevant and uncharacterized enzymes that lack
selective inhibitors.44 Inspired by these biological outcomes and the ability of -methylene--lactones to
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undergo CM, we envisioned the synthesis of palmostatin M derived β-lactone motifs that target RAS
depalmitoylation.

Scheme 18. -Lactones synthesis by cross-metathesis/reduction sequence
2.2.3.1Results and Discussions
2.2.3.1.1 Initial Approach
β-Lactones are an important class of heterocyclic compounds found in several synthetic and natural
products of biological relevance.1 Aside from the prevalence of β-lactones in natural products, they are
considered privileged intermediates in organic synthesis as they offer a broad range of reactivities.2,3 The
Howell group has recently utilized a particular class of β-lactones, α-methylene-β-lactones, in a
ruthenium catalyzed cross-metathesis reaction (see section 2.2.3). Inspired by the efficiency with which
-methylene--lactone undergo CM reaction coupled with diastereoselective reductions, we envisioned a
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synthetic strategy to access palmostatin M analogs 85 and 86 (see section 2.1.4), wherein a CM reaction
between -methylene--lactone 95 and terminal alkenes 96 would generate a library of derivatives with
different R-groups on the C3 chain (-alkylidene--lactone 85).42 -Alkylidene--lactone would then be
subjected to diastereoselective reductions to access-lactones 86 (Figure 27).42

Figure 27. Retrosynthesis of palmostatin M-inspired -lactones
-Methylene--lactone would in turn be prepared from lactonization of -methylene--hydroxy acid
97.45,46 -Hydroxy acid would be accessed from a one-pot, 2-step reaction sequence involving MoritaBaylis-Hillman (MBH) reaction of aldehyde 98 and methyl acrylate (99), followed by hydrolysis.45 A
more direct sequence to prepare -methylene--lactones 95 would involve MBH reaction between
aldehyde 98 and t-butyl thioacrylate (100), followed by mercury-mediated cyclization of MBH adduct
101 (Figure 28).45

Figure 28. Retrosynthesis to -methylene--lactone 95
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We began our investigation into this CM-inspired strategy with the synthesis of amino aldehyde 102,
starting with 1,8-octanediol (103) which we had available (Scheme 19). Subjection of 103 to
monobromintion conditions with 48% aqueous hydrobromic acid in the presence of catalytic amount of ptoluenesulfonic acid (PTSA) afforded 8-bromooctan-1-ol (104) in 83% yield. Nucleophilic aliphatic
substitution of the bromide 104 with dimethyl amine gave compound 105 in 57% yield. This was
followed by a Swern oxidation which converted the alcohol to amino aldehyde 102. The 1H NMR
spectrum of the crude aldehyde product showed to be fairly clean, and therefore it was used in the
subsequent MBH reaction without purification. MBH adduct 106 was obtained in two days by using 1,4diazabicyclo[2.2.2]octane (DABCO) as the organocatalyst.45 A mercury-mediated cyclization attempt on
MBH adduct 106 failed to give the desired α-methylene-β-lactone 107, in spite of the fact that the
starting MBH adduct 106 was consumed, as shown by the 1H NMR spectroscopic data of the crude
mixture (neither characteristic peaks of the starting material nor corresponding lactone product was
observed).

Scheme 19. An attempt to prepare -methylene--lcatone 107 via a mercury-mediated cyclization
To circumvent the problems encountered in our initial approach, we sought a sequence for installation of
the amine functional group after the lactonization step. We decided on a route involving lactonization of a
silyl-protected MBH adduct followed by elaboration of -methylene--lactone. In this approach, methylene--lactone 108 was readily prepared from lactonization of -methylene--hydroxy acid 109.
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The synthesis was initiated from 1,9-nonandiol (110), which was first converted into monoprotected
alcohol 111 in 51 % yield.47 This was followed by a Swern oxidation, leading to the aldehyde 112 in 97%
yield.47 MBH adduct 113 was obtained in 81% yield in two days by using 3-quinuclidinol as the
organocatalyst. Hydrolysis of the MBH adduct 113 gave β-hydroxy acid 109 in 89% yield. A nosyl
chloride mediated lactonization45 provided desired -methylene--lactones 108 in percentage yield
ranging from 38-64% (Scheme 20).

Scheme 20. Preparation of -methylene--lactone 108
Having accessed -methylene--lactone 108, we focused our attention on subsequent steps in the
synthesis. Cleavage of the silyl group using tetra-n-butylammonium fluoride (TBAF) gave no desired
product, even though the starting material was consumed based on 1H NMR of the reaction mixture. We
then sought to use pyridinium p-toluenesulfonate (PPTS), a weakly acidic catalyst, which gave the desired
product 114 albeit, in low yield. An attempt to convert alcohol 114 to bromide under Appel’s condition48
failed, as we did not observe the desired product 115 based on 1H NMR of the reaction mixture (Scheme
21). This was attributed to the conjugate addition of the nucleophilic bromide to the terminal alkene
moiety.

Scheme 21. An attempt to convert alcohol 114 to bromide 115 under Appel’s condition
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Having encountered difficulties in the conversion of alcohol 114 to bromide 115, we decided to carry out
bromination at a later stage of the synthesis, after CM reaction since CM would convert the terminal
alkene into an internal alkene which is normally less prone to conjugate addition. Cleavage of the silyl
groups from -alkylidene--lactone, followed by bromination should yield the bromide. A final
nucleophilic substitution of the bromide with dimethyl amine should provide the desired target 85 (Figure
29a). The reduced β-lactone target 86 would be obtained via reduction, removal of silyl group,
bromination and nucleophilic substitution of the bromide with dimethyl amine (Figure 29b). In the next
section, olefin cross metathesis of -methylene--lactone 108, stereoselective reductions and
incorporation of the amine functional group are described.

Figure 29. Retrosynthesis to palmostatin M-inspired -lactones 85 and 86
2.2.3.1.2 CM of -Methylene--Lactone 108 Followed by Diastereoselective Reductions
After accessing the desired -methylene--lactone 108, CM reaction to obtain -alkylidene--lactone
was explored. Subjection of 108 to ruthenium catalyzed CM mediated by Grubbs 2nd generation catalyst
(90) afforded -alkylidene--lactone 116 with Z-selectivity (Scheme 22).

Scheme 22. CM reaction to access -alkylidene--lactone 116
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Having prepared the -alkylidene--lactones 116, we next sought to finish the synthesis of palmostatin
M-inspired -lactones 85 and 86. Starting with Z-116, cleavage of the silyl protecting group utilizing
PPTS provided alcohol 117 in 91% yield. Appel bromination48 using tetrabromomethane in the presence
of triphenylphosphine gave bromide 119 in 67% yield. It is worth noting that we never observed any
conjugate addition product during bromination reaction as opposed to when bromination was carried out
on -methylene--lactone 114 utilizing similar conditions. A subsequent N-alkylation with
dimethylamine gave Z-isomer of the desired target 85 in 37% yield (Scheme 23). Similar transformations
were applied to access the E-isomer in 22% isolated yield (Scheme 24).

Scheme 23. Synthesis of palmostatin M derived -lactone Z-85

Scheme 24. Synthesis of palmostatin M derived -lactone E-85
The reduced -lactone motifs were obtained by hydrogenation to give the cis-lactone or by 1,4- reduction
using sodium borohydride to obtain the trans product with modest selectivity (Scheme 25).42b
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Scheme 25. Diastereoselective reductions to give cis- and trans--lactones 120
Elaboration of lactones 120 gave access to the cis- and trans-isomers of palmostatin M-inspired β-lactone
86. This was done by incorporation of dimethylamino functionality via cleavage of silyl group, Appel
bromination, and subsequent nucleophilic substitution of the bromide with dimethylamine (Schemes 26
and 27).

Scheme 26. Synthesis of palmostatin M-derived -lactone trans-86

Scheme 27. Synthesis of palmostatin M-derived -lactone cis-86
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In summary, we have showcased the versatile reactive nature of -methylene--lactone and their
applications as useful synthetic intermediates for transformations to more advanced structures. CM
reactions of -methylene--lactones, followed by subsequent diastereoselective reductions, provided the
four palmostatin M analogs (targets 85 and 86). Elaboration of these disubstituted -lactones furnished
palmostatin M derivatives. The following section describe the development of a one-step preparation of
3,4-disubstituted -lactones from -methylene--lactones through Rh-catalyzed conjugate addition of
arylboronic acids to -methylene--lactones.
2.2.4 Rhodium Catalyzed Conjugate Addition of Aryl Boronic Acids
The previous section showcased how -methylene--lactones could be used for the synthesis of
structurally diverse 3,4-disubstituted -lactones via CM and subsequent diastereoselective reductions.
Despite the success of this methodology in assembling focused libraries of 3,4-disubstituted -lactones, it
suffers some drawbacks. First, the CM reaction typically requires high catalyst loading (5–10 mol %).
Secondly, the 1,4-reduction to access the generally more biologically active trans -lactones suffers from
modest diasteroselectivities and yields. Taken together, the limitations make an alternative approach
appealing. Here we report the development of an efficient process for Rh catalyzed conjugate addition,
wherein readily available aryl boronic acids are combined with -methylene--lactones to generate 3,4disubstituted β-lactones (Scheme 29).

Scheme 28. Rh-catalyzed conjugate addition
The conjugate addition of organometallic reagents to enones is a powerful tool for appending organic
residues to cyclic and acyclic substrates.49,50 Substrates used in this reaction are usually ,-unsaturated
ketones, aldehydes, esters, amides, sulfoxides, or nitro compounds. Often referred to as 1,4-addition,
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these reactions use a variety of organometallic reagents, the most common of which are organolithiums,
and cuprates. Reactions involving organometallic reagents are generally run under anhydrous, oxygenfree conditions, leading to difficulty in handling and manipulation of reactions, as well as problems with
broad functional group tolerance. Miyaura and co-workers49 reported the first rhodium-catalyzed
conjugate addition reaction to an enone (methyl vinyl ketone) with phenyl boronic acid (Scheme 30).
Unlike previous transition metal catalyzed conjugate additions, the reaction was done in the presence of
water as co-solvent. After this discovery, the synthetic chemistry community witnessed many advances in
the field of rhodium-catalyzed conjugate addition. Specifically, new rhodium complexes and organoboron
reagents have been developed.50,51 In addition, various substrates, including ,unsaturated esters,
amides, lactones, lactams, nitriles, and aldehydes, have been utilized.50

Scheme 29. The first rhodium-catalyzed conjugate addition reaction reported
The use of endocyclic ,-unsaturated lactones and lactams as candidates for the rhodium catalyzed
conjugate addition transformation has recently been reported. Hayashi and co-workers showcased
conjugate addition of aryl boronic acid to coumarins52 and maleimides53 proceeding under rhodium
catalysis (Scheme 31). Most examples provided products in excellent yields, and in the presence of
appropriate chiral ligands, high enantioselectivities were achieved. Application of similar reaction
conditions (use of KOH, reaction temperature up to 100 oC) to -butyrolactone resulted in a low yield
which was attributed to the potential instability of the 5-membered lactone under the conditions.

86

Scheme 30. Examples of Rh-catalyzed conjugate addition of aryl boronic acids with endocyclic systems
Dihydropyridinones were also utilized in Rh-catalyzed conjugate additions to access 4-arylpiperidinones.54 The products of this transformation can be employed in further transformations. For example, 4arylpiperidinone 122, prepared from dihydropyridone 123, was an intermediate in the synthesis of ()paroxetine,55 a drug used for the treatment of Parkinson’s disease (Scheme 32).

Scheme 31. Rh-catalyzed conjugate addition to dihydropyridinone for the synthesis of ()-paroxetine
While the use of endocyclic ,-unsaturated lactones and lactams has enabled many rhodium-catalyzed
conjugate additions with organoboron reagents, by contrast, the number of related transformations on
exocyclic ,-unsaturated lactones and lactams is more limited, despite the emergence of some important
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recent examples. Frost and co-workers56 demonstrated a rhodium-catalyzed 1,4-additions with -methylenepyrrolizidinones that provided products in good yields with modest selectivity towards the trans-adduct
(Scheme 33). Very recently, Viaud-Massuard and co-workers57 disclosed the conjugate addition of aryl
boronic acids with -benzylidene-7-azaoxindoles.

Scheme 32. Rhodium-catalyzed conjugate addition of exocyclic lactams with aryl boronic acids
In similar work, Frost58 showcased a Rh-catalyzed conjugate addition to benzylidene dilactones derived
from Meldrum’s acid (Scheme 34). This type of substrate usually faces the challenge of instability with
nucleophiles, including water, requiring the need for anhydrous conditions.59 Aryl boronic acids and
potassium trifluoroborate salts were found ineffective, presumably due to their low solubility in organic
solvents. However, novel TMS-protected aryl dioxaborinanes yielded desired products in moderate
yields.

Scheme 33. Rh-catalyzed conjugate addition of benzylidene Meldrum’s acid with organoboron reagents
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The successful realization of Rh-catalyzed conjugate addition reactions to exocyclic ,-unsaturated
lactones and lactams led to our proposition that -methylene--lactones could undergo similar
transformations under rhodium catalysis to give 3,4-disubstituted -lactones in a single step. At the onset,
a number of factors were identified that could impede rhodium-catalyzed conjugate additions on methylene--lactones. First, β-lactones might not be compatible with the most commonly reported
basic/aqueous conditions due to facile ring-opening of the starting material or products.60 Secondly,
control over selectivity in this kind of reaction could be problematic due to the fact that the reaction could
lead to the formation of diastereomers. In the next sections, we summarize the development of a rhodium
catalyzed conjugate addition reactions of -methylene--lactones with aryl boronic acids. The
optimization and scope of the reactions were investigated.
2.2.4.1 Mechanistic Hypothesis and Initial Studies
Motivated by the biological activities displayed in disubstituted -lactones and the previous report on the
Rh-catalyzed conjugate additions on exocyclic ,-unsaturated lactones and lactams, we hypothesized
that -methylene--lactones such as 124 would undergo conjugate addition with organoboron reagents
(Scheme 35). The initial studies, conducted by Dr. Christian A. Malapit (CAM), began with the
investigation of the reaction of -methylene--lactone 124a with phenyl boronic acid in the presence of
Wilkinson’s catalyst.61 Treatment of 124a with phenyl boronic acid delivered a mixture of the desired
conjugate addition product, β-lactone 125a, together with the Heck-type product -alkylidene--lactone
126 (Scheme 35). The Rh-catalyzed conjugate addition to give β-lactone 125a constitutes a one-step
process for disubstituted -lactones from -methylene--lactones, in contrast to the crossmetathesis/reduction sequence described in the previous section. Based on initial results, CAM carried out
optimization in order to: (a) selectively obtain conjugate addition product, (b) prevent decomposition, and
(c) improve the diastereoselectivity of the reaction.
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Scheme 34. Hypothesis and initial studies on the Rh-catalyzed conjugate addition
Herein we report a strategically distinct, one-step approach to access palmostatin inspired -lactones from
-methylene--lactones. Optimization of reaction conditions to improve selectively towards conjugate
addition is summarized, as well as an exploration of the scope of the reaction.
2.2.4.2 Results and Discussions
2.2.4.2.1 Optimization of Reaction Conditions
The formation of Heck-type products in Rh-catalyzed reactions was previously observed when ,unsaturated esters and amides were utilized.61 This competitive pathway was proposed to occur via hydride elimination (versus protonolysis) from the -metallated intermediate 127 (Scheme 36). However,
with ,-unsaturated esters and amides, prior studies had shown that conjugate addition products can be
selectively obtained by using appropriate conditions.
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Scheme 35. -Hydride elimination (versus hydrolysis) from the -metallated intermediate 127
In order to avoid decomposition and to improve selectivity towards conjugate addition, several parameters
were varied including rhodium catalyst, temperature, solvent system, and base additives. Table 2
summarizes the results of the preliminary screening. Switching of the catalyst to [Rh(cod)Cl]2 afforded
complete conversion and a cleaner reaction, although still providing a mixture of conjugate addition and
Heck products (2:1 ratio of 125a/126) (entry 2). Using the [Rh(cod)Cl]2, multiple conditions were tested.
In the absence of the base, very low conversion was observed (entry 3). The competition between Hecktype reaction and conjugate addition has been previously observed and mechanistically rationalized.61 In
some previous studies, it has been demonstrated that conjugate addition or Heck-type reaction can be
selectively achieved by tuning the catalyst, solvent, reactant ratios, and/or additives. For our system, using
a strong base, such as KOH, enhanced conjugate addition relative to Heck reaction (an increase from 2:1
to 3.5:1 ratio of 125a/126) (entry 4). In an attempt to decrease the equivalents of KOH, a decrease in the
conversion and selectivity was observed (entry 5). In addition, lowering of the temperature resulted in a
decrease in the selectivity (entries 6 and 7). Using this information, it was reasoned that increasing the
equivalents of KOH would improve selectivity towards CA product. Surprisingly, the use of 1 eq KOH
resulted in 100% conversion and complete selectivity towards CA product (entry 8). The use of 2 equiv of
KOH (entry 9) gave good selectivity but diminished isolated yield, possibly due to decomposition of the
starting material or products. When other catalysts were screened with the optimized base, temperature,
and solvent (entries 10 and 11), [Rh(nbd)Cl]2 proved equally efficient to [Rh(cod)Cl]2. Subsequent studies
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on the scope of the reaction employing [Rh(cod)Cl]2 as the catalyst and KOH (1 equiv) as the base is
summarized in the next section.

Table 2. Optimization of Rh-catalyzed conjugate addition (CA) of phenylboronic acid to 124a62
2.2.4.2.2 Scope of Rh-catalyzed Conjugate Addition
Using these optimized conditions, I then examined the scope of the reaction by using -methylene-βlactone 108 and organoboron reagents as coupling partners. As summarized in Figure 30, electron rich
and electron-deficient aryl boronic acids are both suitable substrates, delivering 3,4-substituted -lactones
127 in moderate to high yields (63%87%). More importantly, diverse functional groups were tolerated,
92

including phenyl/benzyl ethers (127d/127i), aryl flourides (127f), styrene (127g), phenyl amides (127j)
and phenol (127k). Heterocyclic containing aryl boronic acid (127h) also underwent conjugate addition in
good yield. In general, the lactone diastereomers were separable (see the experimental section). As
previously mentioned, most monocyclic -lactone natural products and close analogues that have been
explored as drugs or probes are trans diastereomers.42b,44,60 Nevertheless, cis--lactones have been shown
to be as potent as their trans-isomers in some cases.39,63 Thus, at this stage, access to both diastereomers is
advantageous from the standpoint of diversification.
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Figure 30. Scope for Rh-catalyzed conjugate addition of phenyl boronic acid to 10862
2.2.4.2.3 Elaboration to Palmostatin M-Derivatives
The promising biological activities exhibited by β-lactones, in particular, disubstituted β-lactones, as
inhibitors of serine hydrolases exposes the need to prepare diverse analogs of these compounds. The
rhodium catalyzed conjugate addition of aryl boronic acids into -methylene--lactones provided a onestep access to diverse disubstituted -lactones as described in the previous section. We then sought to
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explore the installation of the amine functional group at C4 chain of some of these disubstituted lactones for the construction and elaboration of palmostatin M derivatives. The functionalization at C4
chain could be rapidly achieved via short synthetic sequences involving the cleavage of the silyl group,
Appel bromination, and subsequent N-alkylation with dimethylamine (Schemes 37 and 38).

Scheme 36. Cleavage of silyl group

Scheme 37. Appel bromination and N-alkylation with dimethylamine
In summary, the rhodium catalyzed conjugate addition of aryl boronic acids to α-methylene-β-lactones
provided a one-step access to diverse disubstituted β-lactones. Through reaction optimization, selective
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formation of the conjugate addition product over Heck-type coupling product was achieved. Owing to the
compatibility of both electron-rich and electron deficient aryl boronic acids, this methodology provides a
way to diversify advanced synthetic intermediates. Elaboration of some -lactones by installation of the
amine functional group at C4 chain terminal delivered palmostatin M derivatives.
2.3 Conclusion
-Methylene--lactones have been demonstrated to be important intermediates in synthetic and medicinal
chemistry because of their versatile, reactive nature. This property makes them useful synthetic
intermediates for transformations to more advanced structures. Two successful transformations include: a)
olefin CM of -methylene--lactones scaffolds coupled with diastereoselective reductions and b)
rhodium-catalyzed conjugate addition of aryl boronic acids to -methylene--lactones. This work targets
the discovery of novel -lactone inhibitors of N-Ras palmitoylation. The ultimate goal is to identify
additional biochemical targets of the palmostatins and develop new chemical inhibitors with improved
potency and selectivity for palmostatins targets.
2.4 Experimental
2.4.1 General Information
All moisture sensitive reactions were run in a flame-dried flask under N2. THF was dried using a J. C.
Meyer Solvent Dispensing System (SDS) and dispensed under N2. All other solvents were dried over
CaH2 or 4 Å molecular sieves. Deuterated chloroform (CDCl3), was dried over 4 Å molecular sieves. All
starting materials and reagents were purchased from commercial sources and used as received. All 1H
NMR experiments were recorded on a 400 MHz spectrometer. All 13C NMR experiments were recorded
at 100 MHz. Chemical shifts () are given in ppm, and coupling constants (J) are given in Hz. The 7.26
resonance of residual CHCl3 for proton spectra and the 77.23 ppm resonance of CDCl3 for carbon spectra
were used as internal references. High resolution mass spectroscopy (HRMS) was performed on a TOF
instrument with ESI in positive ionization mode.
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Unless otherwise stated, reaction progress was monitored by thin layer chromatography (TLC) performed
on glass plates coated with silica gel UV254. Visualization was achieved by ultraviolet light (254 nm),
0.5% KMnO4 in 0.1 M aqueous NaOH solution and/or 5% phosphomolybdic acid in ethanol. Column
chromatography was performed using silica gel, 40 microns flash silica.
2.4.2 Preparation of 4-(8-tert-butyldimethylsilyloxyoctanyl)-3-methyleneoxetan-2-one (108)

9-(tert-Butyldimethylsilyloxy)nonan-1-ol (111). Sodium hydride (60% dispersion in mineral oil, 3.37 g,
140 mmol,) was suspended in dry THF (250 mL) under N2, and 1,9-nonanediol (15.0 g, 93.6 mmol) was
added at 0 °C in one portion. The mixture was stirred for 30 min; then TBSCl (16.9 g, 112 mmol) was
added in one portion. The reaction mixture was then allowed to warm to ambient temperature, and stirring
was continued for another 20 h. The reaction mixture was then cooled to 0 ᵒC. Saturated aqueous NaHCO3
(300 mL) was added, and stirring was continued for 30 min. The organic layer was separated, and the
aqueous layer was extracted with EtOAc (3 x 250 mL). The combined organic extracts were washed with
brine (200 mL), dried (MgSO4) and concentrated. The crude product was purified by flash column
chromatography on silica gel (hexanes/EtOAc 17:3) to give 111 as a colorless oil (15.4 g. 60%):47,62 1H
NMR (400 MHz, CDCl3) 3.63–3.55 (m, 4H), 1.74 (t, J = 4.8 Hz, 1H), 1.58–1.44 (m, 4H), 1.31 (br s,
10H), 0.87 (s, 9 H), 0.02 (s, 6H); 13C NMR (100 MHz, CDCl3)  63.3, 62.9, 32.8, 32.7, 29.6, 29.4, 26.0,
25.8, 25.7, 18.4, 5.1.
9-(tert-Butyldimethylsilyloxy)nonanal (112). Dimethyl sulfoxide (9.55 mL, 134 mmol) in dry DCM
(200 mL) was added dropwise over 30 min to a solution of oxalyl chloride (5.29 mL, 61.6 mmol) in dry
DCM (120 mL) at 78 °C. Then, a solution of 9-(tert-butyldimethylsilyloxy)nonan-1-ol (111) (15.4 g,
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56.0 mmol) in dry DCM (140 mL) was added over the same period of time, and the mixture was stirred
for another 90 min. Triethylamine (28.5 mL, 205 mmol) was added dropwise, and the resulting slurry was
stirred at 78 ᵒC for 30 min then at ambient temperature for 1 h. The mixture was poured into H2O (150
mL) and extracted with DCM (3 x 200 mL). The combined organic extracts were washed with H2O (300
mL) and brine (200 mL), dried (MgSO4) and concentrated. The crude product was purified by flash
column chromatography on silica gel (hexanes/EtOAc 25:1) to give 112 as a yellow oil (13.2 g, 86%):47,62
H NMR (400 MHz, CDCl3)  9.72 (t, J = 1.8 Hz, 1H), 3.56 (t, J = 6.6 Hz, 2H), 2.37 (dt, J = 7.4, 1.8 Hz,
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2H), 1.61–1.55 (m, 2H), 1.55–1.46 (m, 2H) 1.27 (br s, 8H), 0.85 (s, 9H), 0.01 (s, 6H).

13

C NMR (100

MHz, CDCl3)  202.8, 63.3, 44.0, 33.0, 29.5, 29.4, 29.3, 26.1, 25.9, 22.2, 18.5, 5.1.
Methyl

11-(tert-butyldimethylsilyloxy)-3-hydroxy-2-methyleneundecanoate

(113).

9-(tert-But-

yldimethylsilyloxy)nonanal (112) (13.2 g, 48.3 mmol) and methyl acrylate (7.30 mL, 96.6 mmol) were
combined. 3-Hydroxyquinuclidine (1.54 g, 12.1 mmol) was added, followed by MeOH (1.46 mL, 36.2
mmol). The resulting mixture was stirred for 3 d. MeOH and excess methyl acrylate were removed under
reduced pressure. The resulting residue was diluted with saturated aqueous NH4Cl solution (200 mL), and
extracted with DCM (3 x 150 mL). The combined organic extracts were washed with brine (150 mL),
dried (MgSO4) and concentrated. The crude product was purified by flash column chromatography on
silica gel (hexanes/EtOAc 10:1) to give 113 as a colorless oil (12.7 g, 73%):62 IR (neat) 3461 (br), 2927,
2855, 1719, 1438, 1283, 1094 cm-1; 1H NMR (400 MHz, CDCl3) 6.22 (s, 1H), 5.79 (s, 1H), 4.37–4.28
(m, 1H), 3.78 (s, 3H), 3.59 (t, J = 6.6 Hz, 2H), 2.49 (d, J = 6.9 Hz, 1 H), 1.69–1.59 (m, 2H), 1.51–1.46
(m, 3H), 1.29 (br s, 9H), 0.89 (s, 9H), 0.04 (s, 6H). 13C NMR (100 MHz, CDCl3)  167.0, 143.0, 124.7,
71.3, 63.3, 51.8, 36.4, 32.9, 32.8, 29.6, 29.5, 26.0, 25.8, 18.4, 5.1; HRMS (ESI) calcd for C19H39O4Si (M
+ H)+ m/z 359.2618, found 359.2590.
4-(8-tert-Butyldimethylsilyloxy)octanyl-3-methyleneoxetan-2-one

(108).

Methyl

11-(tert-butyl-

dimethylsilyloxy)-3-hydroxy-2-methyleneundecanoate (113) (12.7 g, 35.3 mmol) was dissolved in MeOH
(64 mL). Aqueous KOH (2 M, 169 mL, 338 mmol) was added, and the reaction mixture was stirred
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overnight at ambient temperature. Aqueous HCl (1M, 250 mL) and brine (250 mL) were added. The
solution was then extracted with Et2O (3 x 100 mL). The combined organic extracts were washed with
brine (200 mL), dried (MgSO4) and concentrated. The crude product, 11-(tert-butyldimethylsilyloxy)-3hydroxy-2-methyleneundecanoic acid (109), was used directly in the next reaction:62 1H NMR (400 MHz,
CDCl3) 6.38 (m, 1H), 5.90 (m, 1H), 4.42 (m, 1H), 3.60 (t, J = 6.6 Hz, 2H), 1.68–1.59 (m, 2H), 1.50–
1.48 (m, 3H), 1.27 (m, 9H), 0.89 (s, 9H), 0.05 (s, 6H); 13C NMR (100 MHz, CDCl3) 170.7, 141.8,
127.3, 71.6, 63.4, 36.2, 32.8, 29.7, 29.5, 29.3, 26.0, 25.8, 18.4, 5.2. 11-(tert-Butyldimethylsilyloxy)-3hydroxy-2-methyleneundecanoic acid (11.3 g, 32.7 mmol) was dissolved in dry DCM (270 mL). Dry
Na2CO3 (31.2 g, 295 mmol) was added, and the resulting suspension was stirred for 30 min. o-Nosyl
chloride (10.9 g, 49.1 mmol) was added, and the resulting mixture was stirred for 3 d. The reaction was
diluted with H2O (150 mL) and DCM (100 mL) while stirring for 20 min. The organic layer was
separated, and the aqueous layer was extracted with DCM (3 x 100 mL). The combined organic extracts
were washed with brine (150 mL), dried (Na2SO4) and concentrated. The crude product was purified by
flash column chromatography on silica gel (hexanes/EtOAc 93:7) to give 108 as a brown oil (4.30 g, 38%
over two steps):62 IR (neat) 2927, 2855, 1822, 1251, 1081 cm-1; 1H NMR (400 MHz, CDCl3)  5.90 (s,
1H), 5.41 (s, 1H), 4.95 (t, J = 6.4 Hz, 1H), 3.59 (t, J = 6.5 Hz, 2H), 1.84 (m, 2H), 1.50–1.43 (m, 4H), 1.30
(br s, 8H), 0.89 (s, 9H), 0.04 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 163.8, 146.7, 115.0, 79.8, 63.4, 33.5,
33.0, 29.6, 29.5, 29.4, 26.2, 26.0, 24.8, 18.6, –5.1; HRMS (ESI) calcd for C18H35O3Si (M + H)+ m/z
327.2355, found 327.2350.
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2.4.3 Preparation of -alkylidene--lactone via olefin cross-metathesis
Catalyst used in olefin cross-metathesis

Z/E-4-(8-tert-Butyldimethylsilyloxy)octanyl-3-decanylideneoxetan-2-one (116). Catalyst 90 (52 mg,
0.061 mmol) was added to a solution of 4-(8-tert-butyldimethylsilyloxy)octanyl-3-methyleneoxetan-2one (108) (0.40 g, 1.2 mmol) and 1-undecene (0.28 g, 1.8 mmol) in dry DCM (70mL). The mixture was
stirred overnight at 40 °C. The next day 1H NMR showed complete consumption of 108. The reaction
mixture was allowed to cool to rt and then concentrated to form a brown residue. The 1H NMR Z:E ratio
of the crude reaction mixture was 2.2:1. Purification by flash column chromatography on silica gel
(petroleum ether/EtOAc 49:1) provided 116 as a colorless oil (0.42 g, 76%). The isomers were separable
by careful column chromatography using the same solvent system. Z-116 (colorless oil) (0.23 g, 42%): IR
(neat) 2925, 2854, 1808, 1251, 1095, 1073 cm-1; 1H NMR (400 MHz, CDCl3) 5.83 (t, J = 7.5 Hz, 1H),
4.81 (t, J = 6.2 Hz, 1H), 3.57 (t, J = 6.6 Hz, 2H), 2.46 (app q, J = 7.4 Hz, 2H), 1.77 (app q, J = 7.0 Hz,
2H), 1.52–1.37 (m, 4H), 1.36–1.17 (m, 22H), 0.87 (s, 9H), 0.85 (t, J = 7.0 Hz, 3H), 0.02 (s, 6H); 13C
NMR (100 MHz, CDCl3)  164.2, 137.7, 136.3, 78.7, 63.3, 33.9, 33.0, 32.0, 29.6, 29.5, 29.4, 29.4, 29.2,
29.0, 26.1, 25.9, 24.7, 22.8, 18.5, 14.2 5.1; HRMS (ESI) calcd for C27H53O3Si (M + H)+ m/z 453.3764
found 453.3776. E-116 (colorless oil) (51 mg, 9.2%): IR 2926, 2854, 1815, 1463, 1251, 1095 cm-1; 1H
NMR (400 MHz, CDCl3) 6.32 (ddd, J = 7.8, 7.8, 1.5 Hz, 1H), 5.01–4.95 (m, 1H), 3.59 (t, J = 6.6 Hz,
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2H), 2.10 (app q, J = 14.9, 7.5 Hz, 2H), 1.97–1.86 (m, 1H), 1.84–1.70 (m, 1H), 1.55–1.40 (m, 6H), 1.39–
1.23 (m, 22H), 0.87 (s, 9H), 0.88 (t, J = 7.2 Hz, 3H), 0.04 (s, 6H); 13C NMR (100 MHz, CDCl3)  164.5,
137.8, 134.1, 79.3, 63.5, 33.5, 33.0, 32.1, 29.6, 29.6, 29.5, 29.5, 29.5, 29.4, 29.0, 28.6, 26.2, 26.0, 24.9,
22.9, 18.6, 14.3, 5.1; HRMS (ESI) calcd for C27H53O3Si (M + H)+ m/z 453.3764, found 453.3750.
2.4.4 Diastereoselective Reductions
2.4.4.1 1,4-Reduction under cobalt catalysis

cis/trans-4-(8-tert-Butyldimethylsilyloxy)octanyl-3-decyloxetan-2-one (120). Z/E-4-(8-tert-Butyldimethylsilyloxy)octanyl-3-decanylideneoxetan-2-one (116) (0.34 g, 0.77 mmol) was dissolved in a mixture of
THF:MeOH (10.3 mL, 8.5:1.8). This solution was cooled to –10 oC, followed by the addition of
CoCl2(PPh3)2 (0.10 g, 0.15 mmol) and then portion-wise addition of NaBH4 (0.17 g, 4.5 mmol) within 10
min. The mixture was vigorously stirred for 2 h between –7 and −5 oC . The reaction mixture was filtered
through a pad of celite, and the celite was washed with CHCl3 (10 mL). The filtrate was washed with 2M
HCl (10 mL), dried (MgSO4) and concentrated. The 1H NMR trans:cis ratio of the crude reaction mixture
was 2:1. Purification by flash column chromatography on silica gel (petroleum ether/EtOAc 49:1)
provided 120 as a colorless oil (0.24 g, 71%). The trans-isomer was separable by careful column
chromatography using the same solvent system. trans-120 colorless oil (0.16 g, 47%): IR (neat) 2925,
2854, 1822, 1463, 1254, 1097 cm-1; 1H NMR (400 MHz, CDCl3) 4.21 (ddd, J = 7.2, 6.0, 4.0 Hz, 1H),
3.60 (t, J = 6.6 Hz, 2H), 3.17 (ddd, J = 8.8, 6.6, 4.0 Hz, 1H), 1.91–1.77 (m, 2H), 1.76–1.64 (m, 2H), 1.55–
1.46 (m, 2H), 1.45–1.22 (m, 26H), 0.89 (s, 9H), 0.90–0.86 (m, 3H), 0.05 (s, 6H); 13C NMR (100 MHz,
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CDCl3)  171.9, 78.4, 63.5, 56.4, 34.7, 33.0, 32.1, 29.8, 29.7, 29.6, 29.5, 29.4, 28.1, 27.2, 26.0, 25.2,
22.9, 18.6, 14.3, 5.1; HRMS (ESI) calcd for C27H55O3Si (M + H)+ m/z 455.3909, found 455.3926.
2.4.4.2 Hydrogenation under palladium catalysis

cis/trans-4-(8-tert-Butyldimethylsilyloxy)octanyl-3-decyloxetan-2-one (120). A solution of Z/E-4-(8tert-butyldimethylsilyloxy)octanyl-3-decanylideneoxetan-2-one (116) (0.23 g, 0.51 mmol) in THF (6 mL)
was hydrogenated by stirring at rt in an atmosphere of hydrogen in the presence 10% palladium on carbon
(0.016 g, 0.015 mmol). After 5 h of stirring, the catalyst was filtered through a pad of celite, and the celite
was washed with CHCl3 (15 mL). The mixture was then concentarated. The 1H NMR trans:cis ratio of the
crude reaction mixture was 1:6. Purification by flash column chromatography on silica gel (petroleum
ether/EtOAc 49:1) provided 120 as a colorless oil (0.17 g, 72%). The cis-isomer was separable by careful
column chromatography using the same solvent system. cis-120 colorless oil (99 mg, 43%): IR (neat)
2925, 2854, 1821, 1463, 1253, 1096 cm-1; 1H NMR (400 MHz, CDCl3) 4.52 (ddd, J = 9.9, 6.3, 4.2 Hz,
1H), 3.60 (t, J = 6.6 Hz, 2H), 3.62–3.55 (m, 1H), 1.82–1.58 (m, 4H), 1.56–1.46 (m, 2H), 1.39–1.25 (m,
26H), 0.89 (s, 9H), 0.88 (t, J = 7.0 Hz, 3H), 0.05 (s, 6H); 13C NMR (100 MHz, CDCl3)  172.5, 75.9,
63.4, 52.9, 33.0, 32.1, 30.4, 29.8, 29.7, 29.6, 29.5, 29.5, 27.8, 26.2, 25.9, 25.7, 24.1, 22.9, 18.6, 14.3,
5.1; HRMS (ESI) calcd for C27H55O3Si (M + H)+ m/z 455.3920, found 455.3939.
2.4.5 Cleavage of silyl protecting group
General procedure
Pyridinium p-toluenesulfonate (PPTS) (0.3 equiv) was added to a solution of silyl ether (1.0 equiv, 0.07
M in EtOH/DCM, 1:1). The resulting mixture was then placed in a pre-heated oil bath (55 oC) for 3 h
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under reflux. The reaction was allowed to cool to rt. Et3N (10 volumes) was added and the reaction
mixture was concentrated. The crude product was purified by flash column chromatography on silica gel.

Z-3-Decylidene-4-(8-hydroxy)octanyloxetan-2-one (Z-117). The general procedure was followed using
Z-4-(8-tert-butyldimethylsilyloxy)octanyl-3-decanylideneoxetan-2-one (Z-116) (0.27 g, 0.59 mmol).
Purification by flash column chromatography on silica gel (hexanes/EtOAc 5:1) provided Z-117 as a
colorless oil (0.197 g, 98%): IR (neat) 3378 (br), 2923, 2854, 1802, 1464, 1146, 1112 cm-1; 1H NMR (400
MHz, CDCl3) 5.84 (ddd, J = 7.9, 7.9, 1.2 Hz, 1H), 4.88–4.82 (m, 1H), 3.64 (t, J = 6.6 Hz, 2H), 2.56–
2.41 (m, 2H), 1.80 (app q, J = 6.7 Hz, 2H), 1.61–1.52 (m, 2H), 1.50–1.41 (m, 2H), 1.40–1.17 (m, 22H),
0.88 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3)  164.4, 137.6, 136.5, 78.8, 63.2, 33.9, 32.9, 32.1,
29.7, 29.5, 29.5, 29.4, 29.4, 29.2, 29.1, 29.0, 25.9, 24.8, 22.9, 14.3; HRMS (ESI) calcd for C21H39O3 (M +
H)+ m/z 339.2899, found 339.2895.

E-3-Decylidene-4-(8-hydroxy)octanyloxetan-2-one (E-117). The general procedure was followed using
E-4-(8-tert-butyldimethylsilyloxy)octanyl-3-decanylideneoxetan-2-one (E-116) (0.11 g, 0.25 mmol).
Purification by flash column chromatography on silica gel (hexanes/EtOAc 5:1) provided E-117 as a
colorless oil (54 mg, 64%): IR (neat) 3345 (br), 2923, 2853, 1808, 1462, 1116, 1033 cm-1; 1H NMR (400
MHz, CDCl3) 6.32 (ddd, J = 7.9, 7.9, 1.6 Hz, 1H), 5.00–4.94 (m, 1H), 3.62 (t, J = 6.6 Hz, 2H), 2.09
(app q, J = 7.5 Hz, 2H), 1.96–1.85 (m, 1H), 1.82–1.69 (m, 1H), 1.60–1.40 (m, 4H) 1.39–1.17 (m, 22H),
0.87 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3)  164.5, 137.7, 134.2, 79.3, 63.1, 33.4, 32.9, 32.0,
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29.6, 29.6, 29.5, 29.5, 29.4, 29.4, 29.0, 28.6, 25.9, 24.8, 22.8, 14.3; HRMS (ESI) calcd for C21H39O3 (M +
H)+ m/z 339.2899, found 339.2904.

trans-3-Decyl-4-(8-hydroxy)octanyloxetan-2-one (trans-118). The general procedure was followed
using trans-4-(8-tert-butyldimethylsilyloxy)octanyl-3-decyloxetan-2-one (trans-120) (0.13 g, 0.28
mmol). Purification by flash column chromatography on silica gel (hexanes/EtOAc 5:1) provided trans118 as a colorless oil (47 mg, 50%): IR (neat) 3332 (br), 2919, 2851, 1794, 1467, 1146 cm-1; 1H NMR
(400 MHz, CDCl3) 4.24–4.17 (m, 1H), 3.63 (t, J = 6.4 Hz, 2H), 3.19–3.11 (m, 1H), 1.90–1.76 (m, 2H),
1.76–1.61 (m, 2H), 1.60–1.50 (m, 2H), 1.48–1.20 (m, 26H), 0.87 (t, J = 5.8 Hz, 3H);

13

C NMR (100

MHz, CDCl3)  171.9, 78.4, 63.2, 56.4, 34.6, 32.9, 32.1, 29.8, 29.7, 29.6, 29.5, 29.5, 29.4, 28.1, 27.2,
25.9, 25.2, 22.9, 14.3; HRMS (ESI) calcd for C21H41O3 (M + H)+ m/z 341.3056, found 341.3079.

cis-3-Decyl-4-(8-hydroxy)octanyloxetan-2-one (cis-118). The general procedure was followed using
cis-4-(8-tert-butyldimethylsilyloxy)octanyl-3-decyloxetan-2-one

(cis-120)

(0.058

g,

0.13

mmol).

Purification by flash column chromatography on silica gel (hexanes/EtOAc 5:1) provided cis-118 as a
colorless oil (32 mg, 75%): IR (neat) 3296 (br), 2918, 2849, 1795, 1468, 1155, 1060 cm-1; 1H NMR (400
MHz, CDCl3) 4.52 (ddd, J = 10.0, 6.4, 4.0 Hz, 1H), 3.63 (t, J = 6.6 Hz, 2H), 3.62–3.55 (m, 1H), 1.81–
1.46 (m, 6H), 1.45–1.18 (m, 26H), 0.87 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3)  172.5, 75.9,
63.2, 52.9, 32.9, 32.1, 30.4, 29.8, 29.7, 29.6, 29.6, 29.5, 29.5, 29.4, 27.8, 25.9, 25.7, 24.1, 22.9, 14.3;
HRMS (ESI) calcd for C21H41O3 (M + H)+ m/z 341.3056, found 341.3083.
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2.4.6 Appel bromination
General procedure
Tetrabromomethane (CBr4) (1.5 equiv) and triphenylphosphine (PPh3) (3 equiv) were added to the
alcohol solution (1 equiv, 0.03 M in DCM) at 0 oC. After 1 h, the reaction mixture was diluted with
petroleum ether (5 volumes) and then concentrated. The crude product was adsorbed onto silica gel (dry
loaded) and then purified by flash column chromatography on silica gel to give the bromide.

Z-4-(8-Bromo)octanyl-3-decanylideneoxetan-2-one (Z-119). The general procedure was followed using
Z-3-decylidene-4-(8-hydroxy)octanyloxetan-2-one (Z-117) (0.20 g, 0.58 mmol). Purification by flash
column chromatography on silica gel (hexanes/EtOAc 49:1) provided Z-119 as a colorless oil (96 mg,
41%): IR (neat) 2923, 2854, 1804, 1463, 1115, 1066 cm-1; 1H NMR (400 MHz, CDCl3) 5.84 (ddd, J =
7.9, 7.9, 1.0 Hz, 1H), 4.87–4.80 (m, 1H), 3.39 (t, J = 6.8 Hz, 2H), 2.55–2.40 (m, 2H), 1.88–1.74 (m, 4H),
1.50–1.37 (m, 4H), 1.36–1.18 (m, 20H), 0.87 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3)  164.3,
137.6, 136.5, 78.7, 34.1, 33.9, 32.9, 32.0, 29.7, 29.5, 29.4, 29.3, 29.2, 29.1, 29.0, 28.8, 28.3, 24.7, 22.8,
14.3; HRMS (ESI) calcd for C21H38BrO2 (M + H)+ m/z 401.2055, found 401.2033.

E-4-(8-Bromo)octanyl-3-decanylideneoxetan-2-one (E-119). The general procedure was followed using
E-3-decylidene-4-(8-hydroxy)octanyloxetan-2-one (E-117) (0.054 g, 0.16 mmol). Purification by flash
column chromatography on silica gel (hexanes/EtOAc 98:1) provided E-119 as a colorless oil (40 mg, 63
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%): IR (neat) 2924, 2854, 1811, 1462, 1118, 1049 cm-1; 1H NMR (400 MHz, CDCl3) 6.33 (ddd, J = 7.8,
7.8, 1.6 Hz, 1H), 5.02–4.94 (m, 1H), 3.40 (t, J = 6.8 Hz, 2H), 2.10 (app q, J = 7.5 Hz, 2H), 1.98–1.70 (m,
4H), 1.57–1.39 (m, 4H), 1.38–1.18 (m, 20H), 0.88 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
164.5, 137.8, 134.2, 79.3, 34.1, 33.4, 33.0, 32.0, 29.6, 29.5, 29.5, 29.4, 29.4, 29.0, 28.8, 28.6, 28.3, 24.8,
22.9, 14.3; HRMS (ESI) calcd for C21H38BrO2 (M + H)+ m/z 401.2055, found 401.2064.

trans-4-(8-Bromo)ocatanyl-3-decyloxetan-2-one (trans-121). The general procedure was followed
using trans-3-decyl-4-(8-hydroxy)octanyloxetan-2-one (trans-118) (0.10 g, 0.31 mmol). Purification by
flash column chromatography on silica gel (hexanes/EtOAc 49:1) provided trans-121 as a colorless oil
(0.12 g, 95%): IR (neat) 2924, 2854, 1822, 1464, 1121 cm-1; 1H NMR (400 MHz, CDCl3)  4.19 (ddd, J
= 7.2, 6.0, 4.1 Hz, 1H), 3.39 (t, J = 6.8 Hz, 2H), 3.15 (ddd, J = 8.8, 6.6, 4.0 Hz, 1H), 1.89–1.77 (m, 4H),
1.76–1.18 (m, 28H), 0.86 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3)  171.7, 78.2, 56.3, 34.6, 34.1,
32.9, 32.0, 29.7, 29.7, 29.4, 29.4, 29.3, 28.7, 28.2, 28.0, 27.1, 25.2, 22.8, 14.3; HRMS (ESI) calcd for
C21H40BrO2 (M + Na)+ m/z 425.2020, found 425.2011.

cis-4-(8-Bromo)ocatanyl-3-decyloxetan-2-one (cis-121). The general procedure was followed using cis3-decyl-4-(8-hydroxy)octanyloxetan-2-one (cis-118) (14 mg, 0.042 mmol). Purification by flash column
chromatography on silica gel (hexanes/EtOAc 49:1) provided cis-121 as a colorless oil (13 mg, 78%): IR
(neat) 2922, 2853, 1821, 1732, 1463, 1122 cm-1; 1H NMR (400 MHz, CDCl3) 4.56–4.48 (m, 1H), 3.63–
3.55 (m, 1H), 3.45–3.35 (m, 2H), 1.90–1.80 (m, 2H), 1.79–1.18 (m, 30H), 0.92–0.80 (m, 3H); 13C NMR
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(100 MHz, CDCl3) 172.5, 75.9, 52.9, 34.2, 33.0, 32.1, 30.4, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.4,
28.8, 28.3, 27.8, 25.8, 24.2, 22.9, 14.3; HRMS (ESI) calcd for C21H40BrO2 (M + H)+ m/z found.
2.4.7 Nucleophilic substitution of the bromide with dimethylamine
General procedure
Dimethylamine in H2O (40%, 1.0 equiv) and NaHCO3 (1.0 equiv) were added to a solution of the
bromide (1.0 equiv, 0.05 M in DMF) and the mixture was heated at reflux while stirring for 24 h. The
mixture was then allowed to cool to rt, concentrated, dissolved in DCM (20 volumes relative to bromide)
and then washed with water (20 volumes x 2). The organic layer was dried (NaSO4) and concentrated.

Z-3-Decanylidene-4-(8-dimethylamino)octanyloxetan-2-one (Z-85). The general procedure was
followed using Z-4-(8-bromo)octanyl-3-decanylideneoxetan-2-one (Z-119) (0.16 g, 0.41 mmol).
Purification by flash column chromatography on silica gel (NH4OH/MeOH/CHCl3 2:4.5:175) provided Z85 as a brown oil (55 mg, 37%): IR (neat) 2926, 2855, 1806, 1713, 1215 cm-1; 1H NMR (400 MHz,
CDCl3) 5.84 (ddd, J = 7.9, 7.9, 1.1 Hz, 1H), 4.86–4.80 (m, 1H), 2.56–2.41 (m, 2H), 2.44 (s, 6H), 1.78
(app q, J = 7.4 Hz, 2H), 1.66–1.55 (m, 2H), 1.49–1.37 (m, 4H), 1.36–1.18 (m, 22H), 0.86 (t, J = 6.6 Hz,
3H); 13C NMR (100 MHz, CDCl3)  164.4, 137.5, 136.6, 78.8, 59.3, 44.6, 33.9, 32.0, 29.6, 29.5, 29.4,
29.4, 29.2, 29.1, 29.0, 27.2, 26.5, 24.7, 22.8, 14.3; HRMS (ESI) calcd for C23H44NO2 (M + H)+ m/z
366.3361, found 366.3441.
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E-3-Decanylidene-4-(8-dimethylamino)octanyloxetan-2-one (E-85). The general procedure was
followed using E-4-(8-bromo)octanyl-3-decanylideneoxetan-2-one (E-119) (0.038 g, 0.095 mmol).
Purification by flash column chromatography on silica gel (NH4OH/MeOH/CHCl3 2:4.5:175) provided E85 as a brown oil (7.6 mg, 22%): 1H NMR (400 MHz, CDCl3) 6.34 (ddd, J = 7.8, 7.8, 1.6 Hz, 1H),
5.01–4.96 (m, 1H), 2.26–2.20 (m, 2H), 2,21 (s, 6H), 2.11 (app q, J = 7.4 Hz, 2H), 1.98–1.85 (m, 1H),
1.83–1.70 (m, 1H) 1.68–1.18 (m, 26H), 0.88 (t, J = 6.3 Hz, 3H).

trans-3-Decyl-4-(8-dimethylamino)octanyloxetan-2-one (trans-86). The general procedure was
followed using trans-4-(8-bromo)ocatanyl-3-decyloxetan-2-one (trans-121) (0.04 g, 0.099 mmol).
Purification by flash column chromatography on silica gel (NH4OH/MeOH/CHCl3 2:4.5:175) provided
trans-86 as a brown oil (12 mg, 33%): IR (neat) 2923, 2853, 1823, 1624, 1464, 1118 cm-1; 1H NMR (400
MHz, CDCl3)  4.21 (ddd, J = 7.2, 5.9, 4.0 Hz, 1H), 3.16 (t, J = 6.8 Hz, 2H), 3.15 (ddd, J = 8.8, 6.6, 4.0
Hz, 1H), 2.35–2.25 (m, 2H), 2.28 (s, 6H), 1.89–1.77 (m, 2H), 1.76–1.65 (m, 2H), 1.53–1.20 (m, 26H),
0.88 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3)  171.8, 78.4, 59.9, 56.4, 45.4, 34.7, 32.1, 29.9,
29.8, 29.7, 29.6, 29.5, 29.4, 28.1, 27.5, 27.2, 25.3, 22.9, 14.3; HRMS (ESI) calcd for C23H46NO2 (M + H)+
m/z 368.3518, found 368.3609.
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cis-3-Decyl-4-(8-dimethylamino)octanyloxetan-2-one (cis-86). The general procedure was followed
using cis-4-(8-bromo)ocatanyl-3-decyloxetan-2-one (cis-121) (0.034 g, 0.084 mmol). Purification by
flash column chromatography on silica gel (NH4OH/MeOH/CHCl3 2:4.5:175) provided cis-86 as a brown
oil (7.6 mg, 24%): IR (neat) 2923, 2854, 1822, 1464, 1119 cm-1;

H NMR (400 MHz, CDCl3)  4.52

1

(ddd, J = 10.2, 6.4, 4.1 Hz, 1H), 3.59 (ddd, J = 8.6, 6.8, 6.8 Hz, 1H), 2.26–2.20 (m, 2H), 2.22 (s, 6H),
1.82–1.18 (m, 32H), 0.88 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3)  172.6, 76.0, 60.2, 52.9, 45.8,
32.1, 30.4, 29.8, 29.8, 29.7, 29.6, 29.6, 29.5, 29.5, 28.0, 27.8, 27.7, 25.8, 24.2, 22.9, 14.3; HRMS (ESI)
calcd for C23H46NO2 (M + H)+ m/z 368.3529, found 368.3510.
2.4.8 Rh-catalyzed conjugate additions of aryl boronic acids to -methylene--lactones 108

General procedure
Aryl boronic acid (1.5 equiv, 0.75 mmol unless otherwise noted) and 1 mol % [Rh(cod)Cl]2 (0.0050
mmol, 2.5 mg) were placed in a reaction tube equipped with a stir bar. The reaction tube was capped with
a rubber septum then filled and back-filled with N2 three times. Aqueous 2 M KOH (1 equiv, 0.25 mL)
was added, followed by the -methylene--lactone 108 (0.50 mmol unless otherwise noted) dissolved in
dioxane (2.5 mL). The resulting yellow solution was stirred in an oil bath at 60 oC for 1 h. The reaction
was quenched with saturated aqueous NH4Cl (5 mL) and extracted with Et2O (3 x 10 mL). The combined
organic extracts were dried (Na2SO4) and concentrated in vacuo. An aliquout of the reaction mixture was
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analyzed by 1H NMR to determine the diastereoselectivity. The crude mixture was purified by flash
column chromatography. In all cases, the trans isomers were obtained as the major products.

trans/cis-3-Benzyl-4-(8-tert-butyldimethylsilyloxy)octanyloxetan-2-one (127a). The general procedure
was followed using 4-(8-tert-butyldimethylsilyloxy)octanyl-3-methyleneoxetan-2-one (108) (0.40 g, 1.3
mmol) and phenylboronic acid (0.24 g, 2.0 mmol). The 1H NMR trans:cis ratio of the crude reaction
mixture was 2:1. Purification by flash column chromatography on silica gel (hexanes/EtOAc 98:2)
provided 127a as a colorless oil (0.39 g, 79%). The trans-isomer was separable by careful column
chromatography using the same solvent system. trans-127a (colorless oil): IR (neat) 2927, 2854, 1821,
1455, 1249,1093 cm-1; 1H NMR (400 MHz, CDCl3) 7.34–7.18 (m, 5 H), 4.27 (ddd, J = 6.7, 6.7, 4.1 Hz,
1H), 3.59 (t, J = 6.6 Hz, 2H), 3.45 (ddd, J = 9.5, 5.6, 4.1 Hz, 1H), 3.16 (dd, J = 14.3, 5.7 Hz, 1H), 3.00
(dd, J = 14.2, 9.3 Hz, 1H), 1.83–1.75 (m, 1H), 1.63–1.55 (m, 1H), 1.52–1.45 (m, 2H) 1.32–1.04 (m, 10H),
0.90 (s, 9H), 0.05 (s, 6H); 13C NMR (100 MHz, CDCl3)  170.9, 137.4, 129.0, 128.8, 127.2, 77.7, 63.4,
57.5, 34.4, 34.0, 33.0, 29.5, 29.3, 29.2, 26.2, 25.9, 24.8, 18.5, 5.1; HRMS (ESI) calcd for C24H41O3Si (M
+ H)+ m/z 405.2825, found 405.2827.
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trans/cis-4-(8-tert-Butyldimethylsilyloxyoctanyl)-3-(4-methoxyphenylmethyl)oxetan-2-one

(127b).

The general procedure was followed using 4-(8-tert-butyldimethylsilyloxy)octanyl-3-methyleneoxetan-2one (108) and 4-methoxyphenylboronic acid. The 1H NMR trans:cis ratio of the crude reaction mixture
was 2.2:1. Purification by flash column chromatography on silica gel (hexanes/EtOAc 40:1) provided
127b as a colorless oil (0.17 g, 85%). The isomers were separated by careful column chromatography
using the same solvent system. trans-127b (colorless oil): IR (neat) 2928, 2855, 1820, 1513, 1247, 1095
cm-1; 1H NMR (400 MHz, CDCl3)  7.13–7.07 (m, 2H), 6.87–6.82 (m, 2H), 4.25 (ddd, J = 6.8, 6.8, 4.2
Hz, 1H), 3.79 (s, 3 H), 3.57 (t, J = 6.6 Hz, 2H), 3.41 (ddd, J = 9.5, 5.7, 4.2 Hz, 1H), 3.09 (dd, J = 14.4, 5.8
Hz, 1H), 2.95 (dd, J = 14.4, 9.0 Hz, 1H), 1.82–1.75 (m, 1 H), 1.63–1.58 (m, 1H), 1.52–1.45 (m, 2H) 1.34–
1.08 (m, 10H), 0.89 (s, 9H), 0.04 (s, 6H); 13C NMR (100 MHz, CDCl3)  171.1, 158.9, 129.9, 129.3,
114.5, 77.6, 63.5, 57.8, 55.5, 34.4, 33.1, 33.0, 29.6, 29.4, 29.3, 26.2, 26.0, 24.9, 18.6, 5.1; HRMS (ESI)
calcd for C25H43O4Si (M + H)+ m/z 435.2931, found 435.2929. cis-127b (colorless oil): IR (neat) 2927,
2854, 1821, 1247, 1094 cm-1; 1H NMR (400 MHz, CDCl3)  7.16–7.11 (m, 2H), 6.88–6.83 (m, 2H), 4.58
(ddd, J = 6.4, 6.4, 3.6 Hz, 1H), 3.95 (ddd, J = 8.8, 7.2, 7.2 Hz, 1H), 3.79 (s, 3H) 3.60 (t, J = 6.6 Hz, 2H),
3.12 (dd, J = 15.0, 7.4 Hz, 1H), 2.92 (dd, J = 15.0, 8.8 Hz, 1H), 1.82–1.75 (m, 1H), 1.71–1.62 (m, 1H),
1.53–1.49 (m, 2H) 1.39–1.24 (m, 10H), 0.89 (s, 9H), 0.05 (s, 6H); 13C NMR (100 MHz, CDCl3)  171.8,
158.7, 129.8, 129.6, 114.4, 76.2, 63.5, 55.5, 53.8, 33.1, 30.6, 29.6, 29.5, 29.4, 29.1, 26.2, 26.0, 25.8, 18.6,
5.0; HRMS (ESI) calcd for C25H43O4Si (M + H)+ m/z 435.2931, found 435.2930.
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trans/cis-3-(1,4-benzodioxane-6-methyl)-4-(8-tert-Butyldimethylsilyloxy)octanyloxetan-2-one (127c).
The general procedure was followed using 4-(8-tert-butyldimethylsilyloxy)octanyl-3-methyleneoxetan-2one (108) and 1,4-benzodioxane-6-boronic acid. The 1H NMR trans:cis ratio of the crude reaction
mixture was 2.2:1. Purification by flash column chromatography on silica gel (hexanes/EtOAc 40:1)
provided 127c as a colorless oil (0.19 g, 89%). The trans-isomer was separable by careful column
chromatography using the same solvent system. trans-127c (colorless oil): IR (neat) 2927, 2855, 1821,
1287, 1096, 1068 cm-1; 1H NMR (400 MHz, CDCl3)  6.80 (d, J = 8.2 Hz, 1H), 6.71–6.67 (m, 1H), 6.64
(dd, J = 8.2, 1.5 Hz, 1H), 4.28–4.23 (m, 1H), 4.23 (s, 4H), 3.59 (t, J = 6.5 Hz, 2H), 3.40 (ddd, J = 9.4, 5.3,
5.3 Hz, 1H), 3.04 (dd, J = 14.4, 5.6 Hz, 1H) 2.88 (dd, J = 14.3, 9.3 Hz, 1H), 1.83–1.77 (m, 1H), 1.64–1.59
(m, 1H), 1.51–1.46 (m, 2H) 1.33–1.08 (m, 10H), 0.89 (s, 9H), 0.04 (s, 6H); 13C NMR (100 MHz, CDCl3)
 171.1, 143.8, 142.8, 130.5, 121.8, 117.8, 117.6, 77.7, 64.6, 64.5, 63.5, 57.6, 34.4, 33.3, 33.0, 29.6, 29.4,
29.3, 26.2, 26.0, 24.9, 18.6, 5.0; HRMS (ESI) calcd for C26H43O5Si (M + H)+ m/z 463.2880, found
463.2872.
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trans/cis-4-(8-tert-Butyldimethylsilyloxy)octanyl-3-(3-phenoxyphenylmethyl)oxetan-2-one

(127d).

The general procedure was followed using 4-(8-tert-butyldimethylsilyloxy)octanyl-3-methyleneoxetan-2one (108) and 3-phenoxyphenylboronic acid. The 1H NMR trans:cis ratio of the crude reaction mixture
was 2.2:1. Purification by flash column chromatography on silica gel (hexanes/EtOAc 39:1) provided
127d as a colorless oil (0.17 g, 72%). The trans-isomer was separable by careful column chromatography
using the same solvent system. Trans-127d (colorless oil): IR (neat) 2927, 2854, 1822, 1488, 1237, 1095
cm-1; 1H NMR (400 MHz, CDCl3)  7.36–7.30 (m, 2H), 7.18–7.13 (m, 2H), 7.13–7.08 (m, 1H), 7.01–
6.94 (m, 4H), 4.28 (ddd, J = 6.7, 6.7, 4.0 Hz, 1H), 3.59 (t, J = 6.6 Hz, 2H), 3.44 (ddd, J = 9.2, 5.8, 4.1 Hz,
1H), 3.14 (dd, J = 14.4, 5.9 Hz, 1H), 2.99 (dd, J = 14.4, 9.0 Hz, 1H), 1.86–1.78 (m, 1 H), 1.66–1.59 (m, 1
H), 1.53–1.46 (m, 2H) 1.35–1.10 (m, 10H), 0.89 (s, 9H), 0.04 (s, 6H); 13C NMR (100 MHz, CDCl3) 
170.9, 157.3, 156.6, 132.1, 130.2, 130.0, 123.6, 119.4, 119.1, 77.6, 63.5, 57.6, 34.4, 33.3, 33.0, 29.6, 29.5,
29.3, 26.2, 26.0, 24.9, 18.6, 5.1; HRMS (ESI) calcd for C30H45O4Si (M + H)+ m/z: 476.3196, found
476.3208.

113

trans/cis-4-(8-tert-Butyldimethylsilyloxy)octanyl-3-(4-methylphenylmethyl)oxetan-2-one (127e). The
general procedure was followed using 4-(8-tert-butyldimethylsilyloxy)octanyl-3-methyleneoxetan-2-one
(108) and p-tolylboronic acid. The 1H NMR trans:cis ratio of the crude reaction mixture was 2.5:1.
Purification by flash chromatography on silica gel (hexanes/EtOAc 40:1) provided 127e as a colorless oil
(0.15 g, 78%). The trans-isomer was separated by careful column chromatography using the same solvent
system. trans-127e (colorless oil): IR (neat) 2927, 2854, 1821, 1249, 1093 cm-1; 1H NMR (400 MHz,
CDCl3)  7.14–7.10 (m, 2H), 7.09–7.05 (m, 2H), 4.26 (ddd, J = 6.8, 4.0, 4.0 Hz, 1H), 3.59 (t, J = 6.6 Hz,
2H), 3.43 (ddd, J = 9.4, 5.6, 4.0 Hz, 1H), 3.12 (dd, J = 14.3, 5.7 Hz, 1H) 2.96 (dd, J = 14.3, 9.2 Hz, 1H),
2.32 (s, 3H), 1.82–1.74 (m, 1H), 1.63–1.58 (m, 1H), 1.52–1.45 (m, 2H) 1.33–1.05 (m, 10H), 0.89 (s, 9H),
0.05 (s, 6H); 13C NMR (100 MHz, CDCl3) 171.1, 136.9, 134.3, 129.8, 128.8, 77.7, 63.5, 57.7, 34.4,
33.6, 33.1, 29.6, 29.4, 29.3, 26.0, 24.9, 21.2, 18.6, 5.0; HRMS (ESI) calcd for C25H43O3Si (M + H)+ m/z
419.2981, found 419.2958.

trans/cis-4-(8-tert-Butyldimethylsilyloxy)octanyl-3-(4-fluorophenylmethyl)oxetan-2-one (127f). The
general procedure was followed using 4-(8-tert-butyldimethylsilyloxy)octanyl-3-methyleneoxetan-2-one
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(108) and 4-fluorophenylboronic acid. The 1H NMR trans:cis ratio of the crude reaction mixture was
1.7:1. Purification by flash column chromatography on silica gel (hexanes/EtOAc 98:2) provided 127f as
a colorless oil (0.16 g, 84%). The trans-isomer was separable by careful column chromatography using
the same solvent system. trans-127f (colorless oil): IR (neat) 2926, 2854, 1820, 1510, 1222, 1092 cm-1;
H NMR (400 MHz, CDCl3)  7.20–7.13 (m, 2 H), 7.05–6.97 (m, 2 H), 4.25 (ddd, J = 6.8, 6.8, 4.1 Hz, 1

1

H), 3.59 (t, J = 6.6 Hz, 2 H), 3.42 (ddd, J = 8.9, 6.0, 4.1 Hz, 1 H), 3.13 (dd, J = 14.4, 6.0. Hz, 1 H), 2.99
(dd, J = 14.4, 8.9 Hz, 1H), 1.84–1.77 (m, 1 H), 1.64–1.57 (m, 1 H), 1.52–1.45 (m, 2 H) 1.35–1.10 (m, 10
H), 0.90 (s, 9 H), 0.05 (s, 6 H); 13C NMR (100 MHz, CDCl3)  170.8, 162.2 (d, JC-F = 244.2 Hz), 133.0 (d,
JC-F = 3.1 Hz), 130.5 (d, JC-F = 8.1 Hz), 116.0 (d, JC-F = 21.4 Hz), 77.5, 63.5, 57.6, 34.4, 33.2, 33.0, 29.5,
29.4, 29.3, 26.2, 25.9, 24.9, 18.6, 5.1; HRMS (ESI) calcd for C24H40FO3Si (M + H)+ m/z 423.2731,
found 423.2732.

trans/cis-4-(8-tert-Butyldimethylsilyloxy)octanyl-3-(2-naphthylmethyl)oxetan-2-one

(127g).

The

general procedure was followed using 4-(8-tert-butyldimethylsilyloxy)octanyl-3-methyleneoxetan-2-one
(108) (0.40 g, 1.2 mmol) and 2-naphthylboronic acid (0.31 g, 1.8 mmol). The 1H NMR trans:cis ratio of
the crude reaction mixture was 2.4:1. Purification by flash column chromatography on silica gel
(hexanes/EtOAc 98:2) provided 127g as a colorless oil (0.49 g, 88%). The trans-isomer was separable by
careful column chromatography using the same solvent system. trans-127g (colorless oil): IR (neat) 2927,
2854, 1819, 1249, 1093 cm-1; 1H NMR (400 MHz, CDCl3)  7.85–7.77 (m, 3H), 7.65 (s, 1H), 7.52–7.44
(m, 2H), 7.32 (dd, J = 8.4, 1.4 Hz, 1H), 4.43 (ddd, J = 6.7, 6.7, 4.1 Hz, 1H), 3.58 (t, J = 6.6 Hz, 2H),
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3.61–3.52 (m, 1H), 3.34 (dd, J = 14.3, 5.6 Hz, 1H), 3.16 (dd, J = 14.3, 9.4 Hz, 1H), 1.82–1.75 (m, 1H),
1.63–1.55 (m, 1H), 1.49–1.41 (m, 2H) 1.25–1.00 (m, 10H), 0.91 (s, 9H), 0.06 (s, 6H);

13

C NMR (100

MHz, CDCl3) 170.9, 134.8, 133.7, 132.6, 128.9, 127.9, 127.7, 127.4, 126.9, 126.5, 126.0, 77.7, 63.4,
57.4, 34.4, 34.2, 33.0, 29.5, 29.3, 29.2, 26.2, 25.9, 24.8, 18.6, 5.1; HRMS (ESI) calcd for C28H43O3Si (M
+ H)+ m/z 455.2981, found 455.2953.

trans/cis-4-(8-tert-Butyldimethylsilyloxy)octanyl-3-(1-methyl-5-indolylmethyl)oxetan-2-one

(127h).

The general procedure was followed using 4-(8-tert-butyldimethylsilyloxy)octanyl-3-methyleneoxetan-2one (108) and 1-methyl-5-indolylboronic acid. The 1H NMR trans:cis ratio of the crude reaction mixture
was 1.6:1. Purification by flash column chromatography on silica gel (hexanes/EtOAc 97:3) provided
127h as a colorless oil (0.15 g, 71%). The trans-isomer was separable by careful column chromatography
using the same solvent system. trans-127h (colorless oil): IR (neat) 2926, 2854, 1817, 1246, 1095 cm-1;
H NMR (400 MHz, CDCl3)  7.42 (s, 1H), 7.28–7.26 (m, 1H), 7.05–7.03 (m, 2H), 6.43 (d, J = 3.0 Hz,

1

1H), 4.31 (ddd, J = 6.7, 6.7, 4.1 Hz, 1H), 3.78 (s, 3H), 3.58 (t, J = 6.6, Hz, 2H), 3.50 (ddd, J = 9.4, 5.4,
4.1 Hz, 1H), 3.26 (dd, J = 14.3, 5.5. Hz, 1H), 3.10 (dd, J = 14.3, 9.3 Hz, 1H), 1.78–1.72 (m, 1H), 1.60–
1.54 (m, 1H), 1.50–1.43 (m, 2H) 1.35–1.05 (m, 10H), 0.90 (s, 9H), 0.05 (s, 6H); 13C NMR (100 MHz,
CDCl3)  171.5, 136.1, 129.6, 129.1, 128.1, 122.5, 120.9, 109.8, 100.9, 77.8, 63.5, 58.2, 34.5, 34.1, 33.1,
33.0, 29.5, 29.4, 29.3, 26.2, 26.0, 24.9, 18.6, 5.0; HRMS (ESI) calcd for C27H44NO3Si (M + H)+ m/z
458.3090, found 458.3059.
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trans/cis-4-(8-tert-Butyldimethylsilyloxy)octanyl-3-(3-benzyloxyphenylmethyl)oxetan-2-one

(127i).

The general procedure was followed using 4-(8-tert-butyldimethylsilyloxy)octanyl-3-methyleneoxetan-2one (108) (0.20 g, 0.61 mmol) and 3-(benzyloxy)phenylboronic acid (0.21 g, 0.92 mmol). The 1H NMR
trans:cis ratio of the crude reaction mixture was 2:1. Purification by flash column chromatography on
silica gel (hexanes/EtOAc 40:1) provided 127i as a colorless oil (0.22 g, 71%). The trans-isomer was
separable by careful column chromatography using the same solvent system. trans-127i (colorless oil): IR
(neat) 2928, 2855, 1821, 1255, 1095, 1027 cm-1; 1H NMR (400 MHz, CDCl3)  7.45–7.36 (m, 4H), 7.35–
7.30 (m, 1H), 7.23 (t, J = 7.9 Hz, 1H), 6.87 (dd, J = 8.1, 2.1 Hz, 1H), 6.82–6.77 (m, 2H), 5.06 (s, 2H),
4.24 (ddd, J = 6.7, 6.7, 4.1 Hz, 1H) 3.58 (t, J = 6.6 Hz, 2H), 3.43 (ddd, J = 9.5, 5.6, 4.1 Hz, 1H), 3.13 (dd,
J = 14.3, 5.7 Hz, 1H) 2.96 (dd, J = 14.3, 9.3 Hz, 1H), 1.81–1.70 (m, 1H), 1.62–1.44 (m, 3H), 1.35–1.15
(m, 10H), 0.89 (s, 9H), 0.04 (s, 6H); 13C NMR (100 MHz, CDCl3)  171.0, 159.4, 139.0, 137.1, 130.2,
128.8, 128.2, 127.7, 121.4, 115.6, 113.6, 70.2, 63.5, 57.4, 34.4, 34.0, 33.1, 29.6, 29.4, 29.3, 26.2, 26.0,
24.9, 18.6, 5.0; HRMS (ESI) calcd for C31H47O4Si (M + H)+ m/z 511.3244, found 511.3223.
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trans-4-[8-(tert-Butyldimethylsilyloxy)octanyl]-3-(3-(N, N dimethylcarbamoyl)benzyl)oxetan-2-one
(127j). The

general

procedure

was followed using 4-(8-tert-butyldimethylsilyloxy)octanyl-3-

methyleneoxetan-2-one (108) and 3-(dimethylcarbamoyl)phenylboronic acid. The 1H NMR trans:cis ratio
of the crude reaction mixture was 1.6:1. Purification by flash column chromatography on silica gel
(hexanes/EtOAc 97:3) provided 127j as a colorless oil (0.16 g, 67%). The cis-isomer was separable by
careful column chromatography using the same solvent system. cis-127j (colorless oil): IR (neat) 2926,
2854, 1817, 1737, 1634, 1461,1389, 1253, 1092 cm-1; 1H NMR (400 MHz, CDCl3) 7.39–7.32 (m, 1 H),
7.27 (d, J = 7.3, 3 H), 4.59 (ddd, J = 9.9, 6.3, 3.5 Hz, 1 H), 3.97 (dd, J = 14.6, 8 Hz, 1 H), 3.58 (t, J = 6.6
Hz,1 H), 3.17 (dd, J = 15.0, 7.9. Hz, 1 H), 3.10 (br s, 3H), 2.98 (dd, J = 15.1, 8.4 Hz, 1 H), 2.97 (br s, 3H)
1.82–1.74 (m, 1 H), 1.68–1.61 (m, 1 H), 1.51–1.47 (m, 2 H) 1.28 (br s, 10 H), 0.88 (s, 9 H), 0.03 (s, 6 H);
C NMR (100 MHz, CDCl3)  171.4, 138.1, 137.1, 129.8, 129.0, 127.2, 125.7, 76.0, 63.4, 53.3, 33.0,

13

30.6, 29.9, 29.8, 29.6, 29.4, 29.4, 26.2, 25.9, 25.7, 18.6, 5.0; HRMS (ESI) calcd for C27H46NO4Si (M +
H)+ m/z 476.3196, found 476.3208.
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trans/cis-4-(8-tert-Butyldimethylsilyloxyoctanyl)-3-(4-hydroxyphenylmethyl)oxetan-2-one

(127k).

The general procedure was followed using 4-(8-tert-butyldimethylsilyloxy)octanyl-3-methyleneoxetan-2one (108) and 4-hydroxyphenylboronic acid. The 1H NMR trans:cis ratio of the crude reaction mixture
was 2:1. Purification by flash column chromatography on silica gel (hexanes/EtOAc 70:30) provided
127k as a colorless oil (0.13 g, 68%). The isomers were separated by careful column chromatography
using the same solvent system. trans-127k (colorless oil): IR (neat) 3402 (br), 2928, 2855, 1819, 1801,
1516, 1252, 1096 cm-1; 1H NMR (400 MHz, CDCl3)  7.07–7.01 (m, 2H), 6.81–6.75 (m, 2H), 5.85 (br s,
1H), 4.25 (ddd, J = 6.9, 6.9, 4.0 Hz, 1H), 3.64 (t, J = 6.8 Hz, 2H), 3.39 (ddd, J = 9.7, 5.3, 4.2 Hz, 1H),
3.12 (dd, J = 14.3, 5.4 Hz, 1H), 2.89 (dd, J = 14.3, 10.0 Hz, 1H), 1.83–1.75 (m, 1H), 1.57–1.48 (m, 1H),
1.29–1.24 (m, 2H) 1.35–0.95 (m, 10H), 0.89 (s, 9H), 0.09 (s, 6H); 13C NMR (100 MHz, CDCl3)  171.3,
155.2, 130.0, 129.2, 116.0, 77.8, 63.7, 58.1, 34.3, 33.2, 32.6, 29.4, 29.1, 29.1, 26.2, 25.6, 24.6, 18.7, 5.0;
HRMS (ESI) calcd for C24H41O4Si (M + H)+ m/z 421.2774, found 421.2746. cis-127k (colorless oil): IR
(neat) 3379 (br), 2927, 2855, 1797, 1516, 1252, 1095 cm-1; 1H NMR (400 MHz, CDCl3)  7.10–7.05 (m,
2H), 6.80–6.75 (m, 2H), 5.35 (br s, 1H), 4.57 (ddd, J = 10.0, 6.3, 4.0 Hz, 1H), 3.96 (ddd, J = 9.0, 7.0, 7.0
Hz, 1H), 3.61 (t, J = 6.7 Hz, 2H), 3.11 (dd, J = 15.0, 7.2 Hz, 1H), 2.91 (dd, J = 15.0, 9.1 Hz, 1H), 1.82–
1.72 (m, 1H), 1.69–1.62 (m, 1H), 1.54–1.47 (m, 2H) 1.37–1.20 (m, 10H), 0.90 (s, 9H), 0.07 (s, 6H); 13C
NMR (100 MHz, CDCl3)  172.0, 154.8, 129.7, 129.7, 115.9, 76.4, 63.7, 53.6, 32.9, 30.4, 29.4, 29.3,
29.3, 29.1, 26.2, 25.8, 25.7, 18.6, 5.0; HRMS (ESI) calcd for C24H41O4Si (M + H)+ m/z 421.2774, found
421.2743.
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2.4.9 Elaboration of -lactones 127
2.4.9.1 Cleavage of silyl protecting group
General procedure
Pyridinium p-toluenesulfonate (PPTS) (0.3 equiv) was added to a solution of silyl ether (1.0 equiv, 0.07
M in EtOH/DCM, 1:1). The resulting mixture was then placed in a pre-heated oil bath (55 oC) for 3 h
under reflux. The reaction was allowed to cool to rt. Et3N (10 volumes) was added and the reaction
mixture was concentrated. The crude product was purified by flash column chromatography on silica gel.

trans-3-Benzyl-4-(8-hydroxy)octanyloxetan-2-one (trans-128a). The general procedure was followed
using trans-3-benzyl-4-(8-tert-butyldimethylsilyloxy)octanyloxetan-2-one (127a) (0.11 g, 0.27 mmol).
Purification by flash column chromatography on silica gel (hexanes/EtOAc 3:2) provided trans-128a as a
colorless oil (70 mg, 89%): IR (neat) 3390 (br), 2926, 2855, 1815, 1455, 1123, 1068 cm-1; 1H NMR (400
MHz, CDCl3 )  7.35–7.14 (m, 5H), 4.30–4.23 (m, 1H), 3.62 (t, J = 6.3 Hz, 2H), 3.48–3.41 (m, 1H), 3.16
(dd, J = 14.2, 5.3 Hz, 1H), 2.99 (dd, J = 13.8, 9.5 Hz, 1H), 1.82–1.71 (m, 1H), 1.63–1.48 (m, 3H), 1.43–
1.00 (m, 10H); 13C NMR (100 MHz, CDCl3)  171.0, 137.4, 129.1, 128.8, 127.3, 77.7, 63.1, 57.5, 34.4,
34.0, 32.9, 29.4, 29.3, 29.2, 25.8, 24.8; HRMS (ESI) calcd for C18H27O3 (M + H)+ m/z 291.1960, found
291.1982.
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trans-4-(8-Hydroxy)octanyl-3-(4-methoxyphenylmethyl)oxetan-2-one

(trans-128b).

The

general

procedure was followed using trans-4-(8-tert-butyldimethylsilyloxyoctanyl)-3-(4-methoxyphenylmethyl)oxetan-2-one (127b) (0.059 g, 0.13 mmol). Purification by flash column chromatography on silica
gel (hexanes/EtOAc 3:2) provided trans-128b as a colorless oil (35 mg, 81%): IR (neat) 3395 (br), 2926,
2854, 1814, 1512, 1245, 1118, 1031 cm-1; 1H NMR (400 MHz, CDCl3)  7.13–7.08 (m, 2H), 6.88–6.83
(m, 2H), 4.25 (ddd, J = 6.8, 6.8, 4.1 Hz, 1H), 3.79 (s, 3 H), 3.67–3.59 (m, 2H), 3.41 (ddd, J = 9.4, 5.8, 4.1
Hz, 1H), 3.09 (dd, J = 14.4, 5.8 Hz, 1H), 2.95 (dd, J = 14.4, 9.1 Hz, 1H), 1.83–1.72 (m, 1 H), 1.64–1.49
(m, 3H), 1.36–1.14 (m, 10H); 13C NMR (100 MHz, CDCl3) ; 171.1, 158.9, 129.9, 129.3, 114.5, 77.6,
63.2, 57.8, 55.5, 34.4, 33.1, 32.9, 29.5, 29.3, 29.2, 25.9, 24.9; HRMS (ESI) calcd for C19H29O4 (M + H)+
m/z 321.2066, found 321.2046.

trans-3-(1,4-Benzodioxane-6-methyl)-4-(8-hydroxy)octanyloxetan-2-one (trans-128c). The general
procedure was followed using trans-4-(8-tert-butyldimethylsilyloxy)octanyl-3-(1,4-benzodioxane-6methyl)oxetan-2-one (127c) (0.027 g, 0.058 mmol). Purification by flash column chromatography on
silica gel (hexanes/EtOAc 3:2) provided trans-128c as a colorless oil (9 mg, 43%): IR (neat) 3420 (br),
2928, 2855, 1818, 1508, 1352, 1067 cm-1; 1H NMR (400 MHz, CDCl3)  6.80 (d, J = 8.2 Hz, 1H), 6.71–
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6.67 (m, 1H), 6.65 (dd, J = 8.2, 1.8 Hz, 1H), 4.29–4.23 (m, 1H), 4.24 (s, 4H), 3.67–3.59 (m, 2H), 3.40
(ddd, J = 9.4, 5.2, 5.2 Hz, 1H), 3.05 (dd, J = 14.4, 5.6 Hz, 1H), 2.89 (dd, J = 14.4, 9.3 Hz, 1H), 1.83–1.73
(m, 1H), 1.65–1.50 (m, 4H), 1.39–1.15 (m, 10H); 13C NMR (100 MHz, CDCl3)  171.0, 143.8, 142.8,
130.6, 121.8, 117.8, 117.6, 77.7, 64.6, 64.5, 63.2, 57.6, 34.4, 33.3, 32.9, 29.6, 29.4, 29.3, 25.9, 24.9;
HRMS (ESI) calcd for C20H29O5 (M + H)+ m/z 349.2015, found 349.1999.

trans-3-(4-Fluorophenylmethyl)-4-(8-hydroxy)octanyloxetan-2-one

(trans-128f).

The

general

procedure was followed using trans-4-(8-tert-butyldimethylsilyloxy)octanyl-3-(4-fluorophenylmethyl)oxetan-2-one (127f) (0.023 g, 0.054 mmol). Purification by flash column chromatography on silica gel
(hexanes/EtOAc 3:2) provided trans-128f as a colorless oil (12 mg, 71%): IR (neat) 3362 (br), 2923,
2854, 1820, 1739, 1510, 1222 cm-1; 1H NMR (400 MHz, CDCl3)  7.19–7.14 (m, 2H), 7.05–6.98 (m,
2H), 4.25 (ddd, J = 6.7, 6.7, 4.0 Hz, 1H), 3.78 (s, 3H), 3.64 (m, 2H), 3.43 (ddd, J = 9.1, 6.0, 4.1 Hz, 1H),
3.13 (dd, J = 14.4, 6.0. Hz, 1H), 2.99 (dd, J = 14.4, 9.0 Hz, 1H), 1.85–1.74 (m, 1H), 1.65–1.50 (m, 4H),
1.38–1.15 (m, 10H); 13C NMR (100 MHz, CDCl3)  170.7, 162.2 (d, JC-F = 244.0 Hz), 133.1 (d, JC-F = 3.0
Hz), 130.5 (d, JC-F = 8.0 Hz), 116.0 (d, JC-F = 21.0 Hz), 77.4, 63.2, 57.6, 34.4, 33.2, 32.9, 29.5, 29.4, 29.3,
25.9, 24.9; HRMS (ESI) calcd for C18H26FO3 (M + H)+ m/z 309.1866, found 309.1868.
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trans-4-(8-Hydroxy)octanyl-3-(2-naphthylmethyl)oxetan-2-one (trans-128g). The general procedure
was followed using trans-4-(8-tert-butyldimethylsilyloxy)octanyl-3-(2-naphthylmethyl)oxetan-2-one
(127g) (0.10 g, 0.23 mmol). Purification by flash column chromatography on silica gel (hexanes/EtOAc
3:2) provided trans-128g as a colorless oil (53 mg, 68%): IR (neat) 3382 (br), 2928, 2855, 1817, 1125 cm; H NMR (400 MHz, CDCl3) 7.81–7.77 (m, 3H), 7.64 (s, 1H), 7.48 (dddd, J = 13.5, 6.9, 1.6, 1.6 Hz.

1 1

2H), 7.32 (dd, J = 8.4, 1.6 Hz, 1H), 4.33 (ddd, J = 6.7, 6.7, 4.1 Hz, 1H), 3.60 (t, J = 6.6 Hz, 2H), 3.56
(ddd, J = 9.8, 5.6, 4.1 Hz, 1H), 3.34 (dd, J = 14.3, 5.6 Hz, 1H), 3.16 (dd, J = 14.3, 9.5 Hz, 1H), 1.82–1.71
(m, 1H), 1.63–1.53 (m, 1H), 1.52–1.43 (m, 2H) 1.37–1.00 (m, 10H);

C NMR (100 MHz, CDCl3) 

13

171.0, 134.9, 133.7, 132.6, 128.9, 127.9, 127.7, 127.5, 126.9, 126.6, 126.1, 77.8, 63.2, 57.5, 34.4, 34.2,
32.9, 29.3, 29.2, 25.8, 24.9; HRMS (ESI) calcd for C22H29O3 (M + H)+ m/z 341.2117, found 341.2135.

trans-4-(8-Hydroxy)octanyl-3-(1-methyl-5-indolylmethyl)oxetan-2-one (trans-128h). The general
procedure was followed using trans-4-(8-tert-butyldimethylsilyloxy)octanyl-3-(1-methyl-5-indolylmethyl)oxetan-2-one (127h) (0.098 g, 0.2 mmol) and PPTS (0.02 g, 0.06 mmol). Purification by flash
column chromatography on silica gel (hexanes/EtOAc 3:2) provided trans-128h as a colorless oil (68 mg,
52%). IR (neat) 3355 (br), 2926, 2854, 1813, 1122, 1077 cm-1; 1H NMR (400 MHz, CDCl3)  7.43–7.40
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(m, 1H), 7.29–7.26 (m, 1H), 7.06–7.02 (m, 2H), 6.44–6.42 (m, 1H), 4.31 (ddd, J = 6.4, 6.4, 4.0 Hz, 1H),
3.79 (s, 3H), 3.61 (t, J = 6.6, Hz, 2H), 3.50 (ddd, J = 9.4, 5.4, 4.1 Hz, 1H), 3.26 (dd, J = 14.3, 5.5. Hz,
1H), 3.10 (dd, J = 14.3, 9.3 Hz, 1H), 1.80–1.69 (m, 1H), 1.62–1.47 (m, 3H), 1.35–1.05 (m, 10H); HRMS
(ESI) calcd for C21H30NO3 (M + H)+ m/z 344.2226, found 344.2206.
2.4.9.2 Appel Bromination
General procedure
Tetrabromomethane (CBr4) (1.5 equiv) and triphenylphosphine (PPh3) (3 equiv) were added to the
alcohol solution (1 equiv, 0.03 M in DCM) at 0 oC. After 1 h, the reaction mixture was diluted with
petroleum ether (5 volumes) and then concentrated. The crude product was adsorbed onto silica gel (dry
loaded) and then purified by flash column chromatography on silica gel to give the bromide.

trans-3-Benzyl-4-(8-bromo)octanyloxetan-2-one (trans-129a). The general procedure was followed
using trans-3-benzyl-4-(8-hydroxy)octanyloxetan-2-one (trans-128a) (0.07 g, 0.24 mmol). Purification
by flash column chromatography on silica gel (hexanes/EtOAc 47:3) provided trans-129a as a colorless
oil (54 mg, 63%): IR (neat) 2926, 2854, 1817, 1454, 1115, 1064 cm-1; 1H NMR (400 MHz, CDCl3 ) 
7.37–7.14 (m, 5H), 4.27 (ddd, J = 6.7, 6.7, 4.2 Hz, 1H), 3.46 (ddd, J = 9.6, 5.5, 4.2 Hz, 1H), 3.39 (t, J =
6.8 Hz, 2H), 3.17 (dd, J = 14.3, 5.6 Hz, 1H), 3.00 (dd, J = 14.3, 9.4 Hz, 1H), 1.88–1.72 (m, 3H), 1.64–
1.52 (m, 1H), 1.43–1.33 (m, 2H), 1.31–1.13 (m, 8 H); 13C NMR (100 MHz, CDCl3)  170.9, 137.4, 129.0,
128.8, 127.2, 77.7, 57.5, 34.3, 34.1, 33.9, 32.9, 29.3, 29.1, 28.6, 28.2, 24.8; HRMS (ESI) calcd for
C18H26BrO2 (M + H)+ m/z 353.116, found 353.1090.
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trans-4-(8-Bromo)octanyl-3-(2-naphthylmethyl)oxetan-2-one (trans-129g). The general procedure was
followed using trans-4-(8-hydroxy)octanyl-3-(2-naphthylmethyl)oxetan-2-one (trans-128g) (0.053 g,
0.15 mmol). Purification by flash column chromatography on silica gel (hexanes/EtOAc 47:3) provided
trans-129g as a colorless oil (47 mg, 75%): IR (neat) 2925, 2854, 1817, 1601, 1463, 1376, 1340, 1269,
1119, 1067 cm-1; 1H NMR (400 MHz, CDCl3) 7.87–7.75 (m, 3H), 7.65 (s, 1H), 7.54–7.43 (m, 2H), 7.32
(d, J = 8.3 Hz, 1H), 4.37–4.29 (m, 1H), 3.56 (ddd, J = 9.4, 4.7, 4.7 Hz, 1H), 3.36 (t, J = 6.7 Hz, 2H),
3.37–3.31 (m, 1H), 3.16 (dd, J = 14.2, 9.6 Hz, 1H), 1.83–1.70 (m, 3H), 1.64–1.51 (m, 1H), 1.37–1.21 (m,
2H) 1.20–0.97(m, 8H); 13C NMR (100 MHz, CDCl3)  170.9, 134.9, 133.7, 132.6, 128.9, 127.9, 127.7,
127.4, 126.9, 126.6, 1261, 77.8, 57.5, 34.4, 34.2, 34.1, 32.9, 29.2, 29.1, 28.6, 28.2, 24.8; HRMS (ESI)
calcd for C22H28BrO2 (M + H)+ m/z 403.1273, found 403.1285.
2.4.9.3 Nucleophilic substitution of the bromide with dimethylamine
General procedure
Dimethylamine in H2O (40%, 1.0 equiv) and NaHCO3 (1.0 equiv) were added to a solution of the
bromide (1.0 equiv, 0.05 M in DMF) and the mixture was heated at reflux while stirring for 24 h. The
mixture was then allowed to cool to rt, concentrated, dissolved in DCM (20 volumes relative to bromide)
and then washed with water (20 volumes x 2). The organic layer was dried (NaSO4) and concentrated.
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trans-3-Benzyl-4-(8-dimethylamino)octanyloxetan-2-one (trans-130a). The general procedure was
followed using trans-3-benzyl-4-(8-bromo)octanyloxetan-2-one (trans-129a) (0.054 g, 0.15 mmol).
Purification by flash column chromatography on silica gel (NH4OH/MeOH/CHCl3 2:2.5:175) provided
trans-130a as a brown oil (15 mg, 31%): IR (neat) 2927, 2855, 1697, 1253, 1097 cm-1; 1H NMR (400
MHz, CDCl3 )  7.35–7.19 (m, 5H), 4.27 (ddd, J = 6.7, 6.7, 4.0 Hz, 1H), 3.45 (ddd, J = 9.5, 5.7, 4.1 Hz,
1H), 3.17 (dd, J = 14.3, 5.7 Hz, 1H), 3.00 (dd, J = 14.3, 9.4 Hz, 1H), 2.25–2.21 (m, 2H), 2.21 (s, 6H),
1.83–1.72 (m, 1H), 1.63–1.52 (m, 1H), 1.48–1.38 (m, 2H), 1.32–1.13 (m, 8 H);

13

C NMR (100 MHz,

CDCl3) ; HRMS (ESI) calcd for C20H32NO2 (M + H)+ m/z 318.2437, found 318.2426.

trans-4-(8-Dimethylamino)octanyl-3-(2-naphthylmethyl)oxetan-2-one

(trans-130g).

The

general

procedure was followed using trans-4-(8-bromo)octanyl-3-(2-naphthylmethyl)oxetan-2-one (trans-129g)
(0.047 g, 0.1 mmol). Purification by flash column chromatography on silica gel (NH4OH/MeOH/CHCl3
2:2.5:175) provided trans-130g as a brown oil (12 mg, 28%): IR (neat) 2925, 2853, 1819, 1115 cm-1; 1H
NMR (400 MHz, CDCl3) 7.85–7.76 (m, 3H), 7.64 (s, 1H), 7.47 (m, 2H), 7.31 (dd, J = 8.4, 1.6 Hz, 1H),
4.33 (ddd, J = 6.7, 6.7, 4.0 Hz, 1H), 3.56 (ddd, J = 9.5, 5.5, 4.1 Hz, 1H), 3.34 (dd, J = 14.3, 5.6 Hz, 1H),
3.17 (dd, J = 14.3, 9.4 Hz, 1H), 2.26–2.19 (m, 2H), 2.22 (s, 6H), 1.83–1.71 (m, 1H), 1.63–1.51 (m, 1H),
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1.43–1.34 (m, 4H) 1.22–1.00 (m, 8H); 13C NMR (100 MHz, CDCl3)  171.0, 134.9, 133.8, 132.7, 128.9,
127.9, 127.8, 127.5, 126.9, 126.6, 126.1, 77.8, 60.1, 57.5, 45.7, 34.4, 34.2, 29.9, 29.5, 29.5, 29.2, 27.9,
27.6, 24.9; HRMS (ESI) calcd for C24H34NO2 (M + H)+ m/z 368.2590, found 368.2589.
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